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Terminal prostate cancer is the result of metastatic spread of the tumour 
from the prostate and is the 2nd leading cause of cancer deaths in men. 
Although in vitro assays have been developed to screen for inhibitors of 
prostate cancer metastasis and cell migration, they routinely utilise 2-
Demensional (2-D) culture of prostate cancer cell lines. Current assays do not 
simulate complexity of the in vivo human tumour microenvironment which 
contains a mixture of normal and transformed epithelial cells and stromal 
cells. Therefore there is a requirement to develop novel 3-D models to 
recapitulate the in vivo tumour microenvironment to understand tumour 
stroma function. Utilising a 3-D co-culture spheroid model incorporating 
primary human tumour stroma with prostate cancer cells we have shown 
that the stroma has a key role in prostate cancer epithelial cell migration and 
motility. By utilising 4-D two-photon imaging and gene expression analysis 
we have analysed the molecular mechanisms of stromal cell mediated 
prostate cancer cell migration, identifying genes that regulate the migration 
process. 
 
Analysis of human tumour stroma indicates a key role in the immune system 
in driving tumour stroma to express a lymphoid stromal phenotype that 
provides the microenvironment for active tumour cell migration. This offers 
an interesting dichotomy that the formation of lymphoid like stroma in 
aggressive tumours may paradoxically deliver help to drive the immune 
response to the tumour whilst simultaneously providing the 
microenvironment for tumour cell migration and metastasis. 
 
The molecular mechanism of prostate cancer cell migration and metastasis 
and stroma-epithelial cell interactions involves a complex balance between 
the adhesion molecule VCAM-1 and two counter ligands VLA-4 and SPARC, 
also known as osteonectin or BM-40. The utilisation of shRNA knockdown, 
Fc chimeric proteins and blocking antibodies, indicates a key role for 
stromal-epithelia adhesion and detachment dependent cell migration 
mediated by VCAM-1, VLA-4 and SPARC. !  
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Chapter 1  
Introduction 
Prostate cancer is the most common cancer in men in the UK with 25% of all 
new cases of cancer diagnosed in men being prostate cancers. Now, more 
than 75% diagnosed are likely to survive their disease beyond five years 
compared to just 30% in the 1970s (Mayor 2012) (Cancer Research UK). 
 
1.1 The Prostate and Prostatic Disease 
1.1.1 The Prostate Gland 
The human prostate is a small exocrine gland, functioning primarily to 
secrete the bulk component of the fluid that makes up seminal fluid. This 
fluid is strongly alkali to modify the acidic environment of the vagina to 
ensure sperm survival post ejaculation. The prostate sits at the base of the 
bladder surrounding the urethra where it also performs a secondary, 
muscular function to control the flow of urine (Maitland 2008). A common 
diagnostic observation of prostatic disease is often the malfunction of this 
muscular function (Sharma et al. 2009). While females do not have a prostate, 
the female Skene’s gland or the female paraurethral gland shares some 
common characteristics including secretory function and anatomical 
positioning to the prostate and is indistinguishable from the male prostate at 
very early stages of development (Thomson 2008). Although extremely rare, 
adenocarcinoma of Skene’s gland closely resembles prostatic 
adenocarcinoma (Pongtippan et al. 2004). 
 
Whilst the normal adult human prostate does not exhibit distinct lobes as 
seen in many other mammals (Timms & Hofkamp 2011) it can be divided in 
to three discreet zones. The peripheral zone (PZ) which surrounds the 
urethra at the posterior of the gland constitutes 70% of the total volume, and 
is the origin of the majority of prostate cancer. The central zone (CZ) 
surrounds the ejaculatory ducts, and accounts for approximately a quarter of 
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the prostate while the transition zone (TZ) surrounds the urethra and 
accounts for 5% of the gland (McNeal et al. 1988). 
 
In humans, prostate development is dependent on male androgens (K. Xu et 
al. 2009) and stromal-epithelial interactions between epithelial cells and the 
prostatic mesenchyme (Thomson 2008; Timms 2008). During early human 
embryo development, in the 10th week of gestation, androgen receptor (AR) 
expression on the local mesenchyme results in the development of a 
secretory structure (Shannon & Cunha 1983). Androgen signaling through 
this AR results in smooth muscle patterning in the mesenchyme, a key 
component of the prostate secondary muscular function (Maitland 2008). 
During the third trimester, testosterone levels in the embryo then drop, 
prostate development ceases, and a quiescent state of the gland is entered. 
The organ remains quiescent until a dramatic change, brought about by high 
pubescent levels of testosterone, leads to a doubling in size of the prostate 
gland, resulting in a mature gland with full secretory function. 
 
The secretory ducts of the prostate contain a bilayer of prostatic epithelial 
cells (Figure 1.1). The first layer on the lumen side of the duct consists of 
prostate specific antigen (PSA) secreting, terminally differentiated, luminal 
cells which express cytokeratins 8 and 18 (Lawson et al. 2010). In between 
these luminal cells, sporadically situated, resides a rare and less well studied 
cell type, the neuroendocrine (NE) cells. They are thought to regulate 
prostate growth and development (Taylor et al. 2010) and interestingly also 
make up a small population (usually <1% of all tumour cells) in all prostatic 
adenocarcinomas (Tai et al. 2011; Sun et al. 2009). Beneath the PSA secreting 
luminal and NE cells lay intermediate or transit-amplifying cells and basal 
cells. This second layer is highly proliferative and undifferentiated 
epithelium, where a very small population of prostate stem cells that can 
give rise to all epithelial cells in the prostate (0.1%) are located (Mackenzie 
2008; Maitland & Collins 2005). Prostate epithelial stem cells express 
cytokeratins 5 and 14 (Lawson et al. 2010) and the epithelial stem cell marker 
CD133 (Promini-1) (Signoretti & Loda 2007) and can, when isolated, 




Stem cells are defined by their potential both to self-renew and to 
differentiate into different effector cell populations (Evans & Kaufman 1981; 
Takahashi et al. 2007). In normal tissues stem cells have a key role in tissue 
homeostasis (Potten & Loeffler 1990). Prostate epithelial stem cells are 
protected from signals that would otherwise lead to their differentiation 
through their location in a protective microenvironment known as the stem 
cell niche (Slack 2000; Xie & Li 2007). Stem cells in their specialised niche 
remain stem-like and only differentiate once they have left the niche, 
undergoing rapid proliferation and differentiation into basal, transit-
amplifying or luminal epithelial cells. The niche is maintained by complex 
stromal signals which have a key role in controlling the prostate stem cell 
environment as well as additional signals from differentiated epithelial cells 
in the immediate vicinity of the stem cell which actively inhibit stem cell 
differentiation (Cunha 1994). The stromal component of the gland has a key 
role in both the development and upkeep of the prostate and secretes a 
complex array of signaling molecules and growth factors (Kooistra et al. 
1995; Lang et al. 2000; Tuxhorn et al. 2002; Mueller & Fusenig 2004; Kooistra 
et al. 1995). 
 
1.1.2 Prostatic Disease 
Prostatitis, Benign Prostate Hyperplasia (BPH) and Prostate Cancer are three 
of the most common prostatic pathologies. 
 
Prostatitis: This condition results from inflammation caused most commonly 
by bacterial infection or physical trauma resulting in epithelial disruption 
(De Marzo et al. 1999; De Marzo et al. 1999). Incidence of prostatitis depends 
on geographical location, criteria of evaluation and the physician carrying 
out the diagnosis, but is reported to be anywhere between 2% and 16% of 
men tested (Krieger et al. 2002). Prostatic inflammation is directly associated 
with the presence of BPH, but prostatitis patients are not predisposed to 
cancer (Delongchamps et al. 2008). 
 
Benign Prostatic Hyperplasia: BPH is non-malignant prostate hypertrophy. 
Both the fibromuscular stromal and glandular epithelial cells undergo 
hyperplasia but the etiopathogenesis of BPH is still largely unresolved (J. 
Tang & J. Yang 2009). Prevalence correlates with age with 8% of younger 
men (ages 31-40) exhibiting BPH. This increases to an incidence of over 80% 
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in men aged 80 and above (Guess et al. 1990). BPH was first described as a 
stromal disease nearly 150 years ago from one of the first histological 
observations of BPH (Timms & Hofkamp 2011). It is now understood that 
paracrine signaling between the stroma and epithelium is essential for 
normal development and disruption of normal paracrine signaling impacts 
on prostate development, leading to prostatic pathologies. This has been 
hypothesised to be a factor in the etiology of BPH involving pathways 
required for normal development becoming disregulated, leading to 
inflammation (Kramer et al. 2007). T cells, B cells and macrophages are all 
chronically activated in BPH and are responsible for producing an array of 
inflammatory cytokines and signaling molecules including the cellular 
growth and differentiation factor, transforming growth factor-" (TGF-") 
(Kramer et al. 2002), which in turn, induces growth of the fibromuscular 
compartment in BPH. 
 
The presence of androgens and an increase in age are factors linked to BPH, 
but the fundamental etiology remains unknown. A correlation has been 
observed between the onset of BPH and the presence of lower urinary tract 
infection leading to localised inflammation. Additionally, changes in 
interactions between stromal and epithelial cells have been observed during 
the development of BPH in the transition zone of the human prostate 
(Shapiro et al. 1992). Changes in gene expression and stroma-epithelial 
interactions in a murine BPH model may not be that informative of the 
etiology leading to the human pathology due to differences in prostate 
anatomy. The discreet zones within a human prostate is not well represented 
by the clear rodent prostate lobular structure. Prostate specific 
overexpression of prolactin induces a BPH like disease in mice, resulting in 
down-regulation of apoptosis-associated genes in prostatic epithelial cells. 
This was coupled with reduced apoptosis and increased proliferation in the 
stromal cells with many of the differentially expressed genes being directly 
associated with the stroma and ECM including secreted proteins such as 
fibronectin, laminin and collagens (Dillner et al. 2003). Gain of function in the 
Notch signaling pathway in both prostate epithelium and the adjacent 
stroma induced a prostatic disease with histological characteristics of human 
BPH. Upregulated Notch caused the inhibition of phosphatase and tensin 
homolog (PTEN) and the activation of the Akt cell survival pathway leading 
to epithelial and stromal expansion (Wu et al. 2011). However, whilst there is 
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no evidence that notch mutations are involved in BPH, and is unlikely to be 
the causative agent in human disease, this demonstrates that paracrine 
signaling in the prostate can alter the epithelial-stromal interactions 
contributing to hyperplasia and other pathological conditions (Timms & 
Hofkamp 2011). 
 
The androgens testosterone and dihydrotestosterone (DHT) have been 
shown to have a role in BPH. Castration results in incomplete prostate 
development, and in men who naturally have low or zero levels of DHT, 
there is a reduced incidence of BPH (Ho & Habib 2011). Removal of 
androgens in the mouse through castration results in prostatic involution, 
which can be rescued by the exogenous delivery of androgens (Colombel & 
Buttyan 1995). Estrogens also have a role in prostate growth and pathology 
but their role in BPH is less clear. The receptors for estrogens; estrogen 
receptor-alpha (ERα) and estrogen receptor-beta (ERβ) work in opposition 
during BPH (Bonkhoff & Berges 2009), with an increase in ERα, leading to 
hyperproliferation in both the stromal and epithelial prostatic compartment, 
while the apoptosis regulator ERβ is lost in the stroma but highly expressed 
in the epithelial cells (Royuela et al. 2001). This results in an increase in the 
stromal cell volume in the prostate. 
 
Prostate Cancer: Prostate cancer exhibits the six traditional hallmarks of 
cancer. Namely; the evasion of apoptosis, self-sufficiency for growth signals, 
insensitivity to anti-growth signals, invasion of tissues and metastasis, 
unlimited replicative potential, and sustained angiogenesis (Hanahan & 
Weinberg 2000). This was updated a decade later to include two emerging 
hallmarks in the deregulating of cellular energetics and the evasion of 
immune destruction, as well as the enabling characteristics which are 
tumour-promoting inflammation and genome instability with mutations 
(Hanahan & Weinberg 2011). Sustained cell proliferation in prostate cancer is 
mediated by many events. Cells of the prostate respond to androgens via the 
AR, and a key regulator of AR expression is Paxillin. Paxillin is a cytoplasmic 
adaptor protein that regulates both extra- and intranuclear AR as well as 
extracellular signal-regulated kinass (ERK) signaling in prostate cancer cells 
(Sen et al. 2010). Elevated in human prostate cancer microarrays, Paxillin 
mediates AR regulated transcription, resulting in cell proliferation (Sen et al. 
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2012). Atypical cell proliferation is also induced via AR through aberrant 
Wnt/"-catenin signaling that regulates the processes of cell differentiation, 
epithelial mesenchymal transition (EMT) and prostate epithelial cell hyper-
proliferation. Although overexpression of Wnt proteins as observed in 
prostate cancer have not been conclusively shown as being solely responsible 
for the stimulation of the Wnt/"-catenin signaling, it is clear that Wnt 
overexpression promotes proliferation - a hallmark of both prostate cancer 
and BPH (Kypta & Waxman 2012). 
 
PTEN regulates many different cellular processes in the prostate including 
proliferation through control of the cell cycle. Usually an attenuator of 
proliferation, PTEN can be mutated resulting in a deregulation of its 
function. Platelet-derived growth factor (PDGF) is a known regulator of cell 
proliferation, particularly in the bone. In the prostate, stromal cell 
proliferation is induced by PDGF which is secreted by both epithelial and 
fibroblastic cells (Kaminski et al. 2006). Deletion of PTEN in vitro in normal 
mouse prostate epithelium resulted in an expression pattern of PDGF similar 
to that previously shown in human prostate cancer cells as well as tumour 
biopsies (Conley-LaComb et al. 2012). It was concluded that PTEN, through 
PDGF and PDGF receptors (PDGFR), can promote and drive prostate cancer 
through sustained cell proliferation and has influence upon other cellular 
processes such as enhanced cell migration, differentiation and phenotypic 
transformation (Conley-LaComb et al. 2012). PTEN is classed as a growth 
suppressor and so too is TP53. Evading growth suppressors and resisting cell 
death are other hallmarks of cancer and in approximately 70% and 25% of all 
human prostate cancers either PTEN or TP53 respectively is lost (Martin et 
al. 2011). Loss of both suppressors in mouse models results in rapid 
development of prostate cancer and an increase in the development of 
invasive adenocarcinoma. TP53 in its absence is no longer able to promote 
apoptosis as is its normal role during cellular stress (Z. Chen et al. 2005). 
 
In order for tumours to grow continually, cancer cells need to acquire 
replicative immortality (Hanahan & Weinberg 2011). Telomeres are regions 
at the terminal of chromosomes containing a nucleotide repeat and over time 
telomeres become shortened resulting from chromosome replication. 
Telomerase is a reverse transcriptase that uses its own RNA template to 
extend telomeres post chromosome replication. Telomerase is constitutively 
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active in prostate cancer cells (Keith et al. 2007) and can be expressed up to 
200-fold in putative prostate cancer stem cells compared to tumour cells from 
the same tissue (T. Xu et al. 2011). This over activity of telomerase effectively 
renders prostate cancer cells immortal allowing them to grow beyond the 
limits of normal cell division.  
 
For cells to sustain a high rate of proliferation and elevated levels of growth, 
tumours need a ready supply of nutrients and oxygen. This is achieved by 
increasing the blood supply via angiogenesis which is essential for 
progression of the disease (Weidner et al. 1993). Vascular endothelial growth 
factor (VEGF) a factor that promotes endothelial cell proliferation and the 
formation of new blood vessels, is up-regulated within prostate tumours and 
increased in the serum of patients with prostate cancer with metastatic and 
castration resistant disease (Tomić et al. 2012). In fact, VEGF levels can be 
used as a diagnostic marker of advanced disease. Thrombospondin-1 (TSP-1) 
acts as a potent angiogenic inhibitor by regulating VEGF through a receptor 
complex comprising CD36, VEG-F receptor 2 (VEGFR2) and "1 integrin in a 
complex cascade of events involving the phosphorylation of VEGFR2 (Zhang 
et al. 2009). In prostate cancer, TSP-1 expression correlates with disease 
severity and is significantly lower in high grade disease. Thus VEGF function 
is significantly higher in tumour tissue compared to BPH tissue. Expression 
was also higher once again for VEGF and lower for TSP-1 in metastatic 
disease as opposed to localised prostate cancer (Kwak et al. 2002). 
 
The loss of E-cadherin promotes cancer cell invasion, and along with 
metastasis, this represents the sixth and final hallmark of cancer (Hanahan & 
Weinberg 2000; Cao et al. 2008). One of the ways E-cadherin-mediated 
motility and invasion can be regulated is through "-catenin. The interaction 
of Protein Kinase D1 (PKD1) with E-cadherin affects cell motility in prostate 
cancer (Jaggi et al. 2005), and is mediated by "-catenin (Syed et al. 2008). 
Using siRNA against PKD1 and E-cadherin resulted in increased 
proliferation and invasion as well as cell migration in the DU-145 prostate 
cancer cell line. This phenotype can be reversed by the addition of "-catenin 
suggesting an important role for this pathway in metastasis (Syed et al. 2008). 
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1.1.3 Prostate Cancer Pathology: Gleason Grade 
Dr Donald F Gleason developed the Gleason grading system for classifying 
adenocarcinoma of the prostate in the 1960s. The Gleason grading system is 
based entirely on histologic and architectural growth patterns of the 
arrangement of carcinoma cells in hematoxylin and eosin (H&E) stained 
prostatic tissue sections (Humphrey 2004; Gleason 1966). The Nine original 
patterns of adenocarcinoma histology (1, 2, 3A, 3B, 3C, 4A, 4B, 5A and 5B) 
are now consolidated into five grades from Gleason grade 1 to 5. Even after 
this simplification around 50% of all tumours contained more than one 
histologic grade. After much debate it was decided that the two grades 
should be averaged by adding the two scores together but not dividing. Thus 
a prostate exhibiting both grades 3 and 4 is classified as being Gleason grade 
7 (Gleason 1992) (Figure 1.2). 
 
1.2 Prostate Cancer Models 
1.2.1 Stochastic versus Stem Cell Model 
Despite intensive investigation, relatively little is known about the 
fundamental causes of prostate cancer. Prostate cancer most commonly 
arises from the peripheral zone (70%) (Berry et al. 2008) and there are at two 
main proposed models of prostate cancer initiation; the stochastic model and 
the stem cell model. The stochastic model states that the tumour is 
homogeneous in that there is no cellular hierarchal structure or function of 
epithelial cells with each cell having the same potential to induce tumour 
formation. Phenotypic heterogeneity often observed in tumours results from 
accumulated epigenetic changes in the expanding clonal population of 
epithelium. Thus the cancer is initiated by and resulting from random 
mutations and subsequent clonal selection and expansion (Wicha et al. 2006). 
The stem cell model for prostate cancer states that the tumour is not simply a 
homogeneous population of inappropriately growing cells and instead has 
hierarchal differentiation. This includes the existence of prostate cancer stem 
cells (CSC). The CSCs are proposed to be a small subset of cells (less than 
0.1%) which are the only cells capable of initiating tumourigenesis. The gold 
standard for identifying cancer stem cells is the ability of these cells to 
recapitulate a tumour in a new host, for example, the transplantation of 




Gene expression in CSCs in prostate cancer has been characterised based 
upon cells exhibiting a CD44+/!2"1hi/CD133+ phenotype which have been 
shown to have stem cell capacity. These cells generate phenotypically mixed 
and differentiated cell types expressing different cell products in line with 
their proposed function. For example, the production of PSA by terminally 
differentiated luminal cells (Collins et al. 2005). The proposed stem cell 
model for tumour persistence post-treatment states that the 
CD44+/!2"1hi/CD133+ tumour cells are AR deficient. This is important when 
considering the efficacy of hormone treatment. Treatments aimed at killing 
rapidly dividing cells (chemotherapy, radiation), to which CSCs would be 
relatively unresponsive are also ineffective and CSCs maintain the ability to 
recapitulate the tumour in full post-treatment (Figure 1.3) (Maitland & 
Collins 2008). 
 
Whilst the exact origin of the initiation of a tumour is unknown, it has been 
proposed that CSCs or cancer initiating cells (CICs) could arise from normal 
stem cells or indeed from more differentiated progenitor cells that have 
regained the ability to self-renew (Vassilopoulos et al. 2008). Stem cells are 
unique in their ability to both maintain their niche via self-renewal and also 
asymmetrically divide to give rise to daughter cells that will differentiate 
down a certain lineage (Knoblich 2008). The longevity of stem cells makes 
them more susceptible to the accumulation of multiple consecutive genetic 
mutations, potentially increasing the risk of transition to CSCs. Of the 581 
genes found to be significantly different in prostate CD133+/α2β1hi CSCs 
compared to their differentiated normal counterparts (CD133-/α2β1low), the 
JAK-STAT pathway, focal adhesion signaling and extracellular matrix genes 
were identified as key processes in the biology of CSCs (Birnie et al. 2008). 
Genetic changes can also occur at the chromosome level in the form of gene 
fusions. The most common genetic rearrangement in human prostate cancer 
is the TMPRSS2-ETS fusion (Mosquera et al. 2007) a byproduct of DNA 
double strand break (DSB) repair gone wrong. One model proposes that 
DSBs occur via androgen stimulation which in rare cases leads to a 
TMPRSS2-ERG fusion (Tomlins et al. 2005; Bartek et al. 2010) commonly 
found in human prostate cancers (Maitland et al. 2011). 
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1.2.2 Non-murine Models of Prostate Cancer 
The past 40 years has seen the establishment of approximately 30 putative 
immortalised human prostate cancer cell lines (van Bokhoven et al. 2003). 
Three classical cell lines are predominantly used in prostate cancer studies. 
In order of establishment the cell lines are DU 145 (1977) (Stone et al. 1978), 
PC-3 (1978) (Kaighn et al. 1979) and LNCaP (1980) (Horoszewicz et al. 1980) 
which originate from brain, bone and lymph node metastases respectively. 
These cell lines have been used in countless studies and have contributed 
vastly to our understanding of many processes involved in prostate cancer 
and tumour formation in general. PC-3 cells carry significant genetic 
abnormalities including aneuploidy which changes over time in culture and 
affects the majority of chromosomes which always results in the loss of 
chromosome 2 and 3 (Ohnuki et al. 1980). 
 
Many other cell lines have been derived from human cancers from as early as 
1948 including the fibrosarcoma derived cancer cell line HT-1080. This cell 
line was first described in 1974 and originates from a biopsy of a 
fibrosarcoma with multiple metastases from a 35-year old male. This cell line 
survived cell culture conditions and has been thoroughly characterised 
(Rasheed et al. 1974). HT-1080 cells were immortal in culture, tumour 
initiating in mice, and contained several chromosome abnormalities 
exhibiting pseudodiploidy (Rasheed et al. 1974). Since then, this cell line has 
been used to analyse cell migration and invasion both in vitro and in vivo 
(Roomi et al. 2006; Armstrong et al. 1982; Mishima et al. 1998). Due to this 
cell line’s spontaneous and random nature of migration in culture, HT-1080s 
were used in this thesis to develop the 3-D model of cancer cell migration 
and used as a positive control for single cell migration. 
 
However, as with all cell line models of disease these systems have their 
limitations. In particular cell lines do not represent the myriad of 
heterogeneity involved in the disease and experiments are often carried out 
in a 2-D environment with no thought to, or representation of, the 3-D 
microenvironment experienced in whole tissues. Furthermore, long-term 
culture of such cell lines leads to the alteration of biological, genetic and 
phenotypic properties. Cancer cells are mutated by definition within the 
primary tumour, but adaptations to culture conditions means that cancer cell 
lines can become mutated beyond what is observed in the original disease. 
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These problems, in part, can be addressed by culturing primary malignant 
prostatic cells and normal epithelial prostatic cells (Peehl 2005). 
 
Methods have been described for culturing cells from many different 
sources; radical prostatectomy, needle biopsies, and bone marrow aspirates 
among others. The primary cultures were established and subsequently 
maintained in conditions similar to those used to culture normal cells. This 
has been successful for all grades of prostate cancer from well-differentiated 
Gleason grade 3 cancers, to poorly differentiated Gleason grade 5 cancers. 
These cells can then be used in experiments similar to those designed for use 
with cell lines only now using a more physiologically relevant cell type. 
 
Alternative non-murine animal models exist in the form of dogs and some 
strains of rat (Rosol et al. 2003; Rosol et al. 2004). Human prostate cancer is 
most closely mirrored by the disease exhibited in dogs, being age dependent 
and showing bone metastasis in a quarter of cases (Winter et al. 2003). 
However, there are obvious limitations with such animal models, 
particularly the dog. There is a long disease latency, a high upkeep cost, long 
gestation periods and little or no room for genetic manipulation. In rats, the 
disease is sporadic, highly variable and rarely exhibits metastases. 
 
1.2.3 Murine Models of Prostate Cancer 
The four main mouse models used to model the human disease discussed 
here are human tumour xenografts, transgenic mice expressing oncogenes 
under the control of prostate specific genes, mice with germline deficiency in 
tumour suppressor genes and prostate specific conditional gene knockout 
mice. 
 
Xenograft models were first described in 1980 when human prostate cancer 
tissue was transplanted into athymic nude BALB/c mice which lack T cells 
and so have limited capacity to reject implanted tissue (Hoehn et al. 1980; 
Valkenburg & B. O. Williams 2011). The xenograft model has been improved 
through the development of more complete immunodeficient mice. Severe 
combined immunodeficiency (SCID) mice have very limited numbers of T 
and B cells and thus allow more efficient engraftment of the xenografts. This 
was further improved by crossing the SCID mice with nonobese diabetic 
(NOD) mice that have functional deficiencies in antigen-presenting cells 
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(APCs) and natural killer (NK) cells. However, although xenografts were 
accepted at a higher rate, there was still considerable rejection, and it wasn’t 
until the development of the most severe immunodeficient mouse, the NSG 
(NOD/SCID/Gamma chain deficient mice) and GcRag (Common Gamma 
chain, Rag deficient mice) mouse models that completely lack NK cells, that a 
significant success rate was observed with xenograft implantation (Shultz et 
al. 2005). 
 
Despite the leap forward in complexity of xenograft models this system has 
its limitations. The lack of a competent immune system, which allows the 
success of the implantation of foreign tissue, could have a direct effect on the 
growth, development and progression of the tumour. In the case of cancer, it 
is clear that the immune system has a critical role in tumour formation in vivo 
(Rakhra et al. 2010; Kundu & Surh 2008; Grivennikov et al. 2010; Tan et al. 
2011; Bollrath & Greten 2009). Additionally, by definition xenograft models 
fail to model the early stages of tumour initiation as these are negated by 
implantation of a mature piece of foreign cancerous material. 
 
It is possible to dissect the early events of disease formation by using the 
transgenic models of prostate cancer. This technique was first used in the 
1980s to investigate brain (Brinster et al. 1984) and lymphoid (Adams et al. 
1985) malignancies. An ideal transgenic mouse model needs to fulfill three 
main criteria. First, to allow a better understanding of the complexities of 
cancer tumour biology in the context of an intact immune system. Second, to 
allow short term studies without comprising on genetic and/or epigenetic 
changes. Third, to allow preclinical evaluation of novel therapies against 
prostate cancer which are accurate and relevant (Jeet et al. 2010). 
 
The best characterised mouse model of prostate cancer is the transgenic 
adenocarcinoma of the mouse prostate (TRAMP) model. The TRAMP model 
utilises the prostate-specific rat probasin promoter to drive expression of the 
Simian Vacuolating Virus 40 (SV40) large and small t antigen (Tag). 
Overexpression of the large T antigen, a proto-oncogene originated from 
SV40, down modulates expression of p53 and retinoblastoma tumour 
suppressors and this, coupled with the effect of the small t antigen effects 
promotes epithelial cell growth and survival, leading to the subsequent 
development of aggressive tumours (Greenberg et al. 1994; Greenberg et al. 
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1995; Gingrich et al. 1996; Gingrich et al. 1997). Metastasis occurs in ~100% of 
TRAMP cases to the lymph nodes and lungs and is rarely found to target the 
bone, kidney and adrenal glands (Gingrich et al. 1999). 
 
A less aggressive variety of the TRAMP model, the LADY mouse model 
spontaneously develops metastases (Venkateswaran et al. 2004) but to a 
lesser extent reaching only the lymph node, liver and lung in two thirds of 
cases. Similar to the TRAMP model, LADY transgenic mice have SV40 driven 
expression of the large T antigen specifically targeted by the rat probosin 
promoter, but lack the expression of the oncogenic small t antigen leading to 
a less aggressive disease phenotype (Valkenburg & B. O. Williams 2011). 
 
There are many further examples of transgenic prostate cancer mouse 
models most of which act to cause prostate cancer via the expression of SV40 
driven T antigen (Ahuja et al. 2005). However these are less representative of 
human prostate cancer in that SV40 T antigen is not normally expressed in 
the human disease and transformation likely does not normally occur in 
terminally differentiated cells. Rather than being the result of a prostate 
specific oncogenic event, the transgenic mouse models of the disease, such as 
TRAMP and LADY, is a result of tissue specific loss of the tumour 
suppressor genes p53 and retinoblastoma. 
 
Gene knockout mice are generated through homologous recombination in 
embryonic stem cells leading to the production of mice that do not express 
the targeted gene due to either deletion of critical exon(s) or insertion of a 
transcriptional or translational stop. However, using germline deficient mice 
it very difficult to determine organ-specific roles for genes due to their role in 
other developmental systems. This is particularly true of genes like the 
retinoblastoma protein that has essential roles in embryo development. 
Unexpected roles for proteins in prostate development and disease have 
been deduced based on observations made from gene knockouts including 
the retinoic acid receptor gamma (RAR$) knockout mouse where 100% of 
male mice exhibited problems in prostate development (Lohnes et al. 1993). 
RARs are transcription factors that mediate retinoid effects and deregulation 
of such factors have been linked to many malignancies (Richter et al. 2002). 
The presence of multiple RARs has been shown from day zero in the mouse 
prostate which suggests that they are important for development (Aboseif et 
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al. 1997). This is compounded by the RAR knockout mouse in which 100% 
male mice develop squamous cell metaplasia in the prostate as well as 
having perturbed prostate developmental. However no carcinoma was ever 
detected (Valkenburg & B. O. Williams 2011).  
 
No germline mouse knockout has been developed that accurately models 
prostate cancer. Many are either embryonic lethal, have developmental 
defects or develop tumours in multiple tissue types. In PTEN-/- Nkx3.1-/- 
mouse (H. Gao et al. 2006) loss of the classic tumour suppressor PTEN 
combined with the loss of the putative tumour suppressor Nkx3.1 leads to 
prostate cancer that can exhibit lymph node metastases (Bethel & Bieberich 
2007). The loss of Nkx3.1 expression in human prostate cancers correlates 
with tumor progression (Bowen et al. 2000). However, it is difficult to 
conclude prostate specific origins for tumours in these mice.  
 
The application of the Cre-loxP recombination system has led to the 
development of prostate-specific gene knockouts. This permits the study of 
genes that would otherwise be embryonic lethal or have developmental 
abnormalities. Briefly, the recombinase protein Cre can be expressed by 
specific tissues using either transgenic mice with Cre under the control of 
tissue specific promoter or knock-in of Cre into tissue specific gene loci. Once 
Cre is expressed, it acts on a pair of 34 base-pair LoxP sites which flank the 
gene of interest leading to recombination and removal of the intervening 
segment of DNA. Cre fused to the estrogen domain has been developed 
permitting induction of cre activity under the control of exogenous 
tamoxifen thereby allowing both tissue and temporal-specific gene targeting 
in the mouse (Metzger & Chambon 2001). 
 
The Cre-lox technology has been used extensively to study gene function in 
development, immune responses and cancer. In the prostate, PTEN, 
retinoblastoma (Rb) and Nkx3.1 have been targeted using prostate specific 
cre leading to a wide and varied range of disease phenotypes. The tumour 
suppressor PTEN, when conditionally knocked-out using the probasin Cre 
transgenic mouse line, causes a full range of low-grade and high-grade 
intraepithelial neoplasia, invasive carcinoma and metastasis, with metastasis 
homing to the lungs and lymph nodes within 12 weeks (S. Wang et al. 2003; 
Kasper 2005). In comparison loss of the putative tumour suppressor Nkx3.1 
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leads to a more benign phenotype only reaching low-grade intraepithelial 
neoplasia with no high-grade intraepithelial neoplasia, invasive carcinoma or 
metastasis (Abdulkadir et al. 2002). Conditional loss of Rb in the prostate 
epithelium increased prostate cell hyperplasia as early as 12 weeks due to an 
Rb-mediated loss of cell cycle control which lead to prostatic disease 
reflective of human prostate cancer (Nagy 2000) (Maddison et al. 2004). 
 
No current mouse model fully represents and recapitulates human prostate 
cancer, in part due to structural differences between human and mouse 
prostate. However, the development of more advanced inducible gene 
knockouts has, and will continue to provide insights into the mechanisms of 
human disease in the context of a fully functional immune system. 
 
1.3 Stroma 
The normal prostate stroma is critical for the correct development and 
maintenance of epithelia (Berry et al. 2008). Correspondingly prostate stroma 
has a key role in BPH and prostate cancer and is implicated in each and 
every stage of prostate carcinogenesis and metastatic disease (Hall et al. 
2002). Tumour stroma has been shown to contribute to the malignant 
characteristics of many other epithelial tumours including mammary 
tumours (Trimboli et al. 2009). For example, loss of the tumour suppressor 
gene PTEN in the stroma results in an acceleration of the initiation, 
progression and malignancy of mammary tumours in mice (Trimboli et al. 
2009). 
 
Stroma is an umbrella term in biology for a wide range of cell types that can 
either be activated in situ and/or recruited to the local tumour environment. 
These include fibroblasts, immune cells and vascular and lymphatic 
endothelial cells, smooth muscle cells and pericytes. Many of these cells 
interact with the extracellular matrix (ECM) components deposited by 
stroma, as well as interacting with the ‘normal’ and transformed cancerous 
cells which all together regulate many aspects of tumourigenicity in a 
tumour microenvironment (Mueller & Fusenig 2004; Tlsty & Hein 2001; Tlsty 
2001; Bissell & Radisky 2001). The complex nature of the three-dimensional 
architecture of the ECM and the numerous cell types that make up the 
tumour microenvironment makes it challenging to dissect. In culture, 
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fibroblasts rapidly outgrow and outcompete other cell types and after only 
one or two passages the primary cultures become morphologically 
homogeneous (Kopantzev et al. 2010). Thus in vitro generated 
microenvironments will differ to those found in vivo. 
 
The crosstalk between epithelia tumour cells and stromal cells during disease 
progression is a burgeoning field of research. Specifically in prostate cancer, 
there are two pathways by which this communication occurs; the efferent 
and the afferent pathway (De Wever & Mareel 2003). Typically at the early 
stages of disease the efferent pathway is thought to control changes to the 
stroma, with transformed epithelial cells releasing soluble factors such as 
transforming growth factor (TGF)-" and platelet derived growth factor 
(PDGF) which can transform fibroblasts into myofibroblasts (Skobe & 
Fusenig 1998; Sieweke et al. 1990) and induces epithelial-mesenchymal 
transition (EMT) as characterised by high levels of Vimentin expression. At 
later stages of disease, the afferent pathway, driven by the now changed 
stroma, acts as the tumour becomes more invasive. The roles are reversed 
and cancer cells now respond to the modified, “reactive” cancer stroma. This 
reactive stroma releases soluble factors and ECM components which can 
induce migration and invasion of the cancer cells in to the local stromal 
environment (Y.-N. Niu & Xia 2009). 
 
Stromal cells in many cancers have been shown to be activated in a way that 
is different to normal conditions. This includes the over-secretion of growth 
factors and pro-migratory ECM components, upregulation of matrix 
metalloproteinases (MMPs) and the induction of inflammation via 
chemokine secretion (Mueller & Fusenig 2004). The fibroblasts in cancer 
stroma have been found to have an influence on the development and 
progression of cancer leading to the potential of stromal-targeted 
therapeutics (Bhowmick et al. 2004). A change in the stroma environment 
throughout the progression of prostate cancer creates an ever changing, 
functionally different microenvironment with the reactive stroma becoming 
enriched for myofibroblasts and fibroblasts, whilst smooth muscle content 
decreases (Tuxhorn et al. 2002). TGF" and PDGF are two common growth 
factors secreted by a range of cells in the tumour (De Wever & Mareel 2003). 
However, the role of TGF" is uncertain with contradictory outcomes being 
seen in terms of tumour progression whether it is inhibited or overexpressed 
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(Bhowmick et al. 2004; Weeks et al. 2001). PDGF has a clearer role in the 
induction of myofibroblast proliferation and differentiation (Shao et al. 2000). 
 
More recently it has been shown that via the secretion by tumour cells of the 
C-C chemokine CCL21 (Shields et al. 2007), a lymphoid-like reticular stromal 
network was induced around melanoma tumours, which shifted the host 
immune response from immunogenic to tolerogenic (Shields et al. 2010). This 
facilitates and enhances tumour progression in a stroma dependent way and 
has furthered the case for therapeutic strategies to target the tumour stroma 
and immune infiltrate in future treatments. CCL21 is a ligand for the C-C 
chemokine receptor CCR7 which is expressed by DCs. Upon activation, 
CCR7 expression is upregulated in DCs allowing them to follow a CCL21 
and CCL19 chemotactic gradient set up by chemokine secreting lymphatics 
and lymph nodes (Randolph et al. 2005). In 3-D, DCs have an enhanced 
response to CCL21 over CCL19 (Haessler et al. 2011). CCR7 is also expressed 
on T cells and has a vital role in the trafficking of such lymphocytes to the 
lymph nodes (Mashino et al. 2002). By secreting CCL21, tumour cells are 
setting up a tumour specific chemokine gradient to which stromal cells and 
immune cells important for tumour progression can home to (Mashino et al. 
2002). 
 
1.4 Microenvironment and ECM 
Although in vitro assays, often using a proteomic approach, have been 
developed to screen for inhibitors at the different stages of metastatic 
prostate cancer, they often utilise cell lines and crucially do not simulate the 
in vivo tumour microenvironment. Aspects of such microenvironments 
include direct focal adhesions between different cell types, the presence of 
multiple cell types including the vascular system, the mix of stromal cell 
types, the collagen architecture and other ECM components. 
 
There are also other features attributed to tumour growth and survival 
which the microenvironment supports such as acidic pH, limited nutrient 
levels, higher interstitial fluid pressure and significant oxygen level 
fluctuation which is thought to directly relate to the abnormal vascular 
network that exists in tumours (Lunt et al. 2009). Not only does the ECM act 
as a support, it can also act as a physical barrier and is one of the first barriers 
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encountered by a cancer cell going through metastasis both on leaving the 
primary tumour and entering the secondary site. The tumour 
microenvironment can undergo significant remodeling during tumour 
growth and metastasis and has a key role in determining therapeutic efficacy 
(Kumar & Weaver 2009). 
 
The ECM is a complex mixture of different proteins including proteoglycans 
and fibres such as collagen, elastin, fibronectin and laminin. Cells interact 
with the ECM through membrane bound receptors such as integrins linking 
the ECM microenvironment to cellular function including changes to 
cytoskeletal organisation (Davis & Senger 2005). Integrins consist of !- and 
"-chains which combine to make an array of heterodimers that interact with 
cell surface receptors such as inter cell adhesion molecule (ICAM)-1, vascular 
cell adhesion molecule (VCAM)-1, CD44, N- and E-cadherin mediating the 
adhesive process (Humphries et al. 2006; Schmidt & Friedl 2010). Many cell 
types contribute to the makeup of the ECM, particularly fibroblasts, a large 
constituent of stroma, which lay down many components of the ECM 
architecture. There are two basic forms of the ECM; the basement membrane 
and the interstitial matrix (Sorokin 2010). 
 
1.4.1 Basement Membrane 
The basement membrane (BM) underlies all epithelia and endothelia tissue. 
Composed of dense ECM it is highly cross-linked and forms a sheet-like 
structure in direct contact with the basal cells of the organ or tissue it 
surrounds (Kalluri 2003). The BM creates a barrier between the cells and the 
interstitial, loose matrix, whilst simultaneously connecting the two entities 
(Timpl & J. C. Brown 1996). During normal processes and events such as 
periods of development, the BM has to be breached and crossed by specific 
cells. During neural crest cell migration from the pharyngeal pouches to 
produce peripheral neurons and the cardiac outflow, neural crest cells have 
to migrate in to and through the BM which was since successfully replicated 
in vitro (Bilozur & Hay 1988). This is particularly important taking in to 
account that cell invasion is key to the pathology of metastatic cancer 
(Kusuma et al. 2012; Yu & Machesky 2012), and indeed many other human 
diseases. Termed one of the hallmarks of cancer, the activation of invasion 
through the BM is one of the first barriers a metastasising cancer cell or 
group of cells has to concur (Hanahan & Weinberg 2011). 
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The BM is not simply a static divide or connective entity between two 
different environments. Cell adhesion, migration, polarity and spreading can 
all be regulated by the BM and this directly modulates the cellular 
cytoskeleton arrangement through signaling from integrins and receptors 
that bind to ECM proteins (Hamill et al. 2009). Laminin is a key component 
of the BM and is known to be key to BM function. Laminin is formed as 
subunits and it is now understood that in humans there are genes that 
encode for five !-, three "- and three $-subunits. These assemble in to at least 
16 familiar heterotrimeric functional laminin proteins (Aumailley et al. 2005) 
which makes determining the role of individual laminin proteins difficult. 
The different laminin forms are thought to have differential functions in 
many biological processes. 
 
The BM is also composed of collagens, fibrillin, perlecan and nidogens. The 
collagen component of most BMs is predominantly collagen IV which 
provides much of the mechanical strength acting as a scaffold and is essential 
for overall BM stability (Pöschl et al. 2004). Collagen is an excellent substrate 
with which cells can bind to. Typically these interactions occur via integrins 
such as !2"1 as well as non-integrin receptors, including the basal cell marker 
CD44 (Khoshnoodi et al. 2008). Cell adhesion to the BM is critical for cell 
polarity as well as structural organisation of the tissue itself. 
 
The other main components of the BM are perlecan, a heparan sulphate 
proteoglycan, and nidogens. Figure 1.4 shows how these two proteins 
interact with specific sites in the laminin protein leading to cross linkage 
with collagen IV thus creating an ordered protein network (Sorokin 2010). 
Both perlecan and nidogen have the ability to further crosslink the matrix by 
being able to bind collagen IV, fibulin, fibronectin and elastin as well being 
able to bind to each other to form a highly tensile ECM (Aszódi et al. 2006). 
 
The BM has a key role in the maintenance of the stem cell niche. Most stem 
cell microenvironments contain a BM which is in contact with stem cells, the 
interactions between the BM and the stem cells is thought to be important in 
the upkeep and regulation of stem cell function (Solozobova et al. 2012). 
 
! 32!
BM complexity allows for extremely tissue specific and site specific 
differences. The BM is a major barrier for cells going through extravasation 
either as a result of development, immune infiltration or metastasis. Electron 
microscopy and ultra-structural studies of BM from different organs is 
consistent with extravasation being site specific. Clear differences in BM 
electron density was seen between BMs in different organs such as the lung, 
kidney and liver, which equate to attachment points that may contain 
adhesion molecules (Paku et al. 2000). 
 
1.4.2 Interstitial Matrix 
The interstitial matrix (IM) along with the BM collectively makes up the 
ECM. The IM is distinctly different in composition to the BM containing a 
vast array of collagens, fibronectins, and proteoglycans (Laurila & Leivo 
1993). Often termed a loose fibrillar network, this is the second component 
after the BM that an extravasating cell encounters. Although adjacent to each 
other, the BM and IM are completely separate structures and no crossover of 
materials, or of mixed matrices, have been reported in normal tissue (Leivo 
1983a; Leivo 1983b). 
 
The difference in the composition of the two matrices is mirrored by the 
different mechanisms that cells employ when transmigrating the ECM. 
Taking leukocytes as an example, it has been shown that the cells take on an 
amoeboid shape aligning with collagen fibres whilst using the fibres as 
tracks (Korpos et al. 2010) which is independent of matrix degradation (Wolf 
et al. 2003). This process of moving through the IM has also been shown to be 
possible in an integrin-independent manner by knocking out the major 
integrins in dendritic cells (DCs). Integrin deficient DCs migrated in an 
identical manner to wildtype DCs and further dynamic imaging revealed a 
role for actomyosin contraction in leukocyte locomotion along a chemokine 
gradient (Lämmermann et al. 2008). This shows that cells have adapted to 
migrate through the ECM by different mechanisms depending on the 
constituency of the matrix, and the varying secondary structures within. 
 
Cancer cells also use tracks created by the fibrillar components of the IM 
(Madsen & Sahai 2010). The mechanisms by which cancer cells extravagate 
and subsequently invade secondary sites are varied and depend upon the 
ECM microenvironment of the tissue. During tumour metastasis, when a 
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cancer cell first encounters a secondary tissue site, integrin and non-integrin 
cell surface receptors engage with the local ECM facilitating tissue entry 
(Gritsenko et al. 2012). By utilising different combinations of cell surface 
receptors and integrins, cells can be selective for different components of the 
ECM thereby creating a signature for specific tissue-type ECMs. 
 
1.5 Cell Migration 
Cell migration involves a complex set of events. These events are dependent 
on the immediate ECM and cellular microenvironment, the signals driving 
the migration process, if cells are migrating as single cells, or a collective cell 
manner. The migration process is key for tissue remodeling during 
embryonic morphogenesis, organ development, immune surveillance, 
wound repair and indeed cancer cell invasion (Friedl & Gilmour 2009). 
Single cell migration has a key role in the function of the immune system, 
higher order collective cell migration is an important process during 
embryonic development but has little role in normal tissue homeostasis. 
 
Collective migration is defined by the cohesive movement of a group of cells 
(Rørth 2009). During collective cell migration, cells migrate in tight groups as 
sheets, sprouts, branches, streams and free groups. An extreme example of 
collective migration is eye migration in flounder and other flat fish (Hildahl 
et al. 2008). Extreme collective cell migration is also observed during fetal 
thymus development where the thymus migrates from its site of origin in the 
3rd pharyngeal pouch to the thoracic cavity, an active process involving 
neural crest cells. This process is dependent on Eph/Ephrin interactions 
between neural crest derived mesenchyme (Foster et al. 2010). The same 
processes observed during development and tissue morphogenesis have 
been observed in invasive carcinoma where groups of cancer cells invade 
surrounding tissues, ECM and vasculature (Friedl 2004; Friedl & Alexander 
2011).  
 
The mechanisms of single cell migration have been extensively studied in 
vitro. Often termed as mesenchymal or amoeboid cell migration this can be 
confusing as multiple different cell types including but not limited to 
mesenchyme can undergo single cell migration. Single cell migration can be 
characterised by five or more steps; protrusion, adhesion, leading edge 
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stabilisation, cell body translocation and detachment of the rear of the cell 
(Ridley et al. 2003) in an integrin dependent process. Whilst exerting forces 
on the ECM, this process usually involves a degree of ECM degradation in 
order to create paths through which the cell can migrate. Tumour fibroblasts 
exhibit this degradation dependent movement, the tracks which they create 
being utilised by following carcinoma cells (Gaggioli et al. 2007; Scott et al. 
2010). The mechanism by which other cell types migrate as single cells is 
markedly different. Leukocytes employ an amoeboid migration tactic which 
is fast and can be up to 30%m/min. This rapid motility means there is 
insufficient time to create strong adhesive interactions rather they form very 
transient interactions and only forming stable interactions during cellular 
activation. Leukocytes do not degrade ECM and thereby do not remodel the 
cellular microenvironment (Shulman & Alon 2012). In contrast fibroblasts 
migrate at velocities of 1%m/min with strong ECM interactions and 
adhesion, utilising a key function of matrix metalloproteinases (MMPs) that 
can lead to ECM degradation (Wolf et al. 2003; Wolf et al. 2007). 
 
Typically, a migratory cancer cell, potentially capable of metastasis, is 
thought to follow a mesenchymal route of migration. This happens through 
the expression of a mesenchymal gene profile potentially through the process 
of EMT. In mesenchymal cells and migrating cancer cells lamellipodia and 
filopodia form a meshwork of branched actin filaments (Chhabra & Higgs 
2007; Small 2010). The force of actin polymerisation toward the leading edge 
of a cell induces the edge to push forward into the area in front of the cell 
driving the cell forward. Active and yet unengaged integrins and receptors 
are continually recycled to and from the leading edge, sampling the ECM 
and cellular microenvironment in front of the cell to determine changes in 
migration direction depending on local environmental cues (Galbraith et al. 
2007). 
 
The process of cellular migration not only requires the actin polymerisation 
and integrin recycling but also the rear edge of the cell has to detach in a 
controlled manner enabling a push from behind. During detachment, 
retracting fibres are formed at the rear of the cell which assist in the 
detachment process. However, this can lead to a loss of membrane with a 
major fraction of integrin-containing membranous material is left behind. 
This action creates migration tracks left by the cell which marks the route it 
! 35!
has taken that have been observed both on glass and on matrix substratum 
(Kirfel et al. 2004). The membranous deposit left behind is rich in "1 integrins 
and results from a membrane ripping process (Palecek et al. 1996; 
Lauffenburger & Horwitz 1996). Tracks laid down by cells, and in particular 
by fibroblasts migrating through the ECM, have been shown to be used by 
cancer cells as routes upon which they can migrate (Scott et al. 2010; Gaggioli 
et al. 2007). Without such routes, some cancer cells may be unable to migrate 
through ECM, thus this particular process of fibroblast lead collective 




Metastasis is defined as the ability of tumour cells in a primary tumour to 
invade other tissues and to spread throughout the body (Selivanova & Ivaska 
2009). Terminal prostate cancer is the result of metastatic spread of the 
tumour from the prostate to peripheral sites primarily the bone and lymph 
nodes. The process involves the migration of the primary tumour cells, 
circulation, homing, invasion and growth of a new tumour (Welch & Rinker-
Schaeffer 1999). 
 
Although the exact molecular pathways required for this process are 
unknown, studies have shown that loss of function of specific genes interfere 
with the metastatic process (Yoshida et al. 2000; X. Yang et al. 1997). 
Classically, metastasis is thought to be preceded by EMT whereby the highly 
polarised and ordered epithelial cells change morphologically in to a 
mesenchymal state losing polarity and gaining migratory capacity (Thiery 
2002). This process involves the down regulation of epithelial proteins such 
as E-cadherin and the upregulation of mesenchymal associated proteins such 
as vimentin (Jechlinger et al. 2003). Briefly, this enables them to breach the 
basement membrane, migrate out in to the ECM and infiltrate either the 
lymphatics or blood vasculature. The disseminated cells have to then 
establish at a secondary anatomical site where outgrowth of the secondary 
tumour occurs (Geiger & Peeper 2009). 
 
Prostate cancer has an extremely high propensity to metastasise to the bone 
(Carducci & Jimeno 2006). There are many features of the bone marrow 
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which make it an attractive place for tumours to seed and grow. These 
features include growth factors such as vascular endothelial growth factor 
(VEGF), high levels of CXCL12 expression, physical features such as hypoxia 
which can stimulate the tumour cells to in turn stimulate osteoclast function 
in a viscous cycle promoting tumour growth in bone (Kingsley et al. 2007). 
Osteonectin, a glycoprotein important in bone formation, has also been 
found to enhance the invasion of prostate cancer cells in to bone through a 
mechanism that remains unclear (N. Chen et al. 2007). 
 
Osteonectin, also known as Secreted Protein Acidic and Rich in Cysteine 
(SPARC) has been linked to cell proliferation, morphology and the binding 
of collagen (H. Sage, Decker, et al. 1989a; H. Sage, Vernon, et al. 1989b). 
Along with being a principal component of the bone microenvironment, 
SPARC expression is increasingly being linked to cancer cells in a variety of 
cancers. In prostate cancer models, SPARC has been shown to induce PC-3 
cell migration (Jacob et al. 1999), and the expression of SPARC has also been 
linked, and correlates with, the progression of the disease (R. Thomas et al. 
2000). 
 
1.7 Cellular function in 2-D versus 3-D cell culture systems 
A key difference between 2-D cell culture and culture involving a more 
complex environment including the ECM and different cell types, is the 
different physiological 3-D context. Cells employ different techniques, 
signaling pathways, morphology and changes in proliferation when exposed 
to a 2-D flat surface that is often plastic or glass, as opposed to a 3-D 
environment consisting of collagen and other ECM components. Typically 
this 3-D environment will also include other cells which becomes critically 
important when trying to recreate in vivo scenarios in vitro. Most cells in vivo 
inhabit a complex 3-D environment and studies comparing cell-matrix 
adhesions and cytoskeletal organisation have shown important differences 
(Rhee et al. 2007). There are, however, important similarities too. Analysis of 
the cytoskeleton and force measurement via traction force microscopy show 
that, despite the differences in many cell behaviours in 3-D compared to 2-D 
environments, the forces generated within either culture system are 
remarkably similar (Kraning-Rush et al. 2011). 
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Signaling pathways employed in 3-D environments can differ significantly or 
not feature at all when considering migration in 2-D. One such pathway is 
the MEK-cofilin signaling pathway in human T cells which exclusively 
mediates migration in 3-D, but not in 2-D. During T cell migration Ras 
localised in the lamellipodium activates MEK which in turns inhibits LIM 
kinase 1. This allows the dephosphorylation of cofilin – a protein that 
remodels f-actin during T lymphocyte migration (Klemke et al. 2010). This 
work was carried out in human T cells, but work carried out on tumour and 
tumour-associated stromal cells showed that the same LIM kinases were 
required for invasive path generation by fibroblasts in tumour cell migration 
in 3-D independent of MEK-mediated regulation (Scott et al. 2010). 
 
Analysis of mesenchymal migration using mouse embryonic fibroblasts 
(MEFs), has shown that the movement of MEFs depends on focal adhesion 
formation and disassembly (Friedl 2004). The focal adhesion protein NEDD9 
has been shown to localise to focal adhesions and has now been shown to 
have a key role in focal adhesion disassembly specifically. MEFs null for 
NEDD9 move faster on 2-D surfaces but significantly slower in 3-D collagen 
matrices (Zhong et al. 2012). Having previously been reported as a pro-
metastatic protein (O'Neill et al. 2007) this is now being considered as a 
potential therapeutic target. 
 
The 2-D approach to cell migration assays continues to be commonly used, 
particularly in high-throughput experiments. This could bias the 
experimental outcomes when investigating, particular when considering 
growth factor-induced cancer cell migration. Whilst the migration properties 
of breast cancer cells in 2-D do not correlate with their behaviour in 3-D, 
there is a robust relationship between membrane protrusions elicited by 
growth factor stimuli and subsequent enhanced migration in 3-D (Meyer et 
al. 2012). Using a panel of seven growth factors and serum, it was shown that 
the acute lamellipodial protrusion dynamics of the breast cancer cells can 
predict motility within 3-D collagen I matrices. By characterising this process 
it is possible to use a 2-D assay, in some instances, to predicts outcomes of 3-
D assays without the need to carry them out (Meyer et al. 2012). The reason 
for the continued use of 2-D assays as opposed to 3-D assays is mainly due to 
technical difficulty. The known differences in cell movement between 2-D 
and 3-D calls in to question whether anti-migratory drugs should be 
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screened in vitro, in 3-D (Zaman et al. 2006; Fraley et al. 2010). A 
comprehensive review concluded that no single in vitro 2-D assay is 
sufficient to analyse migration and that 3-D assays offer a far more complex 
and physiologically relevant model, but there has to be standardisation in 
order to produce efficient quantitative analysis of cell migration in 3-D drug 
screening (Decaestecker et al. 2007). 
 
1.8 Two-photon Imaging Technologies 
Two-photon excitation fluorescence microscopy or multi-photon laser 
scanning microscopy (MP-LSM) has been widely used for imaging cells and 
tissues (Denk et al. 1990). It has many advantages over single photon 
confocal microscopy such as higher depth penetration, less phototoxicity and 
second harmonic generation (SHG). SHG is a second-order nonlinear optical 
process that has symmetry constraints confining signal to regions lacking a 
centre of symmetry (Campagnola et al. 2002). SHG results from secondary 
structures detected in samples when light is reflected back at exactly half the 
excitation wavelength and is collected in a non-descanned detector (NDD). 
This process does not involve the use of fluorescent proteins or fluorophores. 
Collagen I SHG is frequently used in the intravital imaging of tissues 
(Georgiou 2000; Theodossiou et al. 2006). 
 
Two-photon imaging relies on extremely short pulses (in the order of femto-
seconds) of longer wavelength (near infrared) light. A fluorophore is only 
excited when two or more photons are absorbed at twice the normal 
excitation wavelength compared to single photon excitation. As such, half 
the energy is used, thereby lowering the levels of energy the sample 
experiences hence lower phototoxicity (Provenzano et al. 2009). Also, the 
excitation field volume is lowered due to the fact that excitation remains 
strictly within the focal volume thereby further decreasing phototoxicity 
(Squirrell et al. 1999). 
 
The development of two-photon microscopy has greatly enhanced the 
imaging of living tissues and in vitro cell culture models and provides a 
powerful platform for studying single cell behaviour in ever more complex 
microenvironments both in vitro and in vivo. Using two-photon imaging, 
fluorescence lifetime imaging microscopy (FLIM) can be used to monitor 
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metastasis in the context of the tumour microenvironment. Through FLIM, a 
detailed understanding of single cell behaviour within a multi-cellular and 
ECM rich microenvironment has been achieved and has provided key 
insights into the process of tumour metastasis (Provenzano et al. 2009). FLIM 
takes advantage of the intrinsic differential excited state lifetimes of 
fluorophores, both endogenous and exogenous, and can be used to create a 
map of the environment. This phenomenon has been used to study 
molecular parameters, local environment changes, metabolic states of cells 
(Bird et al. 2005) and protein-protein interactions (Becker 2012). This 
technique can utilise the endogenous fluorescence of cellular metabolites. 
 
Intravital imaging using two-photon microscopy has been key to 
understanding how the immune system functions in vivo (Germain et al. 
2012). More recently this approach has been used to study mechanisms of 
bacterial and parasitic infection (Beattie et al. 2010; Beattie et al. 2011; 
Germain et al. 2012; Tam et al. 2011; Chtanova et al. 2008; Junt et al. 2007), 
and to tracking cellular migration and cell fate in 4-dimensions in developing 
mouse embryos (Liu et al. 2011).  
 
Two-photon microscopy has had a significant impact on understanding 
mechanisms of tumour metastasis. Initial studies of GFP expressing breast 
cancer cells in primary tumours in situ with two-photon microscopy allowed 
visualisation of single cancer cell behavior (W. Wang et al. 2002). This study 
allowed for the first time, the correlation between gene array data and in vivo 
observations within the primary tumour (W. Wang et al. 2002). The 
capability of FLIM in cancer studies has been used to study the process of 
tumour cell invasion in a 3-D collagen matrix, which was used to study drug 
uptake and toxicity through its capacity to detect 3-D topography, cellular 
kinetics and biological outputs (Bakker et al. 2012). 
 
By utilising two-photon imaging of in vitro organotypic culture models, the 
role of tumour fibroblasts in remodeling the ECM was analysed in cultures 
where carcinoma cells retained their epithelial phenotype (Gaggioli et al. 
2007). These tumour cells had not undergone EMT which had previously 
been thought to be a prerequisite of epithelial cells to take on a more 
mesenchymal phenotype in order to migrate, invade, and metastasise 
(Thiery 2002). Two-photon imaging of fluorescently labeled fibroblasts 
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mixed with squamous cell carcinoma (SCC) cells allowed deep imaging in to 
the matrix, over time, revealing a leading role for the fibroblasts. The 
fibroblasts were seen to lead a group of migratory SCC cells in to the matrix, 
whereas in the absence of fibroblasts, no invasion was seen despite the 
continued motility of SCC cells being evident (Gaggioli et al. 2007). Later, 
using a similar technique the LIM kinases were shown to have an essential 
role in this process of path generation by leading fibroblast cells during 
collective cancer cell invasion (Scott et al. 2010). 
 
More recently two-photon laser scanning microscopy has also been 
developed as a tool for the diagnosis of superficial skin cancers. Through 
employing the unique properties of such imaging it is possible to visualise 
human skin at the bedside using endogenous flouresecent proteins and 
metabolites including NADH, keratin, melanin and collagen (Paoli et al. 
2009).  
 
The use of two-photon microscopy in using in vitro 3-D models and in vivo 
intravital models is an extremely powerful tool in cancer research. In this 
thesis I have utilised two-photon confocal microscopy to carry out high-
resolution, long term 3-D imaging of human prostate cancer cells to 
investigate the mechanisms of human prostate cancer cell migration. 
 
1.9 Summary and Aims  
The underlying mechanisms leading to the induction of human prostate 
cancer remains unknown. Significant advances have been made in the field 
identifying key signaling pathways and the roles of different cell types and 
proteins in disease progression. Potential targets for drug discovery continue 
to be identified, but to date, there is no vaccine or successful treatments for 
high grade human prostate cancer. Current in vitro models of prostate cancer 
do not recreate the complex microenvironment found in vivo including the 
incorporation of primary human stroma. Whilst mouse models and 2-D 
studies on tumour cells have developed molecular insights into prostate 
cancer formation many questions remain unanswered, particularly in regard 




The role of prostate stroma in cancer cell migration, development and 
metastasis is largely unknown. The molecular mechanism of stroma 
mediated cancer cell migration is an emerging area of cancer biology 
research. The initiating event(s) which leads to prostate cancer becoming an 
invasive metastatic disease is also largely unknown therefore it is important 
to generate and utilise advanced 3-D co-culture methods, to study cell 
migration, invasion and metastasis. 
 
The role of CSCs in tumour metastasis are unknown. It has been shown that 
the putative CSCs in prostate cancer can recapitulate the full complement of 
disease both in vitro and in vivo but the relative capacity of CSCs to migrate is 
unclear. The role of cancer stem cells in the metastasis process may lead to 
new insights into how tumours metastasise and form secondary tumours. 
 
Therefore, the aims of this thesis are to develop an advanced 3-D model of 
cell migration in the context of prostate cancer and utilise this model to 
address a number of questions focused around cancer cell migration. The 
objectives of this thesis are: 
 
1) To develop and validate a 3-D in vitro model of stroma-epithelial cell 
migration within a suitable ECM. 
2) To investigate the role of stroma in cancer cell migration. 
3) To characterise the properties of CSCs within the 3-D model. 
4) To address the molecular mechanism of stroma mediated prostate 
cancer cell migration. !  
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Figure 1.1 Above: H&E stained section of normal human prostate tissue showing 
secretory glands consisting of columnar epithelial cells surrounded by the stroma 
(John Hopkins University School of Medicine). Below: Graphical representation of 
the bilayer of epithelial cells consisting of the luminal cells (yellow) and the 
intermediate and basal cells (orange and green). The stroma (dark blue) is separated 
from the epithelium by a basement membrane (white horizontal line). Adapted 








Figure 1.2 Histologic Grading of Prostate Cancer, then and now. The left panel 
depicts the original histologic patterns for standardising the grading system by 
Donald Gleason himself (Gleason DF, 1966) adapted from Gleason DF, 1992. The 
panels on the right depict H&E stained tissue sections of modern day pathology 
scoring of human prostate cancer. The system grades the primary and secondary 
patterns in the section, which are added together to give a final Gleason score 







Figure 1.3 The stem cell model for the persistence of prostate cancer post therapy. 
The model states that the tumour consists of a hierarchy of differentiated cells 
containing a small population of stem cells, typically 0.1% of the tumour. After 
therapy these cancer stem cells persist and can establish a new tumour. Adapted 
from Maitland et al 2005. !  
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Figure 1.4 Basement membranes are thin (50-100nm) consisting of collagen IV, 
laminin, nidogens, perlecan and several minor glycoproteins (not shown). All four 
proteins become crosslinked creating a highly ordered and robust protein network. 
Adapted from (Sorokin 2010). 






Chapter 2  
Materials and Methods 
2.1 Cell culture 
2.1.1 Human prostate cancer cell lines 
PC-3 and PC-3M prostate cancer cell lines were cultured in Hams Nutrient 
Mixture F12 (HAMS-F12) (Lonza) supplemented with 2mM L-glutamine 
(Invitrogen) and 7% Foetal Calf Serum (FCS) (Hyclone). Both cell lines were 
sourced from ATCC via Yorkshire Cancer Research (YCR) and were 
fingerprint matched by STR analysis (Promega) to original ATCC stocks 
routinely. 
 
2.1.2 Human fibrosarcoma cell line 
The human fibrosarcoma cell line HT1080 was cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) (Sigma-Aldrich) supplemented with 2mM 
L-glutamine and 10% FCS. 
 
2.1.3 Primary prostate stromal cells 
Primary stromal cells isolated from prostate tumour biopsies were cultured 
in Roswell Park Memorial Institute formulation 1640 (RPMI-1640) medium 
(Sigma-Aldrich) supplemented with 2mM L-glutamine and 10% FCS. 
 
2.1.4 Human foreskin fibroblasts 
Human foreskin fibroblasts (HFF) were cultured in Minimal Essential 
Medium (MEM) with Earle’s salts and without L-glutamine (Sigma-Aldrich) 
supplemented with 10% FCS, 2mM L-glutamine, 0.1mM non-essential amino 
acids (Invitrogen) and 1mM sodium pyruvate (Sigma-Aldrich). 
 
All cells and cell lines were cultured at 37°C with 5% CO2. 
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2.1.5 Cell passage 
Once cells had reached between 70-90% confluence, culture medium was 
removed by aspiration and discarded. Cells were then rinsed twice with 
Dulbecco’s phosphate buffered saline (D-PBS) containing no CaCl2 and no 
MgCl2 (PAA) to remove all traces of serum. Typically, 1ml 1XTrypsin-
ethylenediaminetetraacetic acid (EDTA) (Gibco) was added per 75cm2 tissue 
culture flask (Corning) and cell/Trypsin mixture was incubated at 37°C with 
5% CO2 for no more than 5 min. Cells were periodically observed under an 
inverted light microscope until cells became rounded and detached from the 
surface. Cells that remained attached were detached from the surface by 
gentle tapping. Complete growth medium containing FCS was then added 
and cells were removed by gentle aspiration, spun at 300 g for 5 min and 
resuspended in complete growth medium. T25, T75 or T125 tissue culture 
flasks (Corning) were used depending on experimental requirements. 
 
2.1.6 Cryopreservation 
Cells were cryopreserved at a density of 0.5 x 106 cells/ml in a 50:50 mix of 
cell-specific culture medium and freezing medium (FCS containing 20% 
dimethyl sulfoxide (DMSO) (Sigma-Aldrich)). The cells were aliquoted in to 
2ml cryovials (Corning), placed in a ‘Mr Frosty’ freezing container (Nalgene) 
which was then allowed to freeze overnight at -80°C. Cells were stored long-
term in liquid nitrogen (LN2). 
 
Recovery of frozen cells was carried out by thawing in a water bath set at 
37°C until ~90% of the ice had melted. 1ml of complete culture medium, 
prewarmed to 37°C, was then added to the 1ml of cells in freeze medium. 
The cells were removed from the cryovial, spun at 300 g for 5 min and 
resuspended in 5ml complete culture medium, prewarmed to 37°C. Once 
resuspended the cells were added to a tissue culture flask and incubated at 
37°C with 5% CO2. 
 
2.2 Primary culture of human prostate cells 
2.2.1 Separation of stromal cells from epithelium 
Tissue was sourced from Hull and East Yorkshire Hospitals NHS Trust in 
accordance with an agreement between YCR at the University of York and 
the Trust and ethical permission (ref: R0609 – 07/H1304/121). Fresh tissue 
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was rinsed in PBS and sliced. A section was set aside for embedding in 
optimal cutting temperature (OCT) compound for histology, with the 
remainder of the tissue diced in to small pieces. Up to 1g of tissue was then 
digested in 7.5ml of collagenase I solution (5ml RPMI containing 10% FCS, 
2.5ml basal containing 1.35mg collagenase I) and then incubated at 37°C 
overnight on an orbital shaker, shaking gently. The mixture was then spun at 
300 g for 10 min to pellet the cells and the supernatant was discarded. The 
cells were resuspended in 10ml PBS and spun at 300 g for 10 min twice more. 
The final cell pellet was resuspended in 10ml RPMI containing 10% FCS and 
the cells were allowed to settle for 15 min at room temperature. Epithelial 
cells will settle and the supernatant will contain fibroblasts and stroma 
(including haematopoietic cells). The suspended cells were collected with a 
Pasteur pipette and the process of spinning, resuspending and settling was 
repeated twice more or until no more epithelial cells settled out. The 
remaining supernatant contains the fibroblast stromal compartment.  
 
2.2.2 Primary stromal cell culture 
The supernatant from section 2.2.1 was spun at 300 g from 15 min, the 
supernatant discarded and cells resuspended in 15ml RPMI containing 10% 
FCS, 2mM L-glutamine and 1% penicillin/streptomycin. The cells were 
added to a T75 tissue culture flask and allowed to settle for at least 2 days at 
37°C with 5% CO2. This incubation is necessary in order to remove immune 
cells, cell debris and erythrocytes from the culture. After 2 days the media 
was aspirated off and 10ml PBS was added to the flask. Gentle agitation was 
applied by hand to loosen any debris and remove any remaining 
erythrocytes. The PBS was aspirated off and replaced with complete RPMI 
media and cells were allowed to grow until ~90% confluence. 
 
2.2.3 CD133+ selection of epithelial stem cells 
Epithelial cells collected in section 2.2.1 were resuspended in 5ml 1x trypsin 
and incubated at 37°C for 30 min whilst shaking in an orbital shaker at 
80rpm. 10ml complete RPMI containing 10% FCS was then added to halt 
trypsinisation and the mix was spun at 300 g for 10 min. The cell pellet was 




A Biocoat collagen I plate (BD Biosciences) was blocked for 1 hour at 37°C 
with 0.3% BSA in PBS. The prewarmed cell mixture was plated out on the 
blocked Biocoat collagen I plate (3ml per plate) and incubated at 37°C for 20 
min. The media was collected from the plate and retained. The plate was 
then rinsed with 1X PBS and was also retained with the media. The cells 
were spun at 250 g for 10 min. This pellet contains the !2"1low fraction 
(luminal and transit-amplifying cells). 
 
Adhered cells (!2"1high) were collected by incubation with 10x trypsin at 37°C 
for 15 min. Cells were collected in complete RPMI containing 10% FCS and 
the process repeated until all cells were collected. Cells were then spun at 250 
g for 10 min and the pellet resuspended in 300%l MACS buffer (PBS/2mM 
EDTA with 0.5% FCS) plus 100%l FcR blocking reagent and 100%l CD133 
beads (Miltenyi Biotec), mixed well, and incubated at 4°C for 30 min on a 
MACS roller. 3ml of MACS buffer was then added to the mix which was 
then centrifuged at 300 g for 10 min. The supernatant was removed and the 
cell pellet was resuspended in 500%l MACS buffer. 
 
A MACS column was saturated with 500%l MACS buffer and allowed to run 
through. The cells were then added to the column to allow magnetic 
separation. The column was then washed three times with 500%l MACS 
buffer with the flow through containing the CD133- population of cells being 
collected. 
 
To obtain the CD133+ population, the column was removed from the 
magnetic clamp and 1ml of MACS buffer was added to the column. This was 
firmly flushed through with a plunger. The cells were then washed once with 
500%l MACS buffer and spun at 300 g for 10 min. Once the supernatant was 
discarded the cell pellet was resuspended in keratinocyte serum-free 
medium (KSFM). 
 
2.3 Cell transfection 
2.3.1 Fluorescent protein vector transfection 
Prostate cancer cell lines PC-3 and PC-3M were each transfected with pCMV-
GFP and pCMV-tdTomato using Lipofectamine® 2000 Transfection Reagent 
(Invitrogen). 24 hours before transfection, 0.5 x 105 cells were added to a 24-
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well tissue culture treated plate (Corning) in 500%l culture medium without 
antibiotics. 0.8%g plasmid DNA was diluted in 50%l Opti-MEM® Reduced 
Serum Medium (Invitrogen) without serum. 2%l Lipofectamine® 2000 
Transfection Reagent was diluted in 50%l Opti-MEM® Reduced Serum 
Medium without serum. The diluted DNA and diluted Lipofectamine® were 
combined, mixed and incubated for 20 min at room temperature. 100%l of the 
DNA/Lipofectamine® mix was then added to the well containing the cells 
and the plate was mixed by gentle rocking. Cells were incubated at 37°C 
with 5% CO2 overnight. Stable cell lines were created by passaging the cells 
1:10 into fresh growth medium 24 hours after transfection with the medium 
changed a further 24 hours later to selective medium containing 200ng/ml 
G418 (Sigma-Aldrich). After 14 days, the highly fluorescent cell populations 
were sorted on a Beckman MoFlo XDP Cell Sorter. The sorted cells were 
maintained in culture as in section 2.1.1. 
 
2.3.2 Inducible shRNA vector transfection 
Bacterial glycerol stocks containing shRNA constructs (Sigma-Aldrich) were 
streaked for single colonies on to LB-Agar plates containing 100%g/ml 
ampicillin and incubated for 24 hours at 37°C. To obtain plasmid DNA, 
single colonies were picked and grown overnight in Luria Broth (LB) 
containing 100%g/ml ampicillin at 37°C whilst shaking. A Plasmid Midi Kit 
(Qiagen) was used to purify plasmid DNA to a high concentration and 
purity. Plasmid DNA was run on a 1% agarose gel via gel electrophoresis 
and purity was assessed by a NanoDrop (Thermo Scientific). Plasmid DNA 
was transfected in to PC-3 cells using a Neon® Transfection System 
(Invitrogen) using the following electroporation parameters; pulse voltage: 
1250v, pulse width: 30ms, pulse number: 1, cell density: 0.5 x 106 cells/ml, tip 
type: 10%l. Transfected cells were selected for in the presence of 200ng/ml 
neomycin 72 hours after transfection. The cells remaining were treated as a 
bulk culture. Single cell clones were obtained by plating transfected cells in 
to a 96-well tissue culture plate at a density of 0.5 cells/well. Each well was 
checked for the presence of a single cell 24 hours later and marked. Cell 
culture medium was changed every 3 days and once cells were ~80% 
confluent, they were passaged in to larger culture vessels from a 96-well 
plate, to a 48-well plate, etc. until there were enough cells to seed a T75 75cm2 
tissue culture flask. Single cell clones were kept under 200ng/ml neomycin 
selection thereafter. The shRNA construct was induced by adding dioxin-free 
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Isopropyl "-D-1-thiogalactopyranoside (IPTG) (Sigma-Aldrich), 
reconstituted in sterile water, to a final concentration of 100mM in normal 
complete HAMS-F12 media for 3 days. Wildtype PC-3 cells which had not 
been transfected with shRNA were used as experiment controls. 
 
2.4 Collagen 
2.4.1 Collagen preparation 
Type I Collagen was prepared from adolescent rat tails following a protocol 
adapted by myself and Roger Leigh (Coles Group) based on published 
methods (B. R. Williams et al. 1978). Preparation took place under sterile 
conditions with all solutions and equipment 0.2%m filter sterilised and/or 
autoclaved where applicable. Rat tails from juvenile male rats were skinned 
and the proximal and distal ends removed. Each joint was then in turn 
snapped and pulled away from the main body of the tail using a hæmostat 
clamped on either end. The dislocated joint was pulled drawing out the 
tendons through the tail. Tendons were then cut from the dislocated joint 
and placed in sterile water and washed briefly in 95% ethanol before being 
briefly dried and then weighed. Tendons were then dissolved in 50ml 0.5M 
acetic acid per 1g of tendon at 4°C for no longer than 36 hours and 
tendon/acetic acid was then centrifuged for 60 min at 20,000 g at 4°C. The 
supernatant was retained and stored in aliquots at 4°C. In order to reduce 
acidity, dialysis or lyophilisation was used. 
 
Collagen in 0.5M acetic acid was dialysed against a great excess of 0.1X 
DMEM in 0.02M acetic acid at 4°C using high retention seamless cellulose 
tubing (Sigma-Aldrich). The buffer was replaced twice over 3 days and the 
final dialysed collagen was stored in aliquots at 4°C. Collagen concentration 
was determined using a Bradford assay and adjusted to 3.33mg/ml.  
 
Alternatively, collagen in 0.5M acetic acid was also lyophilised in a bench top 
Lyotrap lyophiliser (LTE) and reconstituted in 0.02M acetic acid at a known 
concentration of 3.33mg/ml. 
 
2.4.2 Collagen gels 
Collagen gels were prepared on ice by adding cooled 10X DMEM containing 
phenol red to collagen prepared as in section 2.4.1 to achieve a final DMEM 
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concentration of 1X and a final collagen concentration of 3mg/ml. The 
collagen/DMEM mixture was then neutralised to pH7.0-pH7.5 using cooled 
1M NaOH. The pH was monitored using the phenol red colour change and 
the final pH was confirmed using pH indicator strips (VWR). For single cells 
suspended in collagen, pelleted cells were resuspended in neutralised 
collagen once the growth medium had been removed by aspiration. The 
collagen gel/cell mix was then added to a cooled PEI treated 3.5cm Glass 
Bottom Dish (MatTek) and allowed to set at 15°C for 1hr. Alternatively, 30%l 
collagen alone was added to the centre of a PEI-treated stainless steal washer 
support (internal diameter 6mm) previously adhered to the glass surface of a 
PEI treated 3.5cm Glass Bottom Dish by vacuum grease, all kept on ice. 
Spheroids, as prepared in section 2.13 were then introduced in to the gel by 
pipetting. Once enough spheroids had been added to the gel, the whole dish 
was incubated at 15°C for 1hr to allow collagen gel to set. Enough complete 
growth medium was then added to the dish to cover the gel taking care to 
wet the collagen gel first by adding the medium slowly to prevent 
mechanical disruption of the gel. The dish containing the cells/spheroids in 
collagen was then incubated at 37°C with 5% CO2 before imaging. 
 
2.5 Poly(ethylenimine) surface treatment 
Collagen does not adhere to most surfaces effectively and so to counteract 
this a protocol was developed to surface treat the glass and metal surfaces 
with poly(ethylenimine) (PEI) (Sigma-Aldrich). Glass surfaces and metal 
supports used in the formation of collagen gels were washed once with 95% 
ethanol and allowed to dry. All surfaces to come in to contact with collagen 
were treated with 1% PEI for 10 min and then washed once with 95% 
ethanol. Once dry, the PEI coated surfaces and/or supports were 
functionalised with 1% glutaraldehyde for 30 min followed by washing six 
times with sterile water. All items were then air dried thoroughly before use. 
 
2.6 Matrigel 
Frozen aliquots of Matrigel™ were thawed on ice. All materials to come in to 
contact were kept cool on ice, including pipette tips which had been stored at 
-20°C until use. Once thawed, Matrigel™ was added to the base of a 3.5cm 
glass bottom dish and allowed to set at 37°C for 30 min before the addition of 
2.5ml pre-warmed complete media containing cells. The dish was then 
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returned to the incubator in 37°C with 5% CO2 typically overnight. For gels 
containing cells, the appropriate number of cells were pelleted by 
centrifugation at 300 g for 5 min. Media was removed by aspiration and the 
tube and pellet were cooled on ice for at least 5 min. Cell pellets were 
resuspended in Matrigel™ gently but quickly before being swiftly added to a 
3.5cm glass bottom dish. The gel was set at 37°C for 30 min before the 
addition of 2.5ml complete media pre-warmed to 37°C. The dish was then 
returned to the incubator at 37°C with 5% CO2 typically overnight. 
 
2.7 CFSE labeling of prostate stroma 
Stromal cells were collected from culture flasks via trypsinisation as in 
section 2.1.5. The cells were then washed via centrifugation in serum-free 
RPMI media warmed to 37°C. The cells were then resuspended in warm 
serum-free RPMI media containing 5%M carboxyfluorescein diacetate, 
succinimidyl ester (CFSE) (Invitrogen) (1:2000 dilution from a 10mM stock) 
and incubated for 8 min. After flooding immediately with excess cold RPMI 
media supplemented with 10% FCS, cells were washed once with complete 
RPMI media and twice in serum-free RPMI media at which point they were 
ready to be counted and utilised. !
2.8 Cell tracker staining 
CellTrackerTM Green (CMFDA) (Invitrogen) at a stock concentration of 10mM 
was used to make a dye mixture containing a final concentration of 5%M 
(1:2000 dilution) in serum free media. After warming to 37°C, 5ml of the dye 
mixture was added to cells that had previously been trypsinised from the 
culture flask and pelleted by centrifugation at 300 g for 5 min. The cell/dye 
mix was gently mixed by pipetting and incubated at 37°C for 30 min. Cells 
were pelleted by centrifugation at 300 g for 5 min and the dye mixture 
removed by aspiration. Normal media containing 10% serum was added and 
the cells resuspended by gentle pipetting and the mix incubated at 37°C for a 
further 30 min. Labeled cells were then ready to use. CellTrackerTM Red 
(CMTPX) (Invitrogen) was also used as described for CMFDA in this section, 
however prior to making the initial 5%M dye mixture, undiluted CMTPX 
was mixed 1:1 with Pluronic F-127 (Invitrogen) to facilitate dissolving. 
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2.9 Cytospins and Giemsa staining 
Cells were collected via trypsinisation as in section 2.1.5. 2.0x105 and cells 
were spun at 300 g for 5 min, the supernatant aspirated and discarded and 
cells were resuspended in 200%l PBS. 2.0 x 105 cells in 200%l PBS were spun 
on to polysine slides (VWR) using a cytospin centrifuge at 1800 rpm for 3 
min. Cells were then fixed in 100% methanol and allowed to air dry. Fresh 
Geimsa reagent (3.6ml Sorenson A (9.5g Na2HPO4/L dH2O) + 1.4ml Sorenson 
B (9.07g KH2PO4/L dH2O) + 45ml dH2O + 5.55ml Giemsa stain) was 
prepared and used in which to incubate the slides at room temperature for 20 
min. Slides were then thoroughly rinsed in running water and allowed to air 
dry before coverslips were mounted using DEPEX mounting medium 
(Sigma-Aldrich) and visualised using phase contrast microscopy. 
 
2.10 Immunocytochemistry of prostate stromal cells in 3-D 
Prostate stromal cells in 30%l collagen gels were fixed for 1 hour in 4% 
paraformaldehyde (PFA) at room temperature. Gels were washed three 
times over a total of 30 min in PBS containing 0.5% TritonTM X-100 (Sigma-
Aldrich). Gels were then incubated in PBS containing 0.5% TritonTM X-100 for 
30 min in order to render cells permeable. The f-actin stain Phalloidin Alexa 
647 (Fluka) and the nuclear stain YO-PRO (Invitrogen) were mixed together 
at a dilution of 1:1000 in PBS. Gels were incubated overnight in the dye 
solution at 4°C whilst slowly shaking. The next day, gels were washed three 
times in PBS containing 0.5% TritonTM X-100 over the course of 8 hours before 
being fixed in 4% PFA for 30 min. The PFA was replaced with PBS and the 
gels were imaged on a Zeiss 710 confocal microscope. 
 
2.11 Quantitative Real-Time Reverse Transcriptase PCR 
2.11.1 RNA isolation 
Cells were spun at 300 g for 5 min. The supernatant was aspirated and the 
cell pellet was disrupted by resuspension and agitation in 350%l of RLT 
buffer (Qiagen). RNA was isolated using QIAshredders and RNeasy spin 
columns according to the manufacturer’s (Qiagen) instructions. The eluted 
RNA was quantified for concentration and analysed for purity on a 
NanoDrop (Thermo Scientific). 
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2.11.2 cDNA synthesis 
cDNA synthesis from previously isolated RNA as in section 2.11.1 was 
carried out using an EZ-First Strand cDNA Synthesis Kit For RT-PCR 
(Geneflow). Briefly, 1%g of RNA was added to a primer mixture containing 
1%l 40%M oligo(dT)20 primer and DEPC-Treated water up to a final volume 
of 10%l in a 0.2ml thin-walled PCR micro-centrifuge tube. This was mixed 
gently and incubated at 70°C for 10 min and then rapidly placed on ice. To 
the RNA/Primer mix, 8%l of Reaction Mix (2.5X) and 2%l of 100mM DTT was 
added and mixed gently. The reaction mix was then incubated at 42°C for 60 
min and the synthesis reaction terminated by incubating at 70°C for 15 min. 
The cDNA synthesised was then stored at -20°C or used immediately in RT-
PCR experiments. 
 
2.11.3 Primer design 
Gene specific primers were designed using Gene and Primer-BLAST (NCBI). 
All primers spanned an exon-exon boundary to rule out binding to any 
genomic DNA contamination. Primers were ideally 18-22 base pairs in 
length, resulting in a PCR product of between 75 – 120 base pairs in length, 
with a Tm of 60°C ± 1°C. Primers used for RT-PCR are detailed in Table 2.1. 
 
2.11.4 RT-PCR 
cDNA generated as in section 2.11.2 was diluted to a final volume of 100%l 
by adding 80%l of DEPC-treated water. An RT-PCR mix was made up 
consisting of 12.5%l of SYBR Green (Applied Biosystems), 8.5%l of dH2O, 1%l 
of forward primer (1%M) and 1%l of reverse primer (1%M). The resulting mix 
was added, in triplicate, to the appropriate wells of a MicroAmp Optical 96-
well reaction plate and 5%l of cDNA was added to the RT-PCR mix. After 
being sealed the plate was loaded on to an ABI Prism 7000 RT-PCR machine. 
The RT-PCR was carried out using the following thermal cycling program: 
50°C for 2 min, 95°C for 10 min, 40 cycles of 95°C for 15 sec + 62°C for 30 sec 
+ 72°C for 30 sec, then 72°C for 5 min. The plate was then cooled to 4°C until 
the machine was shut down and data was analysed using the 7000 system 
SDS software. Primers for the housekeeping gene GAPDH were used as a 
housekeeping control to which the expression of target genes was 
normalised to. !  
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Table 2.1 Primers for RT-PCR !  
































































Table 2.1 Primers for RT-PCR, continued !  
































































2.12 Methyl cellulose preparation 
6mg of methyl cellulose (Sigma-Aldrich) was autoclaved and dissolved in 
250ml DMEM or HAMS-F12 medium pre-heated to 60°C. A further 250ml 
room temperature media was added and mixed at 4°C for 2 hours and the 
total 500ml was centrifuged at 2500 g for 1 hour. The clear supernatant was 
retained as a 2.4% (w/v) stock and stored at 4°C in aliquots. 
 
2.13 Spheroid formation 
All spheroids were formed in 0.3% (w/v) methyl cellulose in either DMEM 
or HAMS-F12 media depending on cell type, using a hanging drop culture 
method. This protocol was adapted from Laib et al (Laib et al. 2009). 
Typically, cells (starting number varied between experiments) were spun at 
300 g for 5 min in a Universal tube. The supernatant was aspirated and the 
cell pellet was resuspended in 0.3% (w/v) methyl cellulose to a final cell 
density of 1 x 105/ml. The cell/methyl cellulose mix was then pipetted on to 
the base of a petri dish in discreet aliquots of 25%l to give 2.5 x 103 
cells/droplet. The base of the petri dish was then inverted to create the 
hanging drop culture and incubated overnight at 37°C with 5% CO2. Sterile 
water was added to the petri dish to maintain humidity and prevent 
evaporation of the methyl cellulose. Spheroids which had formed overnight 
were gently washed from the plate with PBS containing 10% FCS prewarmed 
to 37°C and spheroids were then ready to be implanted in to collagen gels by 
pipetting. !
2.14 Imaging 
2.14.1 2-photon microscopy 
2-photon imaging was carried out both on a Zeiss LSM 510 Meta NLO 
microscope and a Zeiss LSM 780 Meta NLO microscope. Typically, images 
were acquired using a C-Apochromat 40x/1.1W Corr UV-VIS-IR objective 
and 3 non-descanned detectors (NDD, LSM 510) or 1 NDD and 2 GaAsP 
detectors (LSM 780). The sample was excited using a Chameleon XR 
Ti:sapphire laser (Coherent) tuned to 870nm. GFP emission was collected via 
a 500-550nm band pass emission filter in NDD2 (LSM510) or GaAsP1 
(LSM780). Td-tomato emission was collected via a 575-640nm band pass 
emission filter in NDD3 (LSM510) or GaAsP2 (LSM780). Second Harmonic 
Generation (SHG) emission of collagen was collected via a 415-435nm band 
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pass emission filter in NDD1 (LSM510 and LSM780). The microscope stage 
was maintained at 37°C by a blackout environmental chamber (Solent 
Scientific, UK). 
 
2.14.2 Confocal microscopy 
All immunohistochemistry and immunocytochemistry experiments were 
imaged using a LSM 710 laser scanning confocal microscope on an 
Observer.Z1 inverted base (Zeiss) using 0.5 and 1.4 numerical aperture (NA) 
20X and 40X objectives (Zeiss). Multiple microscope, filter and laser line 
configurations specific to each experiment were used. For comparative 
imaging and subsequent analysis between samples, laser power and detector 
gain voltage and offset were kept constant. Routinely, multi-track imaging 
was used to minimise bleedthrough. 
 
2.14.3 Stereo microscopy 
Whole tumours resulting from PC-3-tdTomato cells were visualised for red 
fluorescence using a SteReo Lumar stereo microscope (Zeiss) with a BDO100 
mercury lamp. Images were collected with an AxioCam digital CCD camera 
(Zeiss). This set up was also used to look for metastases resulting from PC-3-
tdTomato metastasis from the main tumour. 
 
2.14.4 Bright-field live cell imaging 
Cells were seeded in to 3.5cm glass bottom dishes and allowed to attach 
overnight at 37°C with 5% CO2. Cells were imaged in a live cell imaging 
chamber on an Andor Revolution CD spinning disk microscope scope using 
a 0.5NA 20X objective (Zeiss). The live cell imaging chamber was kept at a 
constant 37°C with a gas supply containing 5% CO2 in air. Images were 
acquired over 6 hour periods at intervals of 5 min unless otherwise stated. 
Analysis was carried out using the imaging analysis software package 
ImageJ. 
 
2.14.5 Transmission electron microscopy 
Whole collagen gels containing HT-1080 cells were prepared by fixation in 
transmission electron microscopy (TEM) fixative composed of 5ml 200mM 
phosphate buffer (pH 7.2), 2.5ml 16% PFA, 1ml 25% glutaraldehyde (Sigma) 
and 1.5ml dH2O to give a final concentration of 4% PFA and 2.5% 
glutaraldehyde in 100mM phosphate buffer. 
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Samples were fixed at 4°C overnight and then washed three times in 
phosphate buffer. Samples were then stored in phosphate buffer at 4°C. 
Fixed samples were stained with 1% (w/v) osmium tetroxide followed by 
dehydration using an acetone series before being embedded in Spurr’s resin. 
Ultrathin sections (approximately 80nm) were transferred to TEM grids and 
were stained with uranyl acetate and Reynold’s lead citrate prior to imaging. 
 
Imaging was carried out using a TECNAI G2 TEM (FEI, Hillsboro, Oregon, 
USA) with a MegaView III CCD (Olympus, Münster, Germany). 
 
2.15 Migration assays 
Migration assays were carried out using 8µm pore size PET trans-well inserts 
for 24-well plates (VWR) in a 24-well plate (VWR). According to the 
manufacturer’s instructions and published techniques (Xue et al. 2009) 800%l 
media was added to the lower well and a defined number of cells were 
seeded on top of the insert in 300%l media at a density equivalent to 80% 
confluence as a proportion of a T75 culture flask, thus, PC-3 cells were 
seeded at 2.8 x104 cells/cm2. At set time points inserts were removed and 
fixed in 4% PFA for 10 min before cells on the upper surface were removed 
by scraping. The membrane was removed from the insert and mounted on a 
glass slide under a coverslip and imaged using an LSM 710 inverted confocal 
microscope. 
 
2.16 Tissue digestion 
Mice were sacrificed and the tumour(s) excised. As much hair, skin and fat 
was removed as possible and all tumours were measured using calipers 
(dimensions X, Y and Z) and weighed to the nearest mg. A small piece 
(approximately 5mm3) of tumour was excised from the main bulk of the 
tissue and cut in to several smaller pieces (approximately 0.5mm3). The 
pieces were placed in digestion buffer 1 (1.5ml RPMI containing 2% FCS + 
37%l Collagenase.D + 2.5%l DNAse I) allowed to digest at 37°C in a heat 
block with vigorous shaking at 900rpm. At intervals of 15 min the tissue 
pieces were mechanically disrupted by pipetting before being returned to the 
heat block. After 60 min the sample was further disrupted mechanically by 
pipetting 5-6 times and spun down at 1400rpm for 5 min. The supernatant 
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was then discarded and 1.5ml digestion buffer 2 (1.5ml RPMI containing 2% 
FCS + 37%l Collagenase.Dispase + 2.5%l DNAse I) was added. The mix was 
then incubated at 37°C for 30 min whilst shaking at 900rpm, with mechanical 
disruption by pipetting performed half way through. After 30 min of 
incubation, 15%l 0.5M EDTA was added and the mix was resuspended by 
vortexing briefly. Cells were then filtered through a 40%m cell strainer 
(Corning) into a 50ml Falcon tube (Corning) containing 8.5ml RPMI 
containing 2% FCS. The filter was rinsed with 10ml RPMI containing 2% FCS 
and cells were spun down at 300 g for 10 min. Cells were resuspended in 
10ml RPMI containing 2% FCS and counted. Typically 1 x 105 cells were spun 
down and resuspended in FACS buffer (PBS containing 0.05% bovine serum 
albumin (BSA)) for analysis by flow cytometry. 
 
2.17 Flow cytometry analysis of cell surface marks 
2.17.1 Antibody staining 
1 x 105 cells were aliquoted into 15ml centrifuge tubes and spun at 300 g for 5 
min and resuspended in 500%l FACS buffer (PBS + 0.05% BSA) and 
incubated on ice for 10 min. Cells were the spun at 300 g for 5 min, 
resuspended in 500%l FACS buffer and spun at 300 g for a further 5 min. 
Cells were then resuspended in 100%l FACS buffer containing specific 
fluorescent or unlabeled primary antibodies or appropriate isotype controls 
at concentrations specified in Table 2.2 and Table 2.3. The cell/antibody mix 
was incubated for 30 min on ice in the dark. 400%l of FACS buffer was added 
to the cells and the cells were spun at 300 g for 5 min. Cells were washed by 
resuspending in 500%l FACS buffer and spinning at 300 g for 5 min twice 
more. Cells were then immediately run on a CyAn ADP flow cytometer 
(Beckman Coulter). For larger sample numbers (≥12) a U bottom 96-well 
microtitre plate (Sterilin) was used and volumes adjusted accordingly. 
 
Where possible, 5%l 7-Amino-Actinomycin D (7-AAD) (BD PharmingenTM) 
was added 10 min prior to flow cytometry acquisition to exclude nonviable 
cells. Cells positive for 7-AAD in FL3 (PE-Texas Red) were deemed 
nonviable and negated in further analysis. 
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2.17.2 Flow cytometry data acquisition and analysis 
Cells labeled with fluorescent antibodies as in section 2.17.1 were run and on 
a CyAn ADP flow cytometer (Beckman Coulter) controlled by the Summit 
software (Beckman Coulter). Isotype control labeled samples, or unlabeled 
samples only where no isotype control antibodies were available, were used 
to set voltages and typically the threshold was set to 1.0%. Offline analysis of 
acquired flow cytometry data was carried out using the Summit software 
package (Beckman Coulter) and FlowJo. 
 
2.18 Frozen sections 
2.18.1 Frozen tissue sections 
Human tissue was collected from the Yorkshire Cancer Research laboratories 
already frozen in Optimal Cutting Temperature (OCT) compound (Tissue-
Tek). Mouse tissue from PC-3 tumours, LL/2 tumours and xenografts were 
removed from mice and a small piece of tissue, typically with a 2-D surface 
of approximately 5mm2, was removed using a scalpel and tweezers and 
placed in a disposable vinyl specimen mold (Cryomold, Tissue-Tek). The 
tissue sample was then completely covered with OCT compound and the 
Cryomold placed directly on dry ice until the OCT turned white indicating 
the sample was frozen. Frozen tissue samples in OCT were stored at -80°C 
until use. A cryostat (Leica Microsystems) was used to cut 10%m thick 
sections which were transferred to a polysine slide (VWR). The sections 
attached to polysine slides were allowed to air dry overnight and were 
stored at -20°C in a sealed slide box containing silica gel beads (Sigma-
Aldrich) to absorb residual moisture. 
 
2.18.2 Frozen collagen gel sections 
Collagen gels and tissue containing GFP+ cells were fixed in 4% PFA for 30 
min at room temperature. After rinsing in PBS, samples were placed in 15% 
sucrose solution in PBS at 4°C overnight. This was changed to a 30% sucrose 
solution for 4 hours after which the samples were embedded in OCT and 
placed on dry ice to freeze. Frozen sections of typically 10%m were cut 




2.19 Immunohistochemistry of frozen tissue sections 
Slides were prepared as in section 2.18. Slides were defrosted at room 
temperature for 30 min and tissue sections were fixed in ice cold acetone for 
10 min. After being allowed to air dry the frozen sections were encircled 
using a hydrophobic Immedge pen (Fisher) and allowed to air dry again. 
Sections were rehydrated in PBS containing 0.05% BSA in slide baths for 15 
min. Sections were then blocked in PBS containing 5% goat serum for 30 min 
at room temperature. Subsequently, sections were washed in PBS containing 
0.05% BSA for 5 min. Primary antibodies were diluted in PBS containing 5% 
goat serum and added to the relevant sections and incubated at room 
temperature for 45 min in the dark. Sections were washed once quickly with 
PBS containing 0.05% BSA and then a further 3 times for 10 min each. If a 
secondary antibody step was required, secondary antibody was diluted to a 
suitable concentration in PBS containing 5% goat serum, added to the 
sections and incubated at room temperature for 30 min in the dark. Sections 
were then washed three times with PBS containing 0.05% BSA for 10 min 
each before a final wash in PBS only. Excess PBS was blotted away and slides 
were mounted using ProLong® Gold antifade reagent with DAPI (Molecular 
Probes) and a 22x50mm #1.5 coverslip (VWR). Slides were kept overnight at 
4°C before being sealed with nail varnish. Frozen tissue sections labeled with 
fluorescent antibodies were imaged using a Zeiss LSM 710 inverted confocal 
microscope. A complete list of all primary and secondary antibodies used in 




Table 2.2 Primary Antibodies 
Specificity Fluor Clone Company Use 
!Cytokeratin, Pan Pur PCK-26 Sigma-Aldrich IHC 
!Cytokeratin, Pan 488 AE1/AE3 eBioscience IHC 
!Hu c-Met (HGFR) FITC eBioclone 97 eBioscience FC 
!Hu CD106 (VCAM-1) Biotin 1G11B1 AbCAM FC, IHC 
!Hu CD106 (VCAM-1) Pur STA eBioscience FC, IHC 
!Hu CD133/1 Pur AC133 Miltenyo Biotec FC 
!Hu CD31 488 M89D3 BD Pharmingen FC, IHC 
!Hu CD45 Pur H130 eBioscience FC, IHC 
!Hu CD54 (ICAM-1) PE HA58 eBioscience FC, IHC 
!Hu CD54 (ICAM-1) Pur. HA58 eBioscience FC, IHC 
!Hu Collagen I Pur 721240 AbCAM IHC, ICC 
!Hu Desmin Pur GR20599-1 AbCAM IHC, ICC 
!Hu Fascin Pur 609505 AbCAM IHC, ICC 
!Hu Fibronectin Pur 743700 AbCAM IHC, ICC 
!Hu Integrin !5 488 eBioSAM-1 eBioscience FC 
!Hu Laminin Pur 047k4763 Sigma-Aldrich FC, IHC 
!Hu SMA Cy3 1A4 Sigma-Aldrich FC, IHC 
!Hu SPARC Pur 443481 AbCAM FC, IHC, ICC 
!Ms CD106 (VCAM-1) 647 429 eBioscience FC, IHC 
!Ms CD11c Pur N418 eBioscience FC 
!Ms CD11c APC N418 BioLegend FC 
!Ms CD3 FITC 390 eBioscience FC 
!Ms CD45 APC 30-F11 eBioscience FC, IHC 
!Ms CD45 Biotin 30-F11 eBioscience FC 
!Ms CD45 APC H130 eBioscience FC 
!Ms CD54 (ICAM-1) Pur YN1/1.7.4 eBioscience FC, IHC 
!Ms CD54 (ICAM-1) 647 YN1/1.7.4 BioLegend FC, IHC 
!Ms EpCAM PE-Cy7 G8.8 eBioscience FC 
!Ms F4/80 647 BM8 BioLegend FC 
!Ms GR1 PE RB6-8C5 eBioscience FC 
!Ms Podoplanin 488 eBio8.1.1 eBioscience FC, IHC, ICC 





Table 2.3 Secondary Antibodies !  
Specificity Fluor Company 
Gt!Ms IgG H+L 488 Invitrogen 
Gt!Ms IgG H+L 594 Invitrogen 
Gt!Ms IgG H+L 647 Invitrogen 
Gt!Rb IgG H+L 488 Invitrogen 
Gt!Rb IgG H+L 594 Invitrogen 
Gt!Rb IgG H+L 647 Invitrogen 
Gt!Rt IgG H+L 488 Invitrogen 
Gt!Rt IgG H+L 561 Invitrogen 
Gt!Rt IgG H+L 594 Invitrogen 
Gt!Rt IgG H+L 647 Invitrogen 
Strepavidin 594 Invitrogen 
Strepavidin 647 Invitrogen 
Strepavidin eFluor 450 eBioscience 
Strepavidin PB Invitrogen 
Strepavidin PE-Cy7 eBioscience 
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2.20 Cell Cycle Analysis (DAPI) 
Cells were collected via trypsinisation as in section 2.1.5 and were washed 
once in PBS and spun at 300 g for 5 min. 1x106 cells were resuspended in 
150%l PBS and placed on ice. 400%l ice cold ethanol was then added whilst 
vortexing at low speed to ensure thorough mixing. Cells were spun at 200 g 
for 3 min in a microfuge and the ethanol/PBS removed. Cell pellets were 
resuspended in 500%l PBS containing 0.15% Triton-X-100 and 1%g/ml DAPI. 
Cells were kept on ice until being run on the flow cytometer. Cell cycle 
analysis was carried out offline using the Cell Cycle Analysis protocol within 
FlowJo. 
 
2.21 Absolute cell counts by flow cytometry 
A known number of cells were typically seeded in to 6-well plates in 
triplicate wells. At specific time points, cells were trypsinised, washed one 
with 1X PBS via centrifugation at 300 g for 5 min before being resuspended in 
100%l PBS supplemented with 0.05% BSA. AccuCheck Counting Beads 
(Invitrogen) were thoroughly resuspended before 100%l of beads was added 
to the cell suspension. The mix was then analysed by flow cytometry. 
According to manufacturers instructions, a minimum of 1,000 bead events 
was required to obtain reliable values. For all experiments, a minimum of 
30,000 bead events was collected. 
 
Offline analysis was carried out and beads were gated upon according to size 
and their fluorescence in FL2 (PE channel). The two populations of beads 
(one fluorescent, one not) were confirmed as being at the correct ratio of 1:1 
and the number of cell events was determined by gating on cell events 
according to FSC vs SSC plot. The absolute number of cells was determined 
by following the formula: !"#$%&!!"!!"##$!!"#$%&'!"#$%&!!"!!"#$%!!"#$%&' !!×! "#$%&!!"!!"#$%!!"#!!" 
 
2.22 Agilent microarray 
RNA was extracted from 8 stromal cell cultures as in section 2.11.1. RNA 
quality was assessed on an 2100 Bioanalyzer (Agilent) which produces an 
electropherogram to assess degradation. An RNA Integrity Number (RIN), 
based on the ratio between human ribosomal peaks, of 7-10 was deemed of 
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sufficient quality to be used in the microarray. RNA was amplified, Cy3 
labeled and hybridised with an Agilent Sure Print G3 Hmn GE 8x60k 
Microarry chip (Agilent Technologies, cat no G4851A) according to 
manufacturers instructions. Raw data was generated by running the .tif files 
generated through Agilent’s Feature Extraction software. Further analysis 
was carried out using Microsoft Excel, R or TreeView (Java). 
 
2.23 Mice 
C57BL/6, Rag-/-, Rag-/-Gc-/-, ROR!t-/-, Wnt1-Cre; R26RYFP and IL-4-GFP 
reporter mice were obtained from the Biological Services Facility (BSF) at 
University of York (UoY). All mice were maintained under specified 
pathogen free conditions at the UoY. All animal care and experimental 
procedures were carried out in accordance with United Kingdom Home 
Office requirements and performed with local ethical approval. 
 
2.24 Statistics 
All data were tested for normality using a Kolmogorov-Smirnov test. 
Percentage datasets were arcsine transformed for use in analyses. Paired or 
unpaired t tests were carried out on data fitting Gaussian distributions and 
Mann-Whitney on non-Gaussian distributed data, where comparisons were 
being made between 2 datasets. For multiple datasets of 3 or more, ANOVA 
was used followed by a Tukey’s post-hoc text. Data was analysed in 
Graphpad Prism and SPSS. !  
! 68!
Chapter 3  
The Role of Tumour Stroma in PC-3 
Migration in vitro in 3-D 
!
3.1 Introduction 
3.1.1 PC-3 Human Prostate Cancer Cell Line 
The human prostatic carcinoma cell line PC-3 has been used extensively in 
cancer research for nearly 40 years. It originates from a human prostatic 
adenocarcinoma metastasis to the bone which, when cultured, showed 
anchorage-independent growth and had the capacity to generate 
subcutaneous tumours in nude mice (Kaighn et al. 1979). The three most 
commonly used human cell lines in prostate cancer research are PC-3, DU-
145 and LNCaP. 
 
These human prostatic cell lines have been functionally and phenotypically 
well characterised. PC-3s, along with all other human prostate cancer cell 
lines with the exception of LNCaP, were initially thought not to express 
androgen receptor (AR) and therefore to be non-responsive to androgens 
(Mitchell et al. 2000). Androgen irresponsive PC-3 cells have been used as 
negative control for AR (Chlenski et al. 2001) and were only responsive to 
Androgens when transfected with a full length functional AR, restoring AR 
expression to the level of LNCaP cells (Marchiani et al. 2010; Bonaccorsi et al. 
2000). However, other groups have shown that PC-3 cells do express a low 
level of AR and therefore has implications on function and regulation within 
the cell in in vitro and in vivo assays (Alimirah et al. 2006). Whether PC-3s are 
responsive to androgens remains unclear, it is quite possible that there are 
multiple different PC-3 cells lines in existence, it is not uncommon for cell 
lines to become contaminated with other lines due to their rapid growth 
capacities. The PC-3 cell line was used in this study due to its basal 
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phenotype, putative stem-like compartment and the ability of PC-3 cells to 
form subcutaneous tumours in mice (S.-N. Tang et al. 2010). 
 
3.1.2 Prostate Stroma and Tumour Stroma 
Prostate stroma has an essential role in the development of the prostate 
gland. Communication between the epithelium and the stroma is 
multifactorial involving diverse factors including ECM deposition and 
remodeling, soluble cytokines, chemokines and growth factors all regulating 
the local microenvironment (Cunha 1994). Androgen signaling has a key role 
in the normal development and maintenance of the prostate throughout an 
individuals lifetime (Cunha et al. 1987). In the prostate; epithelial, endothelial 
and stromal cells, all express AR and are responsive to androgens (Y. Niu et 
al. 2008). One surprising exception are normal prostate stem cells and 
prostate cancer stem cells, which are defined by the expression of the β1 
integrin, CD133 and CD44 and are AR negative, thereby providing a pool of 
cancer cells driving castration-resistant (androgen independent) disease 
(Heer et al. 2007; Oldridge et al. 2011). 
 
More recently the role of stroma in tumour progression has lead to a better 
understanding of the role of the larger tumour microenvironment in cancer 
progression leading to the idea of the tumour-stroma environment. To 
further understand the function of stroma in the prostate gene expression 
analysis of cancer-associated fibroblasts (CAFs) and normal prostate 
fibroblasts has been performed. Numerous proteins were identified that are 
differentially expressed in either source of fibroblast. Asporin (ASPN) and 
osteonectin (SPARC) were both associated with high expression throughout 
the stroma of tumours. Caveolin-1 (CAV-1) however was depleted in 
prostate CAFs, having previously been described in breast CAFs (Finak et al. 
2008; Di Vizio et al. 2009), and predicts early tumour recurrence and poor 
outcome (Orr et al. 2011). 
 
The tissue architecture of the prostate strongly suggests an interplay between 
the stromal compartment and the epithelium, with just a thin basement 
membrane separating the two cell populations (Maitland 2008). The 
epithelium is constantly exposed to strong signals from the stroma, including 
basic fibroblast growth factors (bFGF), transforming growth factor beta 
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(TGF") and other growth factors such as insulin-like growth factor (IGF), 
platelet derived growth factor (PDGF) and epidermal growth factor (EGF) 
(Slater et al. 2000). This is not a one directional relationship, epithelial cells 
have a key role in shaping their own environment by signaling to stroma. In 
cancer the cell-stroma crosstalk is highly interactive (De Wever & Mareel 
2003). These pathways can drive the differentiation of fibroblasts to 
myofibroblasts or lead to the induction of EMT (Tuxhorn et al. 2002). 
Tumour associated stroma, often termed reactive stroma, can now release 
soluble factors, secrete ECM components and importantly increase motility 
and invasion of the cancer cells (Y.-N. Niu & Xia 2009). This was seen 
experimentally whereby CAFs were combined with non-tumourigenic 
epithelial cells which stimulated progression of tumourigenesis in vivo 
(Olumi et al. 1999). 
 
Physiologically, stromal cells have been shown to have a key role in the very 
first step in the tumour metastasis process when the cancer cell escapes the 
local tissue microenvironment and invades the surrounding tissue. Invasive 
path generation by CAFs has been analysed which showed that LIM kinases 
are required for invasive path formation in matrigel through stimulating the 
ECM degradation by stromal cells (Scott et al. 2010). The paths created by the 
stromal fibroblasts in the matrigel form a track of minimal resistance which 
can then be utilised by following stroma and cancer cells in order to invade 
neighbouring tissues. This movement is collective and there is only one 
direction the cells can migrate which is the path of least resistance. This 
process might have some similarities to in vivo metastasis, however it is 
unclear whether this same process is functionally important.  
 
In high Gleason grade tumours the basement membrane surrounding the 
epithelium is already disrupted and the stroma and epithelial cells occupy 
the same environmental space. Metastasis in prostate cancer is strongly 
associated with high grade aggressive tumours. This makes a strong case to 
include stromal cells as well as epithelial cells in an in vitro model when 
modeling the process of tumour cell migration. Thus models analysing 
molecular mechanisms of tumour cell behaviour in the absence of stroma 
will likely identify very different mechanisms to those that occur in the 
presence of stroma. 
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3.1.3 HT-1080 Fibrosarcoma Cell Line 
The HT-1080 fibrosarcoma cell line was first isolated in 1974 (Rasheed et al. 
1974). Since then, HT-1080s have been used as a model cell line to investigate 
tumour cell migration (Wolf et al. 2007), invasion (Armstrong et al. 1982), cell 
metabolism (Roomi et al. 2006), proliferation (Péterfia et al. 2012), tumour 
development (Yamauchi et al. 2012), and tumour metastasis (Mishima et al. 
1998). Because HT-1080s can spontaneously migrate through 3-D collagen 
rich matrices, this cell line was used to set up the 3-D migration model in this 
thesis. 
 
3.1.4 Extracellular Matrix 
Whilst the ECM comprises many different components including fibronectin, 
elastin and laminin, is the most abundant structural protein is collagen. 
Collagens are the most abundant proteins found in animals with collagen I 
being the most abundant protein in the human (Di Lullo et al. 2002). The 
molecules that make up the ECM interact by various different mechanisms. 
This could be as simple entanglement or more substantial cross-linking and 
charge-dependent interactions (Wight & Potter-Perigo 2011). These now 
bioactive polymers can, in part, regulate the biomechanical properties of the 
tissue. The influence of the ECM on cell behaviour ranges from adhesion and 
survival, to proliferation and, most importantly for this chapter, cellular 
migration (McCarthy & Hay 1991). 
 
Collagen comes in over 20 different types of fibrils with Type I, II and III 
being the most common. Stromal cells, and in particular myofibroblasts in 
reactive stroma, synthesize collagen I in high quantities (Lagacé et al. 1985) 
and collagen I is well studied as having a role specifically in cellular 
migration (Friedl et al. 1995; Sorokin 2010; McCarthy & Hay 1991; Wight & 
Potter-Perigo 2011; Gunzer et al. 2000). Collagen I has been used extensively 
as a 3-D matrix for in vitro studies due to it’s physiological relevance and 
biophysical properties that permits formation of high tensile hydrogels 
(Friedl et al. 1998; Friedl et al. 1995; Ma et al. 1997; B. R. Williams et al. 1978). 
In this study, collagen I extracted from rat has been used as an in vitro ECM 
component to produce 3-D hydrogels. Telopeptides, the amino acid 
sequences at the N and C termini of the collagen polypeptide chain, were not 
confirmed to be present in these gels. However, the lack of pepsin digestion 
throughout the extraction protocol and the use of acetic acid to dissociate 
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collagen fibrils rather than digest them, would in all probability leave them 
intact. Telopeptides are needed to form higher-order collagen fibres from 
individual fibrils via the lysyl oxidase cross-linking of adjacent molecules 
(Woodley et al. 1991). 
 
3.1.5 In vitro models of tumour metastasis 
Many in vitro tumour models do not recapitulate the immediate cellular 
tumour microenvironment in 3-D. Migration assays are routinely carried out 
using invasion chambers during which a cell is counted as migratory based 
on its ability to cross an artificial porous membrane typically across a serum 
or chemotactic gradient. Not only does this not take in to account the 
inherent 2-D nature of the initial seeding, but the role of the ECM is difficult 
to model. In essence this type model system does not represent mechanisms 
guiding tumour cell migration within the complexity of the tumour 
microenvironment. 
 
MatrigelTM is a commercial gelatinous protein mixture secreted by 
Engelbreth-Holm-Swam (EHS) mouse sarcoma cells, the exact constituency 
differs from batch to batch. Matrigel is rich in laminin, collagen IV, heparin 
sulfate proteoglycans and numerous growth factors, it crucially lacks a high 
collagen I content. To mimic the basement membrane in tumours a layer of 
MatrigelTM is put on top of the membrane in a similar chamber as described 
above. This assay has been used as an assay of invasive tumour potential, 
although it is a matter of debate the applicability of this model. One potential 
model is that cells settle and the migration through the membrane results 
from enzymatic digestion of the matrigel rather than an active migratory 
process. To improve the matrigel assay an inverse migration assay has been 
developed. Here cells settle on top of the matrigel and then through 
inverting the matrigel the cells begin at the bottom and have to actively 
invade from the bottom up (Scott et al. 2010). It is possible to mix collagen 
with MatrigelTM to create a scaffold that more accurately recreates the 
microenvironment seen by cells in vivo and thus enables enhanced cell 
survival and invasion (Dewitt et al. 2009). Fibrous collagen structures have 




Multi-photon confocal microscopy permits long-term deep florescence 
imaging in 3-D environments with highly reduced phototoxicity permitting 
analysis of highly photosensitive specimens including developing 
mammalian embryos (Squirrell et al. 1999). Using 2-photon microscopy it is 
possible to image cells, at high-resolution, using fluorescent proteins and 
labels, additionally it is possible to image endogenous structural proteins 
through second-harmonic signal generation both in vitro and in vivo 
(Campagnola et al. 2002; Sahai et al. 2005). Collagen can be visualised via 
SHG and is a critical ECM component involved in many cellular processes. 
For particular interest to this thesis it is the reorganisation of collagen I at the 
tumour-stromal interface which can facilitate local invasion (Provenzano et 
al. 2006). 
 
By using a 2-photon confocal microscope configured with a blacked out, 
temperature and gas controlled imaging chamber, it is possible to image 
cellular behaviour over long periods of time. This allows the tracking and 
quantification of single cell (tumour and stroma) movement, migration, 
morphology and interactions. !  
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3.2 Summary and Aims of this chapter 
3-D cell culture models more closely model the in vivo tumour environment 
than 2-D cell culture models. Whilst cell lines have been, and continue to be, 
a valued source of research data, it is important to factor in multiple different 
cell types and ECM found in vivo. Two-photon confocal imaging permits 
long term time lapse imaging of 3-D tumour models minimising cellular 
damage. By using the PC-3 cell line, coupled with primary human prostate 
tumour stroma, in a 3-D collagen rich matrix, this chapter aims to investigate 
the migration of PC-3 cells in the context of stromal cells. The specific role 
and influence of stroma in prostate cancer cell migration and metastasis is 
completely unknown. Therefore, the specific aims of this chapter are: 
 
1) To develop and utilise an in vitro 3-D model of the in vivo prostate 
tumour microenvironment. 
2) To investigate and determine the role of tumour stroma in prostate 
cancer cell migration in 3-D. 
3) To develop a high through put system for the screening of factors on 
3-D cultures of stromal-epithelial cell spheroids. !!  
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3.3 Results 
3.3.1 3-D in vitro model of in vivo type I collagen 
Collagen I was extracted from rat’s tail as in section 2.4.1 and the monomeric 
collagen concentration was ascertained by Bradford Assay and was found to 
be 6.5mg/ml. Dilutions using 0.02M acetic acid were made in the order of 
90% (5.85mg/ml), 80% (5.2mg/ml), 70% (4.55mg/ml), 60% (3.9mg/ml), 50% 
(3.25mg/ml) and 40% (2.6mg/ml). HT-1080 GFP and HT-1080 tdTomato 
cells were combined in a 50:50 ratio and were seeded in to collagen at a 
density of 1.5 x 105 cells/ml. Once gelled at 15°C, the collagen was carefully 
overlaid with complete media and incubated at 37°C with 5% CO2 overnight. 
The following day gels were imaged using 2-photon confocal microscopy as 
described in section 2.4.2. 
 
Prior to imaging, the collagen gels at higher concentrations were much stiffer 
and more robust. Collagen gels at 5.85mg/ml were visually opaque and was 
much drier than the gels containing less collagen. The gel containing just 
2.6mg/ml collagen was far more translucent, but had still gelled and 
remained intact after the addition of tissue culture media. Imaging of the gels 
(Figure 3.1) show in detail collagen fibres using second harmonic 
fluorescence of the collagen fibres. In the gels containing the higher 
concentrations of collagen (Figure 3.1 A,B) there was little to no evidence of 
significant collagen fibril formation. At collagen concentrations just either 
side of 4mg/ml (Figure 3.1 C,D) the gel consists of short thin fibrils with 
spaces opening up between the fibrils. At the lower concentrations of 3.25 
and 2.6mg/ml (Figure 3.1 E,F) the collagen fibrils are distinct and relatively 
long with what appear to be large gaps between them. In Figure 3.1 (F) a cell 
in the centre of the image is shown protruding under a bundle of fibrils and 
through one of these spaces more reminiscent of what is observed in vivo 
(Weigelin et al. 2012). At higher magnification and with higher resolution 
imaging it is possible to observe the individual fibrils of the collagen gel 
revealing the highly complex heterogeneous interconnecting web of fibres 
(Figure 3.2 A). High magnification scanning electron microscopy (SEM) 
(Figure 3.2 B) shows how the individual fibres are in fact interconnecting and 
branching off from one another. 
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To model prostate cancer PC-3 cells were transfected with green fluorescent 
protein (GFP) and were seeded at 1.5 x 105 cells/ml into 3mg/ml collagen 
gels. After gelation at 15°C, the addition of complete HAMS-F12 media 
containing 7% FCS and an overnight incubation at 37°C with 5% CO2 the gels 
were imaged by 2-photon confocal microscopy. PC-3 cells survive in the in 
vitro collagen environment and are observed spreading out in to the collagen 
matrix (Figure 3.2 C,D). 
 
3.3.2 HT-1080 cells use the collagen fibrils as tracks on which to migrate  
HT-1080 cells were introduced in to the optimised collagen gels (section 
3.3.1). The gels were imaged every 20 minutes for 18 hours using 2-photon 
microscopy visualising the cells via GFP fluorescence and the collagen by 
SHG. Initial results from the time lapse imaging and observations of cell 
movement showed that HT-1080 cells spontaneously migrate through the 
collagen matrix. Using high resolution imaging and digital magnification of 
the image, it was possible to observe single cells attaching to, and then 
migrating along, single collagen fibrils (Figure 3.3 A-D). The same collagen 
gels containing HT-1080 cells that were imaged were then fixed and 
processed for transmission electron microscopy (TEM). Analysis of the 
images show that the collagen fibrils that make up the collagen gel at high 
magnification (Figure 3.3 E-G) including a single HT-1080 cell interacting 
with the matrix (Figure 3.3 F). It is possible to observe interactions between 
the cell membrane and the collagen fibrils in the ECM, perhaps specifying 
points of integrin interactions with the fibres. 
 
Two-photon confocal imaging of HT-1080 containing collagen gels was 
performed in standard growth media and the velocity and displacement of 
individual cells was tracked using the software package Volocity 
(Improvision). A MMP inhibitor GM6001 which inhibits collagenase, was 
subsequently added to the growth media surrounding the collagen gels at a 
final concentration of 10%M and cells velocity and displacement quantified 
using 2-photon confocal microscopy. HT-1080 cells in the presence of the 
MMP inhibitor moved significantly further and faster than those in the 
control gels (p<0.001) (Figure3.3 H) consistent with MMPs having a complex 
role in the tumour environment as their activity inhibits tumour cell 
migration whilst having a role in breakdown of the basement membrane. 
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3.3.3 PC-3 cells do not migrate through in vitro collagen gels as single 
cells 
PC-3 GFP and PC-3 tdTomato cells were seeded at a density of 1.5 x 105 
cells/ml in 3mg/ml collagen and imaged using 2-photon confocal 
microscopy. Images were acquired across a 100%m Z depth every 30 min 
over 2 consecutive days. Cell tracking confirmed that PC-3 cells, unlike 
control HT-1080 cells did not migrate through collagen spontaneously 
(Figure 3.3). PC-3 cell filopodia are observed to extend into the matrix but 
not interact. PC-3 cells remained active and alive throughout the two days of 
imaging. To determine if this failure to migrate was a result of no 
chemotactic signal, PC-3 cells were seeded into collagen gels containing a 
gradient of FCS from 7% to 20%. Analysis showed no increase in cell 
migration as compared to cells with no FCS gradient (Figure 3.3 C). 
 
Previously we have shown that the addition of the broad range MMP 
inhibitor, GM6001, increased the migration of HT-1080s through an in vitro 
collagen matrix. Therefore, a 3mg/ml collagen gel containing 1.5 x 105 PC-3 
cells/ml was overlaid with complete HAMS-F12 media containing 7% FCS 
and 10%M GM6001. The addition of GM6001 had no effect inducing PC-3 cell 
migration or behaviour (Figure 3.3 C). 
 
3.3.4 PC-3 cells form a network of interconnecting cells in matrigel 
Matrigel™ contains many of the components that make up the ECM, but 
does not contain collagen I but is a commonly used ECM substrate in cancer 
research. Thus the effect of Matrigel™ on the migration of HT-1080 and PC-3 
cells was determined. Cells transfected with either td-Tomato or GFP were 
mixed 50:50 and either seeded within a 1.5ml Matrigel™ gel or seeded on top 
of an already set layer of Matrigel™. Strikingly, both HT-1080s and PC-3s 
create ordered networks of interconnecting cells when seeded on top of 
Matrigel™ (Figure 3.4 A,C). At 16 hours after seeding, no evidence of 
invasion down in to the matrix is observed in the lateral views in (Figure 3.4 
B,D). When seeded within the 3-D Matrigel™ matrix, cells appeared rounded 
with possible evidence of small apoptotic blebs throughout the gel (Figure 
3.4 E). HT-1080 cells showed significant invasion down in to the matrix in the 
Z dimension after 6 days in culture on Matrigel (Figure 3.4 F). Invasion is 
seen as single cellular strands reaching up to 400µm down in to the matrix 
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perhaps as a result of leading cells digesting the matrix creating a path of 
least resistance for others to follow behind. 
 
3.3.5 Co-culture of PC-3 Cells with tumour stroma reveals stromal cell 
migration and matrix destruction and remodeling 
A significant component of the prostate gland, and prostatic disease 
including BPH and cancer, are stromal cells. Stroma isolated from biopsies of 
patients with different Gleason grade prostate cancers and BPH were 
cultured. To observe stromal cell behaviour and interactions with epithelial 
cells in vitro, tumour stromal cells were labeled with Cell Tracker green dye 
and mixed 50:50 with PC-3-tdTomato cells at a density of 1.5 x 105 cells/ml in 
a 3mg/ml collagen gel. Stromal cells actively migrate through the collagen 
matrix (Figure 3.5). Single cell tracking showed a significant difference 
between the migratory behaviour of the stromal cells and the static PC-3 cells 
in the same gel. Although difficult to quantify in static images, matrix 
destruction occurs, not through enzymatic degradation, but through the 
physical forces applied by the stromal cells attaching to the matrix and 
ripping it apart. What was a stable matrix that contained PC-3 or HT-1080 
cells at the beginning of the time course becomes extremely dynamic, going 
through constant physical remodeling as a result of stromal cell migration. 
Stromal cells were observed to be attached to the collagen matrix to which 
they remain adhered as they move through the matrix thereby pulling and 
ripping the fibres from one another. Some PC-3 cell movement is observed at 
later time points, however this does not appear to be an active migratory 
process rather PC-3 cells are observed being pulled when attached to a 
moving fibre or stromal cell. Single cell tracking shows a degree of stromal 
cell displacement significantly higher than that of PC-3 cells as shown in 
Figure 3.5 (C). 
 
3.3.6 PC-3 cells form tumour spheroids only when co-cultured with 
stroma 
PC-3 cells alone do not form cohesive spheroids. The cells aggregate and 
form loose sheets at the base of the methylcellulose droplet. When handled 
carefully the cell aggregate can be transferred into collagen gels but when 
imaged using confocal microscopy gaps between cells were observed with a 
distinct lack of cell-cell contact (Figure 3.6 A). In contrast the same number of 
stromal cells form tight compact spheroids (Figure 3.6 B). PC-3 cells and 
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stromal cells were mixed at a ratio of 50:50 prior to resuspension in 
methylcellulose and subsequent spheroid formation. The result of mixing the 
two cell types together was the formation of spherical 3-D structures with an 
even distribution of each cell type (Figure 3.6 C). These spheroids were 
robust enough to be washed from the surface of the petri dish with PBS 
containing 10% FCS prewarmed to 37°C, were able to be handled and seeded 
singularly in to collagen gels by pipetting. Analysis of the spheroids by 
confocal microscopy showed no gaps between the different cell types (Figure 
3.6 C ). 
 
3.3.7 PC-3 cells only migrate through collagen from spheroids when co-
cultured with tumour stroma 
We have previously found no evidence that PC-3 cells can migrate through a 
collagen matrix in vitro either as single cells, or as part of a multi-cell 
aggregate. Therefore, PC-3-tdTomato and PC-3-GFP cells were mixed 50:50 
with tumour stromal cells (unlabeled) and formed in to spheroids. Once 
implanted in to collagen gels, the spheroids were cultured for 48 hours prior 
to imaging for a further 18hrs. Analysis of PC-3 only spheroids show a tight 
boundary between the cellular aggregate and the surrounding collagen 
matrix (Figure 3.7 A) with no evidence of PC-3 cell migration into the matrix, 
in contrast to spheroids with 50% tumour stromal cells (unlabeled) where 
there was clear migration of PC-3 cells in to the surrounding collagen matrix 
as shown in Figure 3.7 (B). To visualise stromal cells, CellTracker dyes 
(Invitrogen) were used to directly label primary tumour stromal cells (Figure 
3.7 C,D) in green. Imaging stromal cells in stroma-epithelial spheroid 
revealed interactions between the green stromal cells and the collagen matrix 
as highlighted by the white arrows. These interactions take the form of 
adhesion and contraction bringing the collagen fibres into the centre of the 
spheroid. By 8 hours PC-3 cells (yellow arrow) and tumour stromal cells 
(blue arrow) are observed to enter the surrounding collagen matrix between 
the two spheroids. At the beginning of the imaging window, stromal and 
epithelial cells are evenly dispersed. Throughout the course of the 
experiment stromal cells rapidly occupied the centre of the spheroid with the 
effect of excluding PC-3 cells to the periphery. Stromal cells may have a 
strong preference to adhere to one another than PC-3 cells with the effect 
being spheroid contraction and possible epithelial cell exclusion from the 
spheroid’s centre. 
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3.3.8 Development of a 24-well plate high throughput assay of stroma-
PC-3 spheroids  
To develop an assay that can be used for higher throughput experiments a 
24-well format of the spheroid assay was developed. PEI coated collagen 
support rings were placed in the centre of the wells of a tissue culture treated 
24-well plate (Corning) secured in place with a thin layer of vacuum grease. 
The plate was then cooled on ice for a minimum of 30 min. Monomeric 
collagen was neutralised on ice and 30%l was added to the centre of each ring 
within each of the 24-wells of the plate. Initial tests showed that the 
neutralised collagen in the ring remained liquid for at least 2 hours whilst the 
plate was kept on ice providing ample time to prepare and implant up to 48 
spheroids (2 per well). 
 
Spheroids were prepared and isolated by pipetting using a Gilson P2 
PIPETMAN Classic fitted with a 10%l tip. Spheroids were then carefully 
implanted in to the centre of each gel. A second spheroid was then implanted 
close to the first leaving a gap of less than 1mm between the two. Once all 48 
spheroids had been implanted in to the 24 collagen gels, the 24-well plate 
was placed at 15°C for a minimum of 1 hour or until the collagen gels had 
set. Each gel was overlaid with 1ml complete RPMI media supplemented 
with 10% FCS and placed at 37°C with 5% CO2 for 2 hours. Each spheroid 
pair was imaged via epifluorescence and care was taken to note the position 
of each spheroid pair for each well to allow subsequent imaging at later time 
points. Typically images were retaken at 24 hours and 48 hours post 
implantation (Figure 3.8 A,B). The image analysis software package Fiji was 
used to quantify to the size of each spheroid, the circumference and the 
centroid position of each spheroid in X and Y. The 2-D extended focus 
fluorescent images were first converted to a binary image before 
quantification was carried out (Figure 3.8 C,D). Using these parameters it 
was possible to not only follow the growth of the spheroid in relation to an 
increasing area measurement, but also by using the position of the centroid it 
was possible to measure the movement of spheroid toward each other 
(Figure 3.8 E-G). Measurements revealed no centroid movement for 
spheroids containing solely PC-3 spheroids or for those containing PC-3 cells 
mixed with BPH stroma. Significant centroid movement was measured 
between spheroids containing tumour stroma with PC-3 cells indicating that 
tumour stroma is required in this model for cell migration (Figure 3.8 G). 
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3.4 Discussion 
To understand the molecular mechanisms driving tumour metastasis we 
have developed a 3-D spheroid model that permits dissection of the role of 
stroma and epithelium in prostate cancer cell migration. To do this we have 
utilised collagen, a natural ECM protein, that we polymerised to form in vitro 
collagen matrices in which cells and spheroids were implanted. We selected 
collagen over the more commonly utilised Matrigel because of its links to 
physiological cell migration, its location in normal prostatic tissue and the 
tumour microenvironment. In contrast Matrigel is derived from mouse 
tumour cells, is not found in normal tissues, is difficult to manipulate due to 
its temperature sensitivity and has little secondary structure, thus no second 
harmonic signal generation (SHG) is observed for collagen fibres using 2-
photon confocal microscopy. Collagen fibre SHG could not be observed 
when collagen I was mixed into Matrigel, thus there was no added value to 
using mixed gels. 
 
Surprisingly, in vitro the metastatic PC-3 prostate tumour cell line did not 
migrate as single cells in collagen gels, even with the addition of an FCS 
gradient or a stromal cell monolayer beneath the matrix. Very rarely are cells 
found as single cells in mammalian biology thus cellular migration in vivo 
likely involves either clusters of cells or multiple cell types. In the context of 
tissues cells are in direct contact with one or more other cells of the same, or 
different, type as well as the surrounding ECM. Surprisingly the 
fibroscarcoma cell line HT-1080 did display single cell migration in a 3-D 
collagen matrix in vitro. This may result from the mesenchymal origins of 
this tumour type as mesenchymal cells show high capacity to migrate. There 
have been reports of stromal conditioned media inciting PC-3 migration, but 
this was done using the method of trans-well migration assays (Jacob et al. 
1999). This is whereby cells are placed on to a membrane, sometimes coated 
with collagen, Matrigel or some other ECM component, beneath which is a 
chemo-attractant of some variety. Migration is deemed positive in these cases 
if the cell can pass through the pores and attach the opposite side of the 
membrane. In essence, going from being exposed to a 2-D environment, 
squeezing through a ~7%m pore and ending up on a second 2-D surface 
upside down. Some reports have shown migration of PC-3 cells in 3-D, 
however, on closer inspection of the methods the cells are layered in a 
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sandwich collagen gel. Cells are seeded on to a 2-D flat collagen gel and 
allowed to adhere before the addition of a second gel on top of the first 
(Packard et al. 2009). This exposes the cells to two 2-D surfaces rather than a 
true 3-D environment as in the model reported here. 
 
Although initial work involved analysing cells distributed throughout 
collagen gels this is highly un-physiological. In the absence of cellular 
interactions single cells often go through apoptosis due to the lack of key 
survival factors from near neighbours through the active secretion of 
vascular endothelial growth factor (VEG-F) and fibroblast growth factor 
(FGF) (Korff & Augustin 1998). Some cells, such as the HT-1080 cell line, no 
longer depend on exogenous survival factors and can survive, grow and 
migrate within 3-D collagen environments (section 3.3.2.). HT-1080s not only 
migrate in the collagen gels but also lead to matrix degradation and 
manipulation. This behaviour is very similar to that observed for primary 
human tumour stromal cells, perhaps characteristic of fibroblastic cells. 
Although stroma will migrate in gels through interacting with the ECM, the 
addition of stromal cells was insufficient to induce the migration of PC-3s. 
This experiment is consistent with experiments using a stromal cell 
monolayer beneath the gel or stroma conditioned media, both of which failed 
to promote PC-3 migration. In combination these results would indicate that 
the presence of stromal cells in the vicinity of PC-3s, or components they 
may secrete, is not sufficient for PC-3 cell migration rather it must require 
direct cell-cell interactions between the epithelium and stroma as is observed 
in higher grade tumours in vivo. 
 
PC-3 cells alone failed to form 3-D spheroids when seeded in 
methylcellulose, which is not unusual for epithelial cells unlike mesenchymal 
and endothelial cells, but they will form spheroidal structures over time 
when single cells are embedded in Matrigel (Härmä et al. 2010; Lang et al. 
2001). This process takes 7-10 days with evidence of cell-cell contacts and 
tight junction formation, with the centre of the spheroid being necrotic 
containing cellular debris (Lang et al. 2001). Time-lapse imaging of PC-3 cell 
aggregates (the result of attempting to form spheroids in methylcellulose in 
this study) showed that cell-cell contact of PC-3 on PC-3 cells had no affect 
on the ability of the cells to migrate. Whilst the cells remain intact with no 
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signs of cell death and no sign of a necrotic core, there was no evidence of 
cell migration. 
 
In contrast when PC-3 cells formed in to spheroids in conjunction with 
tumour stromal cells, PC-3 cells became migratory. Morphologically, mixed 
spheroids become highly compacted with tight cell-cell contacts. Time-lapse 
imaging of these spheroids showed that both cell types, the tumour stromal 
cells and the PC-3 cells, underwent active migration. This activity took the 
form of movement of the cells both within the spheroid and also invasion out 
in to the surrounding collagen matrix. By using SHG imaging of the collagen 
fibrils the interaction between stroma and surrounding matrix and the 
physical displacement of collagen are inconsistent with MMPs or matrix 
destruction having a role in prostate cancer cell migration. 
 
PC-3 cells, when seeded as single cells in Matrigel, formed spheroids within 
seven to ten days. They then often underwent a spontaneous transformation 
towards an invasive phenotype after two weeks in culture (Härmä et al. 
2010). This invasive morphology consisted of the extension of filopodia in to 
the surrounding matrix which we believe is inconsistent with migration and 
displacement and is dependent on an MMP dependent process. This is 
contrary to what we have observed whereby PC-3 cell migration is induced 
immediately upon co-culturing with primary human tumour stroma in 3-D 
spheroids. Thus we would speculate that MMP inhibitors might actually lead 
to stronger metastasis potential through enhancing the collagen network 
upon which stroma and epithelial cells in close contact can migrate, perhaps 
consistent with clinical failures of MMP inhibitors for the therapeutic 
treatment of cancer (Coussens et al. 2002; Pavlaki & Zucker 2003). 
 
The difference in behaviour of PC-3 cells in Matrigel compared to collagen, 
mirrors that of HT-1080s. This albeit interesting and beautiful network of 
cells created on top of Matrigel is probably the result of Matrigel expulsion, 
and occurs when many different cell types are placed on top of matrigel 
including endothelial cells. Cells prefer to exclude Matrigel, the formation of 
hexagonal structures is the most thermodynamically stable conformation of 
cell networks. This would suggest that the material itself affects the cells 
similarly whereas before we have seen the two cell types behave differently 
in collagen. Due to the nature of handling Matrigel, the aims of this project 
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and the broad affect of Matrigel on different cell types, Matrigel was not used 
when characterising the molecular mechanisms of prostate cancer metastasis. 
 
Through developing a 24-well plate assay we developed a higher content 
assay that we could use to screen for genes and signaling pathways that 
regulate tumour cell growth and migration in 3-D by using small molecule 
inhibitors and shRNAs. Using this setup will permit rapid analysis of 
stromal cell types, from genetically diverse individuals, different Gleason 
grades of the same tumour type, or stromal cells from a range of different 
types of tumours including breast, pancreas and melanoma. The technology 
also permits the assessment of different prostate cancer lines including 
LNCaP and DU145.  
 
The application of 4-D 2-photon imaging has provided very high rich data 
sets on the behavior of different cell types. Although imaging using 
epifluorescence does not give the level of detail of 2-photon or confocal 
microscopy, using multiple times points allows the tracking of spheroid 
growth and some cell migration, and differences were beginning to emerge 
between spheroids containing different stroma. Further development is 
required to bring this technology to a commercially viable system, in 
particular standardising the distance between the tumour spheroids. This 
could be done utilising a number of methodologies, in particular forming 
collagen gels containing pits at regular intervals may lead to selective control 
of spheroid placement. The spheroids should settle out in these indentations 
and a second collagen gel could be overlaid on the first. Proper 
standardisation would then need to be carried out and experimental 
reproducibility confirmed. 
 !  
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3.5 Conclusions 
PC-3 cells do not migrate as single cells through collagen, but do migrate 
once formed into spheroids when co-cultured with tumour stroma. This is 
consistent with prostate cancer cell migration being stroma dependent, 
mimicking the tumour environment found in vivo. Thus by analysing the 
gene expression of stroma and tumour epithelium may provide insight into 
the mechanisms regulating cancer cell migration. 
 
Primary prostate stromal cells like the HT-1080 fibrosarcoma cells attach to 
and mechanically disrupt the collagen matrix. This was observed both when 
stromal cells were seeded singularly within the collagen gel and when in PC-
3 tumour spheroids. Thus adhesion molecules, particularly integrins and 
associated signaling pathways are likely to have a key role in regulating 
stromal cell function and interactions between the ECM and cancerous 
epithelium. 
 
Through setting up a growth, migration, and invasion assays in vitro using 
spheroids implanted into collagen I hydrogels we have provided a platform 
to investigate the properties and influences of stroma on cancer cell 
migration. Using this method, it is possible to generate 4-D analyses of the 
migration process utilising two-photon time-lapse imaging and subsequent 
single-cell tracking of individual cells. Through developing a high 
throughput system, generation of a genetic screen for pathways regulating 
the 3-D migration of prostate cancer cells has been permitted. !  
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Figure 3.1 3-D reconstructions of HT-1080 GFP (green) and HT-1080 td-Tomato (red) 
cells cultured in 3-D collagen gels (blue) in vitro. From a stock concentration of 
6.5mg/ml 6 gels of decreasing collagen concentration were made (A) 90%, 
5.85mg/ml (B) 80%, 5.2mg/ml (C) 70%, 4.55mg/ml (D) 60%, 3.9mg/ml (E) 50%, 






Figure 3.2 PC-3 cells survive in collagen. 3-D reconstruction of (A) 3mg/ml collagen 
alone set at 15°C and visualised at high-resolution by second harmonic generation 
of 2-photon microscopy. Collagen is false coloured cyan. Bar: 10%m (B) Fine 
collagen fibres as seen by scanning electron microscopy within a collagen gel set at 
37°C. Bar: 2%m. Image courtesy of Amanda Barnes, Coles lab. (C) PC-3 cells 
expressing GFP spreading out in the same collagen gelled under the same gelling 
conditions as (A) 24 hours after cells were implanted with the collagen signal 




















Figure 3.3 HT-1080s use collagen fibrils as tracks to migrate through the matrix. (A-D) 
still frames from time-lapse imaging showing a single HT-1080 cell (green) using a 
collagen fibril (cyan) to migrate along. The leading point of the cell (white arrow in B-
D) attaches to the fibril, and drags itself along leaving a trailing point of the cell behind 
it (yellow arrow in C). (E-F) TEM images showing (E) collagen fibrils within the 
collagen gel, (F) a single HT-1080 cell embedded in the matrix and (G) a close-up of 
possible cell-collagen interactions on the cell periphery. (H) tracking of single HT-1080 
cells showed that after the addition of a broad range MMP inhibitor GM6001, the cells 
migrated further. Bar represents mean±SEM, ***p<0.0001 (t test) (A-D) number 
represents time in hours (h) and minutes (m) (hh:mm) Scale bar in (D): 10%m 
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Figure 3.3 PC-3 cells do not migrate through in vitro collagen as single cells. (A) 2-
photon microscopy image revealing the collagen gel fibres (cyan) and the even 
distribution of PC-3 GFP (green) and PC-3 tdTomato (red) cells throughout the gel. 
(B) The same image as (A) but the SHG signal of the collagen fibres has been 
removed. Both (A) and (B) are images at the start of a 48hour time-lapse. Scale unit: 
63%m. (C) Quantification of single cell tracking displacement over 48 hours in 
collagen of migratory HT-1080 cells compared to PC-3 cells alone. Bar represents 
mean±SEM, ***p<0.0001 (t test) (D) tracking of PC-3 cells alone, PC-3 cells exposed 
to an FCS gradient, and PC-3 cells in the presence of the broad range MMP inhibitor 
GM6001. Bar represents mean±SEM, data not significantly different (two-way 





Figure 3.4 PC-3 cells form an interconnecting network of cells when seeded on top 
of Matrigel but round up in 3-D. (A) The fibrosarcoma cell line HT-1080 forms a 
highly organised interconnecting web of cells when seeded on top of Matrigel in 2-
D. (B) At 24 hours there is no evidence of invasion as seen in this side-on view. 
(C&D) The same is true for PC-3 cells. (E) When seeded within Matrigel, PC-3 are 
observed as round, non-migratory cells. (F) Lateral view of HT-1080s invading in to 
the Z dimension up to 400%m after 6 days in culture. Scale units: (A&B) 83%m, 

















Figure 3.5 Tumour stromal cells interact with and migrate through the collagen 
matrix whereas PC-3 cell do not to the same extent. (A) Tumour stromal cells 
(green) and PC-3 tdTomato cells (red) were seeded as single cells in to a collagen gel 
and imaged over time. Scale unit: 63%m. (B) With the SHG signal of the collagen 
signal removed it is revealed that the green stromal cells are migrating through the 
matrix (blue arrow) whereas the red PC-3 cells are not (white arrow). Scale unit: 
63%m. (C) Quantification of single cell tracking of both cell types. Bar represents 








Figure 3.6 PC-3 cells form loose spheroids compared to spheroids formed by 
stromal cells alone or a 50:50 mix. (A) The result of an attempt to form spheroids 
from solely PC-3 cells. PC-3 GFP (green) and PC-3 tdTomato (red) form loose 
aggregates of cells as seen here by confocal microscopy. Bar: 150%m (B) 
Epifluorescence image of a PC-3 tdTomato only spheroid (red, left) in close 
proximity to a tumour stroma only spheroid (green, right) Bar: 100%m. (C) A 
compact spheroid consisting of PC-3 cells (green) mixed 50:50 with tumour stromal 
cells (red) approximately 2 hours after being implanted in to a collagen gel. Bar: 






Figure 3.7 PC-3 cells only invade the collagen matrix in the presence of stroma. (A) 
A single Z-slice through the centre of a PC-3 only (red & green) spheroid showing 
the unbroken boundary between the cells and the collagen matrix. Bar:15%m (B) The 
same PC-3 cells (red & green) in spheroids with tumour stromal cell (unlabeled) 
clearly invading the matrix. Scale unit: 64%m. (C) Spheroids made from a 50:50 mix 
of PC-3 (red) and tumour stromal cells (green) promote cell migration between two 
spheroids and invasion in to the collagen matrix. Both PC-3 (yellow arrow) and 
stromal cells (blue arrow) exhibit this behaviour. Bar:100%m. (D) The same spheroid 
pair after 48 hours of time-lapse imaging reveals the extent of migration and 








Figure 3.8 Representative results from the 24-well plate format of the spheroid 
growth, migration, and invasion assay. (A) Epifluorescence image of a pair of 
spheroids containing PC-3 cells (red) and tumour stromal cells (green) at the 
beginning of the experiment (0 hr). (B) The same two spheroids imaged 2 days later 
(48 hr). (C) Binary image of the fluorescent image in (A) in to order to analyse the 
spheroid area, perimeter, and centroid position. Dashed grey right-angled triangles 
depicts how the distance between the 2 centroids was calculated. (D) Binary image 
of (B). (E&F) Imaging data reveals that PC-3 only spheroids show no movement 
toward one another whereas spheroids containing both PC-3 and tumours stromal 
cell do. (G) When PC-3 cells are mixed together with BPH stroma in to spheroids, no 
migration is seen. Bar represent mean±SEM,*p<0.01 (paired t test) !  
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Chapter 4  
Investigation of the Molecular 
Mechanisms of Stroma Induced 
Migration 
4.1 Introduction 
4.1.1 Characterising stroma in tumours 
The Gleason grading system is used to grade the severity and level of 
prostate cancer progression. Low grade tumours up to Gleason grade 4 have 
an increase in stromal content relative to normal prostate and an increase in 
the volume of stroma between the glands. However, there is no cancer cell 
infiltration into the stromal compartment. Above grade 4, glands lose the 
supporting stroma and cancer cells exclude and outgrow the stroma to form 
a continuous mass – the tumour (Yanagisawa et al. 2008). The cancer 
associated stroma surrounding the tumour mass continues to expand be it at 
a lower rate than the transformed epithelium. At higher disease grades the 
stroma-epithelial boundary is breached and cancer cells infiltrate the 
surrounding stroma, an event thought to be the first mechanistic step in 
tumour metastasis (Stark et al. 2009). 
 
The interaction of the stroma with epithelial cells during prostate 
development is critical for both normal gland formation and for prostate 
cancer development (Cunha et al. 1987). Stromal derived growth factors, 
including those from the fibroblastic growth factor (FGF) protein family, 
have been shown to promote EMT and cancer progression during high grade 
cancer in mouse models (Abate-Shen & Shen 2007). Stromal FGF10 
expression, and expression of other FGFs in prostate cancer, promotes 
androgen receptor (AR) up regulation through FGF receptor-1 (FGFR1) 
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signaling (Abate-Shen & Shen 2007). FGF10 is however only expressed at 
very low levels in human prostate cancer (Ropiquet et al. 2000) leading to the 
concept that other FGFs may signal through FGFR1 particularly FGF7 or 
FGF22. 
 
The more pronounced the alteration to the prostate tumour 
microenvironment, including loss of smooth muscle cells, an increase in 
fibroblasts, myofibroblasts, and collagen deposition is directly associated 
with a poorer outcome (Yanagisawa et al. 2007). The tumour 
microenvironment is characterised by immune cell accumulation and 
infiltration including macrophages, lymphocytes and mast cells (Kärjä et al. 
2005; Lissbrant et al. 2000; Fleischmann et al. 2009). This immune infiltrate 
has been observed to form highly organised tertiary lymphoid structures, the 
development of which is determined by cytokines such as lymphotoxin and 
TNF-α (Cupedo et al. 2004; Gräbner et al. 2009). The role of inflammation in 
the context of cell migration within tumours has not been investigated and in 
particular, the impact of inflammation on stromal mediated tumour cell 
migration is not well understood. 
 
4.1.2 Tertiary lymphoid tissue 
Tertiary lymphoid tissue (TLT) comprises tertiary lymphoid organs (TLOs). 
TLOs arise in ectopic areas (non-lymphoid sites) throughout the body at sites 
of chronic inflammation resulting from pathogenic infection, autoimmunity 
or tumour induced inflammation. These structures resemble secondary 
lymphoid organs, such as the lymph nodes, including such characteristics as 
organised B and T cell zones, follicular dendritic cells (FDC), fibroblastic 
reticular cells (FRC) and high endothelial vessels (HEV) in highly ordered 
structures (Shields et al. 2010). TLOs act to induce immune responses at the 
site of chronic inflammation by mediating efficient immune responses, 
whether TLOs lead to better or worse disease outcomes is unclear 
(Hjelmström 2001; Salomonsson et al. 2002). The high degree of organisation 
found within a TLO is dependent on activated lymphocytes being present 
(Cupedo et al. 2004). It was shown that TLO induction and organisation was 
dependent on Lymphotoxin (LT) and further cytokines including TNF-α 
have been proven to be required to organise lymphoid like architecture 
(Cupedo et al. 2004; Gräbner et al. 2009; Koning & Mebius 2012). 
! 97!
 
Stromal cells provide the structural basis for both secondary and tertiary 
lymphoid tissues through providing microenvironments where leukocytes 
can migrate and interact permitting development of high affinity adaptive 
immune response through the production of chemokines and cytokines. LN 
stroma contains HEVs, lymphatic endothelial cells (LECs) and mesenchymal 
cell networks (Koning & Mebius 2012). In lymph nodes these multiple 
distinct stromal cells are found in different zones. These include FRCs that 
support the T cells zone, marginal reticular cells (MRC) found in the 
subcapsular zone, B cell stroma and mature FDCs found in B cell follicles 
(Bajénoff et al. 2007). All of these cells are derived from localised 
mesenchymal progenitor cells. MRCs are characterised by the expression of 
the adhesion molecules VCAM-1 and ICAM-1 which are the first markers to 
be upregulated during lymphoid tissue formation initiated by lymphoid 
tissue inducer (LTi) cells (Cupedo et al. 2009). In a process involving 
LTβ receptor signaling mesenchymal precursor cells differentiate into mature 
lymphoid tissue organiser (LTo) cells which up-regulate VCAM-1, ICAM-1 
and chemokine expression. Through selective recruitment and retention LTi 
cells accumulate in the nascent anlagen driving the development and 
maturation of the organ and ultimately give rise to MRCs found in adult 
lymph nodes (Vondenhoff et al. 2009). LN stromal cells can be identified by 
the differential expression of podoplanin, the endothelial receptor CD31 and 
do not express the haematopoietic marker CD45 (Koning & Mebius 2012). 
Non-haemaopoietic cells that express podoplanin (GP38 in mouse, GP36 in 
human) are either lymphatic endothelium or mesenchymal-derived stromal 
cells. Podoplanin is highly upregulated during inflammation and has since 
been used as a marker of activated stroma (Roozendaal & Mebius 2011; Link 
et al. 2007). 
 
4.1.3 TLOs in cancer 
TLOs have been reported in lung cancer (Dieu-Nosjean et al. 2008), breast 
cancer (Coronella-Wood & Hersh 2003), ovarian cancer (Milne et al. 2009), 
and colorectal cancer (Suzuki et al. 2002). TLOs have been shown to be 
adjacent to tumours and can act as a site of anti-tumour adaptive immune 
responses (Pagès et al. 2010). In human lung tumours associated TLOs 
consisting of mature DC and T cell clusters as well as B cell follicles were 
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highly predictive for patient survival. It has been speculated that tumour 
associated TLT derived memory cells migrate to the draining LN to develop 
a central memory response against micro-metastases, hence prolonged 
survival (Dieu-Nosjean et al. 2008). TLOs that display a highly organised 
structure, with distinct T and B cell zones, have also been shown in colon 
cancer mucosa. Links to patient survival have yet to be determined but the 
presence of these ectopic structures may either have a role in sustaining the 
inflammatory environment surrounding the tumour or might be appearing 
as a result of chronic inflammation (Bergomas et al. 2011). TLOs associated 
with cancerous tissues demonstrate that T and B lymphocytes are being 
recruited and activated by antigens in the context of the tumour 
microenvironment. Although TLOs likely promote an adaptive immune 
response, it is not fully understood how a tumour can use cancer associated 
immune structures, cells and cytokines to its advantage. This could be 
important in understanding how tumour cells migrate and ultimately 
metastasise from the primary tumour site and particularly why TLT might be 
both beneficial yet correlate with a poor prognosis in some advanced cancers. 
 
4.1.4 Murine Lewis Lung Carcinoma cells (LL/2) 
The Lewis Lung carcinoma cell line (LL/2) was established in 1980 and is 
used as a syngeneic model of tumour formation in C57BL/6 wild type mice 
(Zupi et al. 1980). The cell line is hypotetraploid, tumourigenic and can 
undergo metastasis in vivo and as such has become a very well established 
model of tumour formation and spread (Duś et al. 1985). LL/2 cells have 
been used to study therapeutic administration efficacy of chemotherapy 
agents (Lai et al. 2009; Pan et al. 2012), mecahnisms of tumour cell growth, 
migration, and invasion of surrounding tissues as well as cancer metastasis 
(Heinke et al. 2012; Sipos et al. 2012; Kaluza et al. 2011). 
 !  
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4.2 Summary and Aims of this Chapter 
Changes occur in stromal organisation and function with increased disease 
progression resulting in changes to stroma-epithelial crosstalk. Thus both cell 
types have a key role in on-going changes to the cancer microenvironment. 
During tumour formation, stromal cells change from a permissive role to a 
more instructive role promoting epithelial cell proliferation, migration and 
invasion of surrounding tissues in higher grade tumours. Therefore the 
stroma has an essential role in the metastasis process. However, how tumour 
stroma can influence tumour cell metastasis and the mechanism by which 
this occurs, is unknown. It is also little understood how the immediate 
immune environment, often occupied by multiple TLOs can impact on long 
term patient survival and short term cancer cell behaviour. Therefore, by 
utilising the 3-D tumour spheroid model in combination with gene 
expression analysis, and flow cytometry with in vivo murine tumour models, 
the aims of this chapter are: 
 
1) To investigate the role of cancer associated stroma in prostate cancer 
cell migration. 
2) To determine a molecular mechanism for this migration. 
3) To investigate the impact of inflammation on the migratory capacity 
of prostate cancer stroma and tumour cells. 
4) To determine a possible role for innate lymphoid cells and TLOs in 
tumour growth. !  
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4.3 Results 
4.3.1 High Gleason Grade stroma and tumour cells disrupt prostate 
architecture 
Primary human BPH and high Gleason grade cancer tissue samples were 
sectioned and stained with DAPI (nuclear), anti-pan-cytokeratin (epithelial) 
and anti-collagen I (stroma). In BPH the glandular epithelial cell architecture 
is adjacent but separate to the prostate stroma (Figure 4.1A&C). Higher 
magnification imaging (Figure 4.1 C) shows the boundary between the 
epithelial cells (red) and collagen I staining in the stromal zone (green) 
showing complete separation of the epithelium and stromal cell 
compartments. In contrast high Gleason grade tumour architecture is 
disrupted with no glandular structures (Figure 4.1B&D). In higher grade 
tumours the cancerous epithelial cells are intermingled in the same space as 
the stromal cells (Figure 4.1 D). The cancer cells are phenotypically less 
differentiated and have a more uniform round morphology, as opposed to 
the hierarchy of oblong epithelial cells found in the glands in BPH tissue 
sections. 
 
4.3.2 High Gleason Grade stroma but not BPH stroma elicits PC-3 cell 
migration 
Early passage stroma cultured from patients exhibiting high Gleason Grade 
prostate cancer was formed in to 3-D spheroids with PC-3 cells as previously 
described. The same process was carried out for early passage stroma from 
BPH cultures. Confocal images of spheroids taken at the assay end point for 
both spheroid sets shows a strong difference in how the cells have migrated 
(Figure 4.2 A&B). High Gleason stromal cells migrated out of the spheroid in 
to the surrounding collagen matrix whereas BPH stromal cells remain within 
the spheroid. Interestingly, the same pattern is observed with the PC-3 cells 
in the mixed spheroids. PC-3 cells in spheroids containing high Gleason 
grade stroma migrated out of the spheroid in association with the 
accompanying stroma. However, PC-3 cells which are formed in spheroids 
with BPH stroma show no evidence of outward migration. To quantify the 
migration process, single stromal cells and single PC-3 cells were tracked in 
3-D for each spheroid over 48 hours (Figure 4.2 C&D). A clear difference is 
seen in the migration of both cell types between the two spheroid sets. A 
significant increase in cell displacement over 48 hours is shown for PC-3 and 
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stromal cells in high Gleason spheroids compared to those in BPH spheroids 
(Figure 4.2 E). 
 
4.3.3 The migratory capacity of high Gleason Grade stroma is lost over 
time in culture 
The identical Gleason grade 9 tumour stromal cells used in section 4.3.2 were 
passaged sequentially through culture. At each passage, spheroids were 
formed which contained PC-3 cells mixed with tumour stromal cells from 
that passage at a ratio of 1:1. Confocal imaging data (Figure 4.3 A) is shown 
from tumour stromal cell passages 1, 4, and 7. The results clearly show a 
drop in cell migration for both cell types despite PC-3 cells being otherwise 
insensitive to prolonged in vitro cell culture. Spheroid growth and spread as 
measured by 2-D surface area from extended focus images was significantly 
reduced as early as stromal passage 4 (Figure 4.3 B&C). 
 
4.3.4 Gene expression analysis of stroma 
Tumour stroma from several donors were individually cultured through 
multiple passages over time. At early passage, where possible as early as 
passage 1, mRNA was extracted from stromal cell pellets. mRNA was then 
extracted at each passage over six successive passages. 
Stroma Source Passage Number 
BPH Passage 3 
BPH Passage 10 
Gleason 6 Passage 1 
Gleason 6 Passage 6 
Gleason 8 Passage 1 
Gleason 8 Passage 6 
Gleason 9 Passage 1 
Gleason 9 Passage 6 
 
RNA quality was assessed on a BioAnalyser and samples were amplified and 
then Cy-3 labeled and hybridised with an Agilent Sure Print G3 Human GE 
8x60k Microarray Chip (cat no. G4851A, Agilent Technologies) and analysed 
through a fully integrated Agilent platform. Raw data was normalised using 
Agilent analysis software (GeneSpring) providing robust multichip average 
(RMA) normalization to allow for meaningful comparisons across samples. 
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Figure 4.4 (A) shows the order in which the samples were loaded on to the 
chip which correlates to a full expression profile map, with clustering, 
analysed using TreeView (Figure 4.4 B). All early passage samples, with the 
exception of BPH, cluster closely with the same sample at later passage. It is 
unknown why the two samples from BPH did not fall in together but could 
relate to differential etiological causes of the BPH. Figure 4.4 (C) shows the 
expression profile of genes involved in matrix remodeling, migration and 
cancer metastasis across the early passage sample for BPH, mid-range 
Gleason Grade 6 tumour stroma, and higher Gleason Grade 8 tumour 
stroma. Although, perhaps counter intuitively, some major ECM remodeling 
proteins such as MMP1 and MMP3 are down-regulated in higher Gleason 
grade stroma in this analysis, the adhesion molecules VCAM-1 and ICAM-1 
are strongly upregulated. 
 
4.3.5 Flow cytometric analysis of cancer tumour stroma reveals a possible 
role for adhesion molecules and podoplanin 
Tumour stromal cells from different individual human cancers were 
analysed for podoplanin (GP36), ICAM-1 and VCAM-1 expression. As a 
comparator the PC-3 cell line was also analysed. Briefly, all cells were 
collected at early passage (except the immortalised PC-3 cell line) and were 
washed and stained with antibodies specific for podoplanin, ICAM-1, and 
VCAM-1 and analysed by flow cytometry (Figure 4.5 A). At early passage all 
tumour stroma samples expressed high levels of these proteins, with some 
sample to sample variation (Figure 4.5 B). This is markedly different from 
PC-3 cells which show no expression of these stromal antigens. A direct 
correlation similar to that seen in lymphoid stroma was found between the 
expression of VCAM-1 and ICAM-1 (Figure 4.5 C). Stromal cells that were 
used in the experiments in section 4.3.3 during which a decline in migratory 
capacity was observed over time in culture, were correspondingly down 
regulating podoplanin, VCAM-1 and ICAM-1 expression during passage 
(Figure 4.5 D). Expression of all three markers, particularly VCAM-1, were 
high at early passage (green line Figure 4.5 D) and were reduced to almost 
background levels by late passage (blue lines in Figure 4.5 D). 
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4.3.6 Human, but not mouse xenograft tumour stroma resembles tertiary 
lymphoid tissue stroma 
VCAM-1, ICAM-1 and Podoplanin are all molecules that are strongly 
expressed on stroma in both secondary and tertiary lymphoid tissues (TLT) 
(Honda et al. 2001; Peduto et al. 2009). TLT develops in a variety of different 
tissues in chronic infection including tuberculosis and influenza (Roozendaal 
& Mebius 2011) and in autoimmune diseases including atherosclerosis, 
Sjrogen’s syndrome and multiple sclerosis (Gräbner et al. 2009). The 
lymphoid-like stroma associated with some tumours has been observed to be 
very similar to that of tertiary lymphoid stroma including expression of 
chemokines and recruitment of immune cells (Shields et al. 2010). Therefore, 
to determine the possible role for different adaptive and innate immune cells 
in tumour stroma composition we have used a xenograft model by which 
primary human prostate cancer tissues are grafted in to γc-/- RAG2-/- mice 
which have no mature B and T lymphocytes, NK cells, nuocytes and highly 
reduced numbers of RORγ+ innate lymphoid cells (ILCs). Once the tumour 
was established (~38 days) the mice were sacrificed and the tumours were 
recovered. The tumour was digested and dissociated in to single cells and 
human leukocyte antigen (HLA) negative host derived mouse cells were 
characterised by flow cytometry. These cells included infiltrating immune 
cells, stromal fibroblasts and endothelial cells. The non-epithelial host cells 
were found to contain a significant immune infiltrate with F4/80+ 
macrophages (23%), CD11c+ dendritic cells (1.3%) and GR1+ neutrophils 
(4.9%), making up the majority of host cells. HLA- CD45- presumed 
mesenchymal cells were gated on and analysed for the expression of 
podoplanin, CD31, VCAM-1 and ICAM-1 to investigate stroma composition 
with 9% of the cells being CD31+ endothelial cells and 30% mesenchymal 
stroma (Figure 4.6 C). 
 
The mouse stroma, in contrast to primary human Gleason grade 8 stroma, 
showed very low levels or no detectable podoplanin, VCAM-1 and ICAM-1 
expression (Figure 4.6 A). However, there is still evidence that the tumour is 
exposed to an inflammatory environment with a large CD45+ F4/80+ 
macrophage (Figure 4.6 B), dendritic cell and neutrophil infiltrate. Thus 
lymphocyte derived cytokines have a key role in driving tumour stromal cell 
inflammation. It is therefore not unsurprising that this type of mouse model 
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rarely gives rise to metastases when using the prostate cancer cell lines like 
PC-3, thus the requirement to use either in vitro models of human stromal 
cell activation or the use of syngenic tumour models to understand the 
molecular and cellular events driving tumour stroma activation in vivo.  
 
4.3.7 Inflammatory cytokines rescue a lost High Gleason Grade Tumour 
Phenotype in stromal cells 
During prolonged periods in culture in vitro, we have shown that prostate 
stromal cells lose their capacity to induce and support prostate cancer 
epithelial cell migration. This correlated with a loss in expression of 
podoplanin, VCAM-1, and ICAM-1. Our analysis of xenograft models 
showed that a large tumour component comprised CD45+ F4/80+ 
macrophages indicating that the tumour was still a potentially highly 
inflammatory environment, but failed to generate reactive lymphoid stromal 
like gene expression in tumours, implicating a specific role for lymphoid 
specific cytokines. 
 
To investigate the effect of inflammatory conditions on human prostate 
cancer associated stroma we used an inflammatory cytokine mix consisting 
of tumour necrosis factor-alpha (TNF-!), lymphotoxin-beta (LT-") and 
interleukin-4 (IL-4) as these are key lymphoid cytokines that could be 
delivered by infiltrating B and T cells and/or innate lymphoid cells and have 
previously been shown in the laboratory to induce tertiary lymphoid stroma 
(unpublished). These cytokines were added to stromal cells, which had 
reached passage 6 in culture, for a period of 72 hours. The cells were then 
analysed for podoplanin, VCAM-1 and ICAM-1 expression by flow 
cytometry. All three markers were significantly up-regulated thus high 
passage stroma responds to the inflammatory cytokine cocktail to take on the 
expression pattern observed in primary non-cultured stroma (Figure 4.7) 
with a tight correlation between the expression of adhesion molecules post 
treatment (Figure 4.7 B). Quantification across three independent 
experiments showed a significant increase in all three markers (Figure 4.7 C). 
 
4.3.8 Treatment of late passage tumour stroma with inflammatory 
cytokines rescues the migratory phenotype of early passage tumour stroma 
TNF-!, LT-" and IL-4 treated stromal cells that had been previously through 
6 passages in culture and untreated control stroma were then formed in to 
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separate spheroids with PC-3 cells. Single stromal cells and single PC-3 cells 
were tracked in a 3-D migration assay through collagen showing a major 
change in stromal cell behaviour (Figure 4.8). Treating the stroma with 
inflammatory cytokines induced the stromal cells to migrate, permitting the 
secondary migration of PC-3 cells. Importantly in this experimental setup, 
PC-3 cells had never been in direct contact with the inflammatory cytokine 
cocktail thus the induction of cellular migration was dependent on 
reactivated stroma. 
 
4.3.9 Syngeneic model using Lewis Lung Carcinoma cell line LL/2 
To determine in vivo which cell types were required to activate stroma the 
syngenic LL/2 tumour cells were subcutaneously injected in to wild type 
and gene knockout backgrounds. All mice were on the C57BL/6 mouse 
background (H2b), RAG2-/- mice with no T & B cells, $c-/- RAG2-/- mice 
deficient in B, T and NK cells and have very limited numbers of ILCs, and 
ROR$t-/- mice that lack ROR$t ILCs, T helper (Th) 17 and Th22 cells. 
Tumours were excised three weeks post-injection, trimmed of hair, skin, and 
fat and were weighed and measured. The tumours taken from $c-/- RAG2-/- 
mice were significantly larger than those from all three other strains. This 
was true of their weight and also volume (Figure 4.9). Thus it is likely that 
natural killer cells have an active role in reducing tumour cell volume. 
Tumours were dissociated into single cell suspension with 
collagenase/dispase and stained for CD45 and the epithelial cell adhesion 
molecule (EpCAM). Double negative cells were gated from the digested 
tumour stroma population (Figure 4.10 A) and the cells analysed for 
expression of podoplanin and CD31 (Figure 4.10 B). Podoplanin 
quantification shows significantly less expression in the tumour stroma 
originating from $c-/- RAG2-/- and RAG2-/- mice compared to B6 controls 
directly implicating a key role for T and B lymphocyte derived signals and 
cytokines in tumour stroma activation (Figure 4.10 C). To determine if this 
was dependent on Th17 or Th22 lymphocytes, podoplanin expression was 
analysed in ROR$-/- mice, however a large level of variation was found 
between the samples making it impossible to draw any statistical conclusions 
and so would have to be repeated. Similarly the coordinated expression of 
VCAM-1 and ICAM-1 on Rag2-/-, γc-/-Rag2-/- and RORγ-/- tumour stroma was 
significantly reduced compared to C57BL/6 wild type control mice 
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consistent with T lymphocytes having a key role in activating stromal cells in 
the tumour microenvironment (Figure 4.10 D&E). 
 
4.3.10 Cancer stem cells migrate rapidly in tumour spheroids 
To determine the behaviour of CSCs in the in vitro spheroid 
microenvironments, tumour cells were isolated from high Gleason tumours 
based on the CSC phenotype CD44+/α2β1high/CD133+ (Collins et al. 2005). 
From six, 6cm dishes, up to 3,000 tumour stem cells were recovered, and 
stained with CellTracker dye and added to the hanging drop culture 
containing primary prostate tumour stroma and PC-3 cells as previously 
described. Analysis of CSCs showed they were highly migratory within the 
spheroids (Figure 4.11) A single CSC, highlighted by a white box in Figure 
4.11 is shown spreading across the surface of the right hand spheroid during 
the first 12-18 hours. The cell then migrates to the left hand spheroid before 
migrating out in to the collagen matrix. Once within the matrix, the cell stalls 
before going through cell division on the second day. One of the daughter 
cells then migrates back toward the spheroids whilst the second daughter 
cell remains stationary within the matrix outside of the spheroids, consistent 
with stem cells having high migratory capacity compared with more 
differentiated cancer cells. CSCs were confirmed to be tumour initiated in 
soft agar colony formation assays as well as in in vivo tumourigenicity 




Higher Gleason grade tumour but not BPH stromal cells will actively 
migrate through a 3-D in vitro collagen matrix. PC-3 cells will only migrate 
from the spheroid through the matrix in the presence of tumour and not BPH 
stroma. BPH is not an invasive or metastatic disease and instead is a hyper 
proliferative disease in both the stromal and epithelial prostatic 
compartments (Maitland 2008). Little evidence exists for the collective or 
single cell migration in BPH and there is no evidence for epithelial metastasis 
or breakdown of glandular integrity (Chang et al. 2012). In prostate cancer, 
particularly high Gleason grade tumours, metastasis occurs to peripheral 
sites including the bone, lymph nodes, and lungs. In advanced prostate 
cancer metastasis is found in the liver and brain (1-2%)(Abdulghani et al. 
2008). Stroma from high Gleason grade human prostate tumours have 
previously been shown to migrate in vitro in 2-D culture, as well as some 
early 3-D Matrigel models (Hall et al. 2002). Here, for the first time, we have 
shown that in a collagen I rich matrix, only early passage high Gleason grade 
tumour stroma can elicit the prostate cancer cell migration in vitro. This 
behaviour is lost over time in culture and is not evident at all for BPH 
stroma. Loss in cell migration correlated with a loss in podoplanin, VCAM-1 
and ICAM-1 expression. Whereas the role for podoplanin in stromal 
mediated cell migration is unknown, cell migration via adhesion molecule 
dependent processes has been extensively studied in other systems including 
leukocyte migration. 
 
Initial findings from gene expression analysis on different tumour grades 
and BPH stromal cells showed higher adhesion molecule expression in 
higher grade tumours. Further conformation of this expression profile was 
done using antibodies specific for VCAM-1, ICAM-1 and podoplanin, a very 
similar expression pattern to that found in TLT. TLOs in tumours should 
drive vigorous anti-tumour immune responses but surprisingly TLOs in 
cancer have been linked to poor prognosis, which is contrary to their 
potential to generate high affinity immune responses as is observed in 
autoimmune disease (Kuerten et al. 2012; Pezzolato et al. 2012). As TLO 
formation requires chronic inflammation and localised influx of lymphocytes 
for their development, this might signify the presence of an unproductive 
immune response in the tumour which is driving a hyper inflammatory 
! 108!
tumour micro-environment through pro-inflammatory cytokine expression 
which induces TNF-α, LTβ and IL-4. We showed that after exposure of 
cultured tumour stroma to these three cytokines, cancer stroma which had 
lost the capacity to migrate is now able to elicit PC-3 migration and regains 
its high Gleason phenotype found in primary isolated cells. The reactive 
prostate cancer associated stroma resulting from exposure to an 
inflammatory environment may be the catalyst for local invasion and 
subsequent metastasis by cancer cells into surrounding tissues including 
draining lymphatics leading to lymph node metastasis. This process may 
involve invasive path generation (Scott et al. 2010) whereby the reactive 
stroma invades the surrounding tissue and matrix creating a path of least 
resistance for the cancer cells to follow. 
 
Reactive tumour stroma was not observed in the murine xenograft models. 
Stroma recovered from tumours greater than one month after the 
subcutaneous injection of PC-3 cells, do not express podoplanin, VCAM-1 or 
ICAM-1 expression. Although we did not conclusively show why reactive 
tumour stroma does not develop, the absence of the adaptive immune 
system and absence of ILCs and NK cells in the $c-/- RAG2-/- mice will lead to 
a failure of TLT formation and a lack of TNF-α, LTβ or IL-4 receptor 
signaling will occur in the stromal progenitor cells. A large F4/80+ 
macrophage infiltrate could potentially produce IL-4, however there is no 
evidence that they can drive expression of lymphoid stromal specific gene 
signatures in tumour stromal cells in vivo. Thus the model of PC-3s injected 
in to immune deficient mice is not a robust model of human metastatic 
disease. Although PC-3 cells show some metastatic potential these 
experiments are done by transferring the cells intravenously into mice, thus 
the first step in the metastasis process is bypassed. The inherent nature of 
subcutaneous injection of a large population of cancer cells bypasses the 
normal formation of tumour microenvironments in the prostate. But perhaps 
the lack of a reactive stromal environment has a key role in the lack of 
progression of disease in this model. Thus the requirement to utilise models 
of prostate cancer that arise spontaneously in mice. 
 
Using a syngeneic model of LL/2 cell carcinoma which is not rejected by the 
immune system it is possible to study the mechanisms driving tumour 
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stroma induction. LL/2 is an extremely aggressive lung cancer cell line from 
C57BL/6 mice which rapidly forms solid tumours after subcutaneous 
injection in syngeneic mice. The LL/2 model has been successfully used by 
immunologists analysing stroma in tumours and there has been good 
evidence that it can generate a reactive stroma that has a role in immune 
responses (Kraman et al. 2010). We found that podoplanin, VCAM-1 and 
ICAM-1 were rapidly induced on tumour stroma, consistent with B and T 
cell mediated reactive stroma induction. The failure of reactive stroma 
formation in the absence of B & T lymphocytes is consistent with a unique 
role for the adaptive immune response in stromal cell activation. In the 
future it will be interesting to determine which T or B cell populations are 
responsible for generating reactive stroma through using B cell (Ighm-/-), αβ 
T cell (TCRα-/-), γδ T cell (TCRδ-/-), Th17/22, CD4 (class II-/-) or CD8 T cells 
(β2M-/-) mice. 
 
Podoplanin is expressed by stromal cells, specialised epithelial cells, some 
macrophages and on lymphatic vessels and the increase in the numbers of 
podoplanin positive vessels in a tumour occurs as a result of 
lymphangiogenesis. This is used as a diagnostic marker in some tumour 
types (Swartz & Lund 2012). However, reports are conflicting as to whether 
this predicts a poor outcome (Pula et al. 2011; Kitano et al. 2010) or a 
favourable outcome for patients with cancer (Yamanashi et al. 2009). Whilst 
podoplanin can be found at the leading edge of some tumours and is 
expressed on some tumour cells (Kato et al. 2005), we found no evidence for 
the expression of podoplanin by PC-3 cells. Therefore any interaction 
between podoplanin and its ligand CLEC-2, may have role in stromal 
mediated tumour metastasis rather than direct effects on transformed 
epithelial cells. CLEC-2 in the immune system is highly expressed by 
dendritic cells and platelets and potentially neutrophils. Podoplanin is 
rapidly up regulated on mesenchymal stroma in secondary lymphoid tissues 
during infection and podoplanin has previously been shown to be up-
regulated by CAFs (Kitano et al. 2010). Invasive lung carcinoma was 
associated with podoplanin expressing CAFs whereas fibroblasts within 
noninvasive disease were all negative (Kawase et al. 2008). In prostate 
tumour stroma, we found a clear association with podoplanin expressing 
stroma and higher Gleason grade, which in turn is associated with highly 
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migratory stromal cell behaviour. The loss of migratory capacity through 
culture correlates strongly with loss of podoplanin expression consistent 
with a requirement for podoplanin or the podoplanin gene expression profile 
in tumour cell migration and likely arises from loss of the stimulatory 
background. In the future it will be interesting to determine if co-culture of 
lymphocytes with stroma is sufficient to maintain phenotype or whether this 
requires an antigen specific response. This, combined with the lowered 
adhesion molecule expression by the stroma could be part of a mechanism 
that contributes to the migration, invasion and metastasis of prostate cancer 
cells. At this stage it is not possible to draw definitive conclusions for the role 
of podoplanin in this model. Podoplanin expression by the transformed 
stroma in this model and the fact that this tumour stroma elicits PC-3 
invasion of the matrix, could suggest a role for podoplanin in marking 
activated tumour stroma. 
 
Intercellular adhesion molecule-1 (ICAM-1) and vascular adhesion molecule-
1 (VCAM-1) are both adhesion molecules involved in integrin binding and 
cell migration. When ICAM-1 binds to integrins on leukocytes they become 
attached to the vascular endothelium resulting in migration in to the 
interstitial space (Springer 1994). VLA-4 expressed on leukocytes interacts 
with VCAM-1 to promote migration and cell-cell interactions. VCAM-1 is 
expressed on activated vascular endothelium (Cybulsky et al. 1991) and 
binds to VLA-4 which is expressed on the surface of leukocytes (Alon et al. 
1995). The process of cancer development, invasion, and metastasis involves 
cell migration and thus it is likely that some of the mechanisms used by the 
immune system may have a key role in tumour cell migration and 
interactions. Recent reports have linked podoplanin with a novel partner 
CD44 (the major hyaluronan receptor) which together promote directional 
cell migration in an epithelial mouse model of squamous carcinoma (Martín-
Villar et al. 2010). But evidence is still contradictory as to it’s association in 
human cancers and the role of podoplanin in cancer associated stroma 
remains unknown (Pula et al. 2011; Kitano et al. 2010; Chuang et al. 2009). 
Together this might lead to a model of tumour migration where VCAM-1, 
ICAM-1 and podoplanin have a role in regulating metastasis.  
 
! 111!
Putative prostate cancer stem cells as defined by CD44+/α2β1high/CD133+ and 
isolated from primary culture showed significant migration in our primary 
culture model and active cell division. The high level of α2β1 integrin, also 
known as VLA-2, expressed by CSCs permits direct binding of collagen and 
the use of the fibrils along which to migrate. A process seen used by HT-
1080s migrating through the same collagen in vitro matrix. α2β1 expression 
has already been shown to promote collagen binding and cell migration in 
other cell types such as Th17 cells migrating to sites of inflammation 
(Boisvert et al. 2010). This was a direct contrast to PC-3 cells and more 
mature prostate cancer cell lines that must migrate in a collagen I 
independent process as they lack the integrin expression profile required to 
interact with the ECM and thus migration must depend on cellular 




Figure 4.1 Normal prostate architecture is lost in high Gleason tumour tissue. (A) 
BPH tissue section stained for collagen I (green) to mark the stroma, pan-cytokeratin 
(red) to mark the epithelial cells, and DAPI (blue) for nuclei. The glandular structure 
of the tissue can clearly be seen. (B) Tumour tissue section stained with the same 
markers shows a loss of architecture, an overgrowth of epithelial cancer cells (red) 
and disorganised stroma (green). (C) zoomed image of (A) showing the clear 
boundary between the epithelia of the gland and the surrounding stroma. (D) 
zoomed in image of (B) highlighted the strong collagen I staining (green) of the 






Figure 4.2 High Gleason stromal cells migrate further than BPH stroma and 
influence PC-3 migration in 3-D. (A) Pair of BPH stroma/PC-3 spheroids imaged 
after 48hr in 3-D culture in collagen. (B) second pair of spheroids containing tumour 
stroma. (C) quantification of BPH stromal and PC-3 cell migration over 48hr. (D) 
quantification of tumour stromal and PC-3 cell migration over 48hr. (E) 
Quantification of PC-3 cell displacement over 48 hours. (F) Quantification of single 
PC-3 cell displacement over 48hr. Bar: 71%m. Bar represents mean±SEM, 




















Figure 4.3 Migratory behaviour of stromal cells is lost over time in culture. (A) 
Comparison of spheroid growth and cell migration over 48 hours for spheroids 
containing PC-3 cells (red) and tumour stroma (green) at either passage 1, 4, or 7 
over 48 hours. (B) 2-D spheroid area over time. (C) 2-D spheroid area change over 





















Figure 4.4 Gene expression analysis of a range of stromal cells over time in culture. 
(A) a table showing the collection of tumour stromal samples from Gleason 6, 8, and 
9, and one from BPH ranging from early to late passage in culture. (B) Part of the 
full expression profile map, with clustering, analysed using Treeview. (C) a table of 
genes involved in matrix remodeling, migration and cancer metastasis showing the 
relative difference in expression between BPH, mid-range Gleason 6 and high 
Gleason 8. !  
A! B!

































Figure 4.5 Prostate tumour stroma phenotypically resembles TLT. (A) 
Representative plot from one high Gleason tumour stroma sample showing the high 
level of VCAM-1, ICAM-1, and Podoplanin expression (blue line) against isotype 
controls (red line) (B) 6 tumour stroma samples were analysed and compared to the 
expression level of PC-3 cells which express very little of each marker. (C) a linked 
plot shows the potential link between the 3 proteins with high levels of VCAM-1 
correlating with high levels of ICAM-1 and podoplanin. (D) Expression of VCAM-1, 
ICAM-1, and Podoplanin at passage 1 in culture (green line) compared to passage 6 








Figure 4.6 Analysis of mouse infiltrate in to human xenograft models. (A) 
representative plots of the expression of podoplanin (GP38), VCAM-1, and ICAM-1. 
Cells gated on CD45- CD31- expression. (B) The majority of CD45+ cells are F4/80+ 
as shown here. (C) Analysis of total mouse infiltrate, the hematopoietic population 
and tumour stroma. !  
Mouse tumour infiltrate.
Marker Cell Type Percentage No. experiments
CD45+ Haematopoetic 45.4 5
CD31+ Endothelial 9 5
CD45- CD31- Tumour Stroma 30 5
Haematopoetic cell analysis (CD45+).
Marker Cell Type Percentage No. experiments
F4/80 Macrophages 51.5 4
CD11c Dendritic Cells 3.15 2
GR1 Neutrophils 10.95 2
Analysis of tumour stroma (HLA- CD45- CD31-).
Marker Cell Type Percentage No. experiments
VCAM Vasculare Cell 0 2
Adhesion Molecule













Figure 4.7 Inflammatory cytokines can rescue a high Gleason phenotype lost in 
passage through culture. (A) Representative histogram showing the level of VCAM-
1 expression in non-treated, high passage, tumour stroma (Control – black line) 
against the same cells treated with an inflammatory cytokine cocktail (Treated – red 
line) compared to the isotype control (grey shaded). (B) Dot plots from the same 
experiment showing the raise in the level of expression of both VCAM-1 and ICAM-
1 for the control and treated cells. (C) Quantification across 3 separate experiments 
of the expression levels of podoplanin, ICAM-1 and VCAM-1 for control and treated 













Figure 4.8 Inflammatory cytokines induced stromal cell migration and thus PC-3 
migration. (A) Time-lapse imaging over 3 days for spheroids containing non-treated 
control vs treated stromal (red) both containing PC-3 cells (green). Scale unit: 64%m 
(B) Single cell tracking for stromal cells and PC-3 cells in control and treated 
spheroids. Quantification of cell displacement for stromal cells (C) and PC-3 cells 
(D) in control and treated spheroids. Bar represents mean±SEM, ***p<0.0001 (t test) 
























Figure 4.9 Analysis of tumours resulting from subcutaneous injection of LL/2 cells 
in to mice from 4 different genetic backgrounds. Injections carried out by Dr Mark 
Coles (A) tumour weight and (B) tumour volume at 14 days. (n≥3); bars show 
means±SEM, ANOVA with post-hoc Tukey showed $c-/- RAG2-/- to be significantly 





Figure 4.10 FACS analysis of LL/2 tumours. (A) Gating strategy to pull out the 
CD45- EpCAM- tumour stroma (B&C) the expression of podoplanin and CD31 
across each mouse background (n≥3); bars show medians ± SE (D&E) the expression 
of VCAM-1 and ICAM-1 for each genetic background. (n≥3); Data was arsine 
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Figure 4.11 Primary human prostate cancer stem cells migrate in 3-D in vitro with 
tumour stroma/PC-3 spheroids. (A-L) Time-lapse imaging over 3 days of primary 
human prostate cancer stem cells (green) incorporated in to tumour stroma/PC-3 
spheroids (red). Each image represents a 6 hour time point over 66 hours. A single 
CSC (white box in A) is tracked over time migrating out of the spheroid (B-H) 
before dividing (I-K) with one cell moving further in to the matrix and one cell 









Chapter 5  
A Role for SPARC and VLA-4 in 
Prostate Cancer Cell Growth and 
Migration in 3-D 
!
5.1 Introduction 
5.1.1 Vascular Cell Adhesion Molecule-1 (VCAM-1) – VLA-4 interactions 
We have previously shown that VCAM-1 expression is regulated on tumour 
stroma. VCAM-1 is also expressed on activated vascular endothelium as a 
result of inflammatory signals including TNFα and IL-4 and has a key role in 
leukocyte extravasation into tissues (Cybulsky et al. 1991). VLA-4 (also 
known as integrin α4β1) is the counter ligand for VCAM-1 that is expressed 
by leukocytes (Elices et al. 1990). Binding of VLA-4 to VCAM-1 results in the 
tethering of migratory leukocytes to the endothelial cells, permitting 
transmigration through the vascular endothelium and into the interstitial 
space of peripheral tissues (Alon et al. 1995). 
 
Most of our understanding of the molecular and biophysical mechanism of 
VCAM-1-VLA-4 interactions has been carried out on leukocytes and 
understanding its role in the processes of tethering, adherence, and 
diapedesis. Using blocking monoclonal antibodies (mAb) to the !4 integrin 
component of VLA-4, it has been shown that the migration and diapedesis of 
THP-1 cells is dependent on VLA-4-VCAM-1 interactions (Ronald et al. 
2001). More recently Natalizumab (a humanized antibody against the !4 
integrin) has been developed as a therapeutic for Multiple Sclerosis (MS), 
preventing VCAM-1-VLA-4 mediated leukocyte migration into the 
peripheral nervous system. The antibody was developed as a therapeutic 
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after it was discovered that anti-!4 antibodies prevented the accumulation of 
leukocytes in the central nervous system, and stopped the development of 
experimental autoimmune encephalomyelitis (EAE) in rats which has been 
used to model MS for several decades (Yednock et al. 1992). Two clinical 
trials in patients with MS resulted in an increase in the proportion of patients 
remaining relapse-free (76% and 67%) compared to patients in the placebo 
control group (53% and 46%) (Noseworthy & Kirkpatrick 2005). The Food 
and Drug Administration (FDA) approved Natalizumab for the treatment of 
patients with relapsing forms of MS in November 2004 (www.fda.gov). 
Although clinically highly effective, blocking VLA-4 using Natalizumab has 
lead to human polyomavirus mediated encephalitis in very small numbers of 
patients resulting from acute immunosuppression. Blocking both VLA-4 and 
VCAM-1 independently and together has been analysed in an experimental 
model of neuritis and found that in all three cases increased T cell apoptosis 
was observed indicating a potential alternative role for VCAM-1-VLA-4 
interactions (Leussink et al. 2002).  
 
Fibronectin, an alternative ligand for VLA-4, and VCAM-1 are both strongly 
expressed on bone marrow stroma. Analysis of hematopoietic progenitor 
cells adhesion to bone marrow stroma has shown a role for these interactions 
(Simmons et al. 1992). Additionally VLA-4 has been shown to mediate the 
attachment of myeloma cancer cells to bone marrow stroma, and was found 
to be the sole source of adhesion to VCAM-1 and fibronectin expressed by 
stromal cells (Sanz-Rodríguez et al. 1999; Sanz-Rodríguez et al. 2001). 
Analysis of human oral squamous cell carcinoma cell lines shows that 70% 
express VLA-4, and could interact with VCAM-1 on adjacent vascular 
endothelium (Song et al. 2012). Importantly, this study also showed that 
TNF-! expression from the tumour stimulated the expression of VCAM-1 on 
the endothelium resulting in tighter cell adhesion and fusion of the tumour 
to the endothelium. Treatment with anti-VCAM-1 or anti-VLA-4 blocking 
mAb, resulted in a significant decrease in cell adhesion and completely 
blocked fusion of tumour cells to the adjacent blood vasculature (Song et al. 
2012; Leussink et al. 2002). 
 
High expression of VCAM-1 correlates with the Gleason grade tumour 
stroma, and VCAM-1 high grade tumour stroma induces the migration of 
PC-3 cells thus it is possible that VCAM-1 has a significant role in tumour 
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cell migration. This could be through its transmembrane ligand VLA-4 or 
through an alternative ligand secreted protein, acidic and rich in cysteine 
(SPARC). 
 
5.1.2 Secreted Protein, Acidic and Rich in Cysteine (SPARC) 
SPARC, also known as osteonectin and BM-40, has been shown to have roles 
in cell repair, proliferation, and spreading (H. Sage, Decker, et al. 1989a; H. 
Sage, Vernon, et al. 1989b). SPARC expression has been linked to multiple 
different types of cancer including colorectal cancer (Porte et al. 1995), lung 
cancer (Bendik et al. 1998), human breast cancer (Gilles et al. 1998), and 
ovarian cancer (T. J. Brown et al. 1999). Although the mechanism of how 
SPARC functions is unknown, different cancers have implicated different 
potential mechanisms including a role in regulation of MMPs and tumour 
cell growth. 
 
SPARC expression has been analysed in prostate cancer in comprehensive 
panels of primary tumours, metastatic foci, and prostate cancer cell lines. 
Analysis showed that high levels of SPARC mRNA and protein correlated 
with metastatic foci, and that although expression was detected in glandular 
epithelial cells of normal tissue, expression was higher in these foci and in 
some primary prostate cancer samples. Thus the differential expression of 
SPARC indicates it may have an important role in prostate cancer 
progression (R. Thomas et al. 2000). Presently, the role of SPARC in prostate 
cancer growth and metastasis is mechanistically unknown. 
 
SPARC is a 40kD acidic glycoprotein, containing a cysteine-rich single 
polypeptide. The mature protein is glycosylated and SPARC predominantly, 
although not exclusively, acts as a secreted protein where it can bind 
collagen through a collagen-binding domain (Sasaki et al. 1998). SPARC was 
initially thought to be produced solely in bone and was identified as a 
chemoattractant found in bone conditioned media. Purified, SPARC was 
shown to promote DU-145 and PC-3 prostate cancer cell migration but not 
non-bone metastasising cell lines including B16-F10 mouse melanoma and 
HT-1080 fibrosarcoma. Specifically, SPARC induced an increase in the 
collagenase/gelatinase A protease MMP-2 activity in DU-145, PC-3 and also 
the breast cancer cell line MDA-MB-231. SPARC did not induce any change 
in MMP activity in B16-F10 and HT-1080 cells. Analysis of breast and 
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prostate cancer cell lines reactive to SPARC as shown by an increase in 
MMP-2 activity, in a Boyden chamber assay showed increased cancer cell 
invasiveness through a collagen IV matrix suggesting a role for SPARC 
induced MMP-2 activity in those cancer cells that exhibit bone metastasis 
(Jacob et al. 1999). 
 
Genetic polymorphisms in SPARC have been identified including five 
common variations in the 3’-untranslated region (UTR) (Winder et al. 2012). 
These polymorphisms, including three single nucleotide polymorphisms 
(SNPs) found in the 3’UTR have been linked to bone density and bone mass 
(Delany et al. 2008). More recently SNPs located in the coding region of the 
SPARC gene have been significantly associated with cancer. An individual 
SNP in the 3’UTR has been strongly linked to a predisposition to gastric 
cancer recurrence (Winder et al. 2012) whereas another has been shown to be 
significantly associated with hepatocellular carcinoma (Segat et al. 2009). 
 
It has been shown that SPARC can act to reduce metastasis and therefore act 
in a protective manner. Melanoma metastasis formation has been shown to 
reduce via a SPARC-dependent mechanism. Endothelial progenitor cells 
contribute to melanoma tumour growth and progression to a metastatic 
disease (D. Gao & Mittal 2009). However, more recent studies have shown 
that endothelial progenitor cells when preconditioned with tumour cell 
condition media, were able to physically interact with tumour cells, in a 
SPARC dependent manner (Defresne et al. 2011). The pre-conditioned 
endothelial progenitor cells, took on a defensive role and increased their 
phagocytic characteristics with the capacity to eliminate tumour cells. The 
overexpression of SPARC was observed in these cells after exposure to 
conditioned media, and subsequent experiments using recombinant human 
SPARC recapitulated the anti-tumour cell behaviour (Defresne et al. 2011). 
This is contrary to numerous studies that link SPARC overexpression in 
tumour cells to a pro-invasive role (H.-Y. Wang et al. 2012; Derosa et al. 2011; 
S. Thomas et al. 2011; Said et al. 2009). In addition, high levels of SPARC 
expression in colorectal cancer are associated with better disease outcome 
(Chew et al. 2011). The role of SPARC is highly contextual. SPARC 
expression in colorectal cancer is exclusive to stromal mesenchymal cells and 
not in tumour cells (Chew et al. 2011) whereas in prostate cancer expression 
is clearly seen in the tumour cells in vivo and in prostate cancer cells lines 
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(Said et al. 2009) where high levels of SPARC is associated with poor 
prognosis and increased metastatic disease. 
 
SPARC, when overexpressed in a hepatocellular carcinoma cell line using 
adenovirus expression system, has no observed effect on cellular numbers 
and or cell cycle check point in 2-D cell culture (Atorrasagasti et al. 2010). 
However, when grown as spheroids in 3-D the SPARC overexpressing cells 
showed a clear reduction in the rate of proliferation, and mild increase in 
apoptosis, as compared to non-transfected controls (Atorrasagasti et al. 
2010). In vivo, the human SPARC overexpressing human hepatocellular 
carcinoma cells failed to form tumours in an athymic mouse model and 
survival of tumour cells was decreased. The failure in tumour growth might 
originate from an observed increase in macrophage infiltration in to the 
tumour site (Atorrasagasti et al. 2010). Contrary to what was shown in 
hepatocellular carcinoma cells, overexpression of human SPARC in human 
melanoma cells promoted cell survival resulting from an increase in the 
degradation of tumour suppressor p53. Western blot analysis showed that 
SPARC activates Akt, leading to phosphorylation of MDM2 inactivating p53 
(Fenouille et al. 2011). 
 
To further study the role of SPARC in the development and function of 
normal tissues, mice with a homozygous null mutation in the SPARC gene 
(SP-/-) mice were generated (Gilmour et al. 1998; Norose et al. 1998). These 
mice were shown to exhibit high levels of adiposity. The number of 
adipocytes as well as the cell size was significantly increased but not to the 
detriment of body weight compared to control mice. In this case SPARC was 
proposed to limit the accumulation of subcutaneous fat in mice primarily by 
regulating adipocyte size and number (Bradshaw et al. 2003). SP-/- mice also 
exhibit osteopenia – a loss in bone mineral density (Mansergh et al. 2007), 
early-onset cataractogenesis (Yan & E. H. Sage 1999) and accelerated wound 
healing (Bradshaw et al. 2002). Subsequently these mice were crossed with 
the TRAMP mouse model, surprisingly these mice developed tumours at a 
faster rate. This goes against the link between high levels of SPARC 
expression found in aggressive human tumours and the expression of 
SPARC in many human cancer cell lines (Said et al. 2009). Collectively these 
results indicate a limited role for SPARC in a primary TRAMP model of 
prostate cancer, but an overall complicated role in development and 
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tumourigenesis depending on cell type and microenvironment. Tumour 
growth in SP-/- mice using a mouse Lewis lung carcinoma is enhanced 
suggesting a role in tumourigenesis which is non-prostate specific. Thus the 
context of SPARC expression is critical to understand its function.  
 !  
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5.2 Summary and Aims of this Chapter 
VCAM-1 and VLA-4 have a key role in leukocyte adhesion and migration, 
more recently a potential role for VCAM-1-VLA-4 interactions has been 
shown in sarcoma cell migration. However a role for both proteins in 
prostate cancer cell migration is unknown. A second ligand that binds to 
VCAM-1, SPARC, has been highlighted as having a possible role in prostate 
cancer (R. Thomas et al. 2000), thus we hypothesise that competition between 
membrane bound VLA-4 and secreted SPARC has a key role in regulating 
the adhesion/de-adhesion process of VCAM-1 mediated prostate cancer cell 
migration. 
 
By utilising gene expression analysis, shRNA knockdown, 4-D imaging of 
spheroids and an in vivo xenograft mouse model the aims of this chapter are 
as follows: 
 
1) To investigate the levels of SPARC and VLA-4 expression, in BPH, 
across a range of primary prostate tumour samples and prostate 
cancer cell lines. 
2) To characterise the phenotype of PC-3 SPARC knockdowns. 
3) To investigate and determine the role of VCAM-1 ligands SPARC and 
VLA-4 in prostate cancer cell migration in 3D. 
4) To investigate the possible role of SPARC in human tumour 
development in vivo. ! !
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5.3 Methods 
5.3.1 Immunofluorescence of SPARC protein expression 
The PC-3 WT parent cell line and 3 different PC-3 SPARC knockdown clones 
(section 2.3.2) were seeded on to sterile 13mm circular coverslips in the 
bottom of a 24-well tissue culture plate. The cells were allowed to adhere 
overnight at 37°C with 5% CO2 for 48 hours. All wells were then washed 
once with PBS and fixed with 4% PFA for 10 min. 
 
Once washed twice more with PBS, the cells were stained with phalloidin, 
anti-SPARC antibody, and counterstained with DAPI to stain for f-actin, 
SPARC and DNA respectively. 
 
After a second fixation step of 4% PFA for 10 min, the 13mm coverslips were 
mounted on to glass slides using ProLong Gold antifade reagent (Invitrogen) 
and imaged the following day, after an overnight incubation at 4°C, via 
confocal microscopy on an LSM 710 confocal microscope (Zeiss). 
 
5.3.2 Subcutaneous injection of PC-3 cells in to γc-/- RAG2-/- mice 
PC-3 wildtype cells resuspended in 3mg/ml collagen I at a cell density of 
7x106 cells/ml. The same procedure was carried out for PC-3 SPARC 
knockdown cell line. A mix was also made consisting of both cell types at a 
ratio of 1:1 to give a total cell density of 7x106 cells/ml. Cells were mixed 
with collagen in order to recapitulate the in vitro microenvironment in which 
experiments leading up to this point had been carried out, to create a solid 
plug to stop cells escaping immediately post-injection, and to rule out any 
exogenous effects of other co-injection material such as Matrigel. 
 
Five γc-/- Rag2-/- mice were subcutaneously injected for each group (15 mice 
in total) each receiving 5x105cells in 100%l collagen and mice were sacrificed 
and tumours removed 5 weeks post injection. Tumours were cleaned of all 
hair, skin and fat, and then measured using calipers and weighed on a fine 
balance. Subcutaneous injections were carried out by Dr Mark Coles. 
 
5.3.3 VCAM Fc binding 
PC-3 cells in culture were first washed twice with Dulbecco’s PBS, then 
collected by using a PBS-based non-enzymatic cell dissociation buffer 
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(Invitrogen), which allows for ligand binding studies via gentle cell 
dissociation. 1x105 PC-3 cells per sample were spun at 300 g and the 
supernatant discarded. The cell pellet was then resuspended in 100%l PBS 
supplemented with 0.05% BSA and the wash process repeated once more. 
VCAM Fc protein was reconstituted in PBS to a stock concentration of 
100%g/ml. PC-3 cells were incubated in 100%l PBS containing VCAM Fc 
protein (final concentration of 20%g/ml) at 37°C for 30 minwith regular, 
gentle mixing. After a single wash with PBS supplemented with 0.05% BSA, 
cells were resuspended in anti-human IgG secondary antibody conjugated to 
PE at a concentration of 1:100. Cells were incubated for a further 30 min 
before being washed once and resuspended in 500%l PBS supplemented with 
0.05% BSA. Cells were then analysed by flow cytometry. !  
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5.4 Results 
5.4.1 SPARC and VLA-4 expression in primary tumour cells 
We have previously shown that VCAM-1 was expressed by primary human 
prostate tumour stroma (Chapter 4). Typically, high expression correlated 
with tumour stroma from higher Gleason grade tumours and from fresh, 
early passage cells. VCAM-1 expression was lost by the stromal cells over 
time in culture and lower levels of VCAM-1 expression were detected in 
tumour stroma originating from lower Gleason grade tumour and stroma 
from BPH samples. Therefore we analysed the expression of VCAM-1 
ligands, !4 and "1 integrin subunits and SPARC by qRT-PCR in primary 
prostate cancer cells and prostate cancer cell lines. RNA was extracted from 
epithelial cells from a range of tumours as detailed below. cDNA was 
synthesised from this RNA and a qRT-PCR was carried out using primer 
pairs specific for !4 integrin, SPARC, and GAPDH was used as an internal 
housekeeping control. 
 
Analysis was carried out using the ABI software to ascertain Ct values from 
which the relative expression of the target genes was worked out. Analysis of 
SPARC expression shows expression levels correlate with Gleason grade 
tumour cells tested (Figure 5.1). Compared to two lower Gleason grade 6 
tumours, expression of SPARC is approximately 15- to 20-fold greater. 
Relative to PC-3 cells which are known to express high levels of SPARC (S. Y. 
Wong et al. 2008) the expression in primary prostate tumour cells is up to 30-
fold higher. One complication with this analysis was that these prostate 
tumour cells contain a non-homogeneous distribution of luminal, basal, and 
transit-amplifying epithelial cells between different samples. 
 
The pattern of SPARC expression in primary cells originating from BPH 
tissue is less clear. All three samples showed relatively high levels of SPARC 
expression compared to the PC-3 control cells. The lowest being 10-fold 
greater expression than that found in PC-3 cells, and the highest being 
approximately 20-fold in two of the BPH cases. 
 
Integrin !4 expression does not, at this stage, appear to follow a clear pattern. 
The highest expression of !4 integrin is exhibited by one of the Gleason grade 
6 tumour samples (Figure 5.1 B), however a sample from a different patient 
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of the same Gleason grade shows very little expression. The same random 
expression of !4 integrin is observed in the 3 BPH samples tested. However, 
consistently these samples express either the same, or lower levels of !4 
integrin compared to PC-3 cells. However what is unclear is how this 
correlates to the overall number of !4 integrin expressing epithelial cells. 
 
5.4.2 SPARC and VLA-4 expression in prostate cancer cell lines 
The prostate cancer cell lines PC-3, LNCaP, and VCAP were all tested for the 
expression of SPARC and !4 integrin by qRT-PCR. 5x105 cells were pelleted 
via centrifugation, washed once with PBS and lysed to extract RNA via an 
RNeasy kit (QIAGEN). cDNA was synthesised from this RNA and the 
expression of SPARC and !4 integrin was analysed using gene specific 
primers. 
 
The results of the qRT-PCR are shown in Figure 5.1 (C&D). Relative to PC-3 
cells, the expression of SPARC in LNCaP and VCAP was undetectable. 
Again relative to PC-3s, the two other cell lines express very little VL-4 with 
expression undetected in LNCaP cells. Thus the percentage of PC-3 cells 
expressing VLA-4 was determined by dual antibody staining for both !4 and 
β1 integrin subunits analysed by flow cytometry (Figure 5.1 E). Interestingly 
although all PC3 cells expressed the β1 integrin only a small percentage 
expressed α4. The level of α4 integrin staining is low showing a low level of 
expression on small percentage of cells. This was compared to T cells which 
in this case were used a positive control. T cells were isolated from leukocyte 
cones (NHS Blood and Transplant) using RoetteSep technology (Stem Cell 
Technologies), stained for !4 integrin and analysed by flow cytometry. T cells  
are known to express VLA-4 (Alon et al. 1995; Muraro et al. 2000), and 60% of 
T cells were positive for !4 integrin in this instance (Figure 5.1 F). 
 
5.4.3 shRNA knockdown of SPARC in PC-3 cells 
To further investigate the role of SPARC function in PC-3 cell migration, 
inducible shRNA constructs were sourced to knockdown human SPARC 
mRNA (Sigma-Aldrich) in PC-3 cells. 
 
Plasmid DNA was introduced in to PC-3 cells as described in methods 
section 2.3.2 and bulk cultures of polyclonal transfected PC-3 cells as well as 
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single cell clones were cultured under selection until stable. Bulk cultures 
and single cells clones were analysed for SPARC mRNA knockdown with, 
and without, the addition of the inducible factor IPTG. Dioxine-free IPTG 
(Sigma-Aldrich) was added to the growth media of the cells at a final 
concentration of 1mM and 72 hours incubation was allowed for full 
induction of the shRNA as according to the manufacturers instructions. RNA 
was extracted from 0.5x106 cells and SPARC mRNA levels were detected via 
qRT-PCR. The results are shown in Figure 5.2. 
 
SPARC mRNA levels remained unchanged in the bulk cultures without the 
addition of IPTG. After 3 days of induction, levels of SPARC mRNA dropped 
by approximately 25% but with a large variability across triplicate cultures. 
 
Of the 24 single cell clones, 6 survived long term culture under selection for 
sequential passages to increase numbers. Namely; PS1, PS3, PS5, PS10, PS14, 
and PS17. All 6 clones turned out to be markedly different in the expression 
levels of SPARC mRNA. Indeed some clones exhibited an increase in SPARC 
mRNA levels relative to the PC-3 wild type control, most notably PS10 
whose levels rose as much as 20-fold without induction which decreased to a 
10-fold rise after being induced by IPTG, again relative to the PC-3 wild type 
control. Of the 6 clones, PS5 exhibited the most efficient knockdown with 
levels of SPARC mRNA knockdown of 85% and 80% without and with 
induction respectively. This was consistent in subsequent tests and future 
cultures (Figure 5.2 D). Based on this, the PS5 clone was used as a non-
inducible shRNA knockdown of SPARC mRNA levels in future experiments. 
 
To further strengthen experiments, several more PC-3 SPARC knockdown 
clones were made using the same system and clones were selected for based 
on their efficiency of SPARC knockdown without the need for IPTG 
induction. This resulted in 2 further clones (PS1a and PS1b) that had close to 
100% knockdown as shown in Figure 5.2 (D). These were treated as clones 
containing a non-inducible vector and so knockdown was assumed to be 
constitutive without the need to add IPTG. 
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5.4.4 PC-3 SPARC knockdown clones are markedly different to PC-3 WT 
parent cell line in morphology 
Analysis using immunofluorescence of PC-3 cells deficient for SPARC 
expression showed clear differences in cellular morphology (Figure 5.3 A). 
Loss of SPARC protein affects both the cells shape and size. PC-3 cells are 
typically non-circular and mesenchymal in shape, and in the range of 30-
60%m in length with evidence of focal adhesion sites that co-localise with 
SPARC (white arrows in Figure 5.3 A). A proportion of the SPARC 
knockdown cells are in excess of 250%m in diameter and have taken on a 
round, flat, and epithelial like morphology. Whilst the size of wild type cells 
remains homogeneous with close to 100% of the cells falling in the range of 
30-60%m, there are clear differences in the size of the cells within the SPARC 
knockdown clones. The SPARC knockdown clones range from WT sizes of 
approximately 40%m up to cells as large as 250%m. However, from a shape 
morphology point of view, this is consistent, with all SPARC knockdown 
cells exhibiting a very uniform round cell shape. These cells exhibit high 
levels of cortical actin at the periphery of the cell (yellow arrow heads in 
Figure 5.3 A) which is not observed in WT controls. 
 
The levels of SPARC protein expression was quantified using an anti-SPARC 
antibody (Figure 5.3 B). Whilst there is some staining on the knockdown 
cells, this is consistent with the shRNA knockdown not being 100% efficient. 
The overall levels of SPARC protein, as measured by anti-SPARC antibody 
staining and mean pixel fluorescence intensity across 3 independent fields of 
view, were significantly lower in the three PC-3 SPARC knockdown cell lines 
tested as compared with PC-3 WT cells. 
 
5.4.5 Knocking down SPARC in PC-3 cells increases motility in 2D 
PC-3 WT and SPARC knockdown cells were seeded on to a 3.5cm glass 
bottom dish and allowed to attach overnight in HAMS-F12 media. The 
following day the cells were imaged via bright field microscopy as described 
in methods section 2.14.4. Single cells were tracked from two or more 
independent experiments using the manual tracking plugin within the 
software package ImageJ. 
 
PC-3 WT cells retained their original morphology (Figure 5.4 A-C) with wild-
type cells appearing more mesenchymal in shape as opposed to the large 
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round phenotype of the SPARC knockdown cells. Analysis shows the 
SPARC knockdown cells move at a significantly faster velocity. PC-3 cells 
tended to move around one another in particular at times of cell division. 
However, PC-3 SPARC knockdown cells moved rapidly and often 
independent of any cell-cell contact. 
 
5.4.6 Knocking down SPARC in PC-3 cells inhibits migration in 3-D in 
spheroids containing cancer tumour stroma 
High Gleason grade, early passage tumour stroma was used in conjunction 
with PC-3 SPARC knockdown cells in a 3-D spheroid assay. As a control, 
spheroids were also made using the same tumour stroma, and PC-3 WT cells. 
 
Both sets of spheroids were implanted in to collagen I gels and imaged via 2-
photon microscopy. Representative images at 3 separate time points for both 
sets of spheroids are shown in Figure 5.5 (A&B). Imaging clearly shows that 
in both sets of spheroids, the stromal cells in green have migrated in to the 
collagen as previously observed. However, only control PC-3 cells migrated 
significantly into the collagen. The majority of PC-3 SPARC knockdown cells 
remain within the spheroid with very few migrating in to the matrix. Single 
cells were tracked and measurements are shown in Figure 5.5 (C). While the 
displacement of stromal cells remains unaffected in both spheroid sets, there 
is a significant reduction in the displacement of PC-3 cells with reduced 
levels of SPARC protein. 
 
5.4.7 PC-3 SPARC knockdown cells fail to establish tumours in vivo  
To investigate a possible role for SPARC in vivo, PC-3 wildtype (control) and 
PC-3 SPARC knockdown cells were introduced in $c-/- Rag2-/- mice via 
subcutaneous injection in collagen either as a pure population or as a mixture 
with PC-3 WT cells. 
 
Tumours were successfully recovered from 14 mice at the end of the 
experiment, leaving only one failing to establish (the mixed cells) which was 
then absent in subsequent analysis. Tumours were first cleaned of all hair, 
skin and fat, and then measured using calipers (Figure 5.6). The volume of 
the tumours resulting from the injection of PC-3 WT cells only, was 
significantly higher than that of the volume of the tumours consisting of PC-
3 SPARC knockdown cells (p=0.035). The difference between wildtype and 
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the 50:50 mix of cells was not significant (p=0.07) but a strong difference was 
observed. Tumour weight, as expected, followed the same pattern when 
comparing PC-3 wildtype tumours to the SPARC knockdown tumours and 
to the mixed cell tumours. However, a statistically significant difference was 
not observed in either case (P=0.08 and 0.14 respectively). 
 
5.4.8 PC-3 SPARC knockdown cells are in G2/M arrest but still 
proliferate in vitro 
To determine if a defect in proliferation in the SPARC knockdown cells lead 
to failure or a delay in tumour growth, cell cycle analysis and a proliferation 
assays were carried out PC-3 wild type cells, and three PC-3 SPARC 
knockdown clones. In each case 1x106 cells were collected, and treated as in 
section 2.20 with offline cell cycle analysis carried out using FlowJo. 
 
Analysis of control PC-3 cells (Figure 5.7 A) showed that 65% of cells were in 
G1, G0 or interphase, 16.1% of the population were in S-phase during which 
cells are replicating their DNA, and finally 18.3% were in G2/M phase, 
typical of a rapidly dividing tumour cell line.  
 
In contrast, analysis of PC-3 SPARC knockdown clones show there is an 
increase in G2/M phase (40.2% of cells in G2/M) consistent with a block in 
cell cycle progression. Two other independent knock-down clones also show 
a G2/M blockade to a slightly lesser extent (data not shown). 
 
In addition to cell cycle analysis, the comparative rate of proliferation was 
investigated to control cells. PC-3 WT tdTomato cells were mixed with non-
fluorescent PC-3 SPARC knockdown cells and counted using AccuCheck 
Counting Beads (section 2.21). Cells were counted from 3 triplicate wells for 
each time point. 
 
Figure 5.7 (D) shows that whilst still proliferating, the SPARC knockdown 
clone grew significantly slower than that of their wildtype counterparts. Sub 
culturing timings during culture was similar which could be accounted for 
by the size difference between the two cells types. 
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5.4.9 A sub-population of PC-3 cells bind VCAM-1 
By utilising a VCAM Fc chimeric protein (R&D Systems) the possibility of 
VCAM-1 binding being instrumental in the migration of PC-3 cells was 
investigated. Based on previous results showing that VCAM-1 expression 
decreases over time in culture on stromal cells, which correlates with a loss 
in the ability to induce PC-3 migration, the hypothesis was the consideration 
that the binding of VCAM-1 by PC-3 cells was necessary for migration. 
 
PC-3 WT and SPARC knockdown cells were analysed for their ability to bind 
VCAM Fc. Figure 5.8 (A) shows that there is an 11.8% PC-3 population that is 
binding VCAM Fc. This population is small but mirrors migration data 
gathered so far showing that some but not all PC-3 cells migrate in the 
model. PC-3 SPARC knockdown cells showed an increase in the levels of 
VCAM Fc binding to 21.8% in Figure 5.8 (B). Figure 5.8 (C) shows the 
significant increase in the level of VCAM Fc binding across three 
independent experiments. 
 
To investigate if SPARC protein could outcompete the binding of VCAM-1 
by other ligands, recombinant human SPARC (rhSPARC) was added to the 
staining cocktail alongside VCAM Fc protein at a concentration of 20%g/ml. 
Figure 5.8 (D) shows a drop in VCAM Fc staining with the addition of 
rhSPARC to PC-3 WT cells. Although a smaller decrease is observed this is 
statistically significant (p=0.04) showing that rhSPARC is possibly binding to 
the VCAM Fc protein which in turn blocks this binding to ligands on the 
surface of PC-3 WT cells. 
 
5.4.10 Recombinant human SPARC affects 2-D morphology and cellular 
migration in 3-D.  
SPARC is a secreted protein. However, we and others have observed 
intracellular SPARC that could have potential roles in regulating cellular 
morphology consistent with the changes observed in cells with decreased 
amounts of SPARC protein. Therefore, the effect of exogenous rhSPARC was 
used to determine if it could modify cellular phenotype in 2-D and 3-D. 
 
PC-3 SPARC knockdown cells were seeded on to glass coverslips and 
rhSPARC protein added (30%g/ml) as previously described (Wendt et al. 
2010; Bradshaw et al. 1999). Analysis of cells for SPARC and f-actin 
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expression (Figure 5.9 A&B) shows that the morphology of PC-3 SPARC 
knockdown cells is partly restored to wild-type by the addition of rhSPARC 
to the media. Although the cell shape is still not as mesenchymal as control 
cells, the size of each cell has been reduced significantly to a size resembling 
that of wild-type cells according to cell diameter (Figure 5.9 C). Cells were 
measured within independent fields of view across 2 separate experiments. 
 
PC-3 WT cells and PC-3 SPARC knockdown cells in 3-D spheroids with high 
Gleason, low passage stromal cells (green) were embedded in to collagen I 
matrices in the presence of 30%g/ml rhSPARC (Figure 5.9 E). While no 
significant changes in the migration of the stromal cells with and without the 
addition rhSPARC was observed, there is a slight increase in the mean 
average of the migration of PC-3 SPARC knockdown cells with the addition 
of rhSPARC compared to PC-3 SPARC knockdown cells without exogenous 
rhSPARC. However the result was statistically not significant (Figure 5.9 F). 
 
5.4.11 Inhibiting VLA-4 using a blocking mAb 
PC-3 WT cells were formed in to spheroids with high Gleason grade stroma 
as previously described. One set of spheroids were then embedded in to 
collagen I matrices and incubated in normal full growth media. A second set 
were embedded in separate collagen matrices and incubated in full growth 
media supplemented with 20%g/ml anti-human-VLA-4 blocking antibody 
(Elan Pharmaceuticals). Both sets of spheroids were imaged via two-photon 
microscopy for a period of 48 hours. 
 
Images at the end of 48 hours are shown in Figure 5.10 showing spheroids in 
normal growth media (A) and in media supplemented with anti-VLA-4 
antibody (B). Stromal cell (red) migration was unaffected by the presence of 
the antibody. However, there is a difference in the morphology and 
migration of PC-3 cells with and without anti-VLA-4 blocking antibody. The 
white arrows in Figure 5.10 (A) show the normal mesenchymal phenotype of 
PC-3 wildtype cells. The yellow arrows in Figure 5.10 (B) show that in the 
presence of the anti-VLA-4 blocking antibody, PC-3 cells have taken on more 
of a round phenotype. Cells were tracked and PC-3 cells in the presence of 
anti-VLA-4 blocking antibody exhibited significantly shorter displacements 
consistent with a role for VCAM-1 and its ligands, SPARC and VLA-4 in 
prostate cancer migration (Figure 5.10 C). 
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5.5 Discussion 
The link between the expression of SPARC and the progression of prostate 
cancer to a metastatic disease has previously been observed (R. Thomas et al. 
2000). There has also already been some work on the effect of exogenous 
SPARC purified from bone conditioned media, on the behaviour of cancer 
cells in vitro (Jacob et al. 1999). However, the mechanism by which SPARC 
works is little understood and the importance of its expression in human 
disease is unknown and controversial. 
 
In this chapter we have shown that SPARC expression of primary epithelial 
cells is higher in higher Gleason grade tumours. It was also shown that 
SPARC expression is high in primary cells from BPH. Although it is 
uncertain why this difference is observed, BPH is a non-malignant 
pathological disorder which is mainly a stromal mediated disease. However, 
the epithelium is not normal. Whether or not SPARC expression in BPH is 
important is unknown as it is very challenging to obtain normal human 
prostate epithelium.  
 
Of the prostate cancer cell lines analysed only PC-3 cells express SPARC at 
significant levels. These cell lines differ in many ways, PC-3 cells originate 
from an advanced androgen independent tumour with evidence of bone 
metastasis. In contrast LNCaP and VCAP cells both originate from metastatic 
lesions in lymph node and bone respectively and are androgen responsive 
whereas PC-3 cells are non-responsive to androgens (Rahim et al. 2011). 
However it is unclear if the relationship between androgen sensitivity and 
SPARC mediated migratory capacity is true. The difference in expression 
pattern is compounded by lack of VLA-4 expression by these cells. It is 
possible that LNCaP and VCAP cells can migrate by a VCAM-1 independent 
process. Interestingly, although LNCaP cells do not express VCAM-1, it can 
be induced to express the adhesion molecule under pro-inflammatory 
conditions in vitro (C. P. Wong et al. 2009). Whether expression of VCAM-1 
on epithelial cells is important in tumour growth and migration is unknown. 
 
Exogenous soluble human SPARC has been shown to promote the 
invasiveness of prostate cancer cell lines LNCaP, VCAP and PC-3 in vivo (N. 
Chen et al. 2007) and is consistent with the function of SPARC in prostate 
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cancer based on its believed function as a secreted protein. However, using 
shRNA knockdown of SPARC the strong phenotypic changes in PC-3s can 
only partially be rescued by the addition of soluble human SPARC. 
Moreover, SPARC effects the cell cycle in addition to migration behaviour 
and this itself might result from changes to cell adhesion and morphology, 
but intracellular SPARC might bind to and effect the function of key proteins 
in the cell. The addition of soluble rhSPARC to the 3-D spheroid only 
marginally improved PC-3 cell migration. This might result from soluble 
SPARC being present in the wrong place at the wrong point in time in the 
migration process as physiologically, SPARC is normally expressed strongly 
at focal adhesions. Alternatively most of the soluble SPARC may become 
immobilised on the collagen matrix on account of its collagen binding 
domain.  
 
Interestingly , SPARC deficient PC-3 cells fail to efficiently establish tumours 
in vivo. Although cell cycle progression was affected by the knockdown of 
SPARC, tumour cells still proliferated in vitro albeit at a slower rate. The 
G2/M blockade was insufficient to inhibit the expansion of cells in vitro and 
is unlikely to account for the absence of tumours in vivo. Therefore, SPARC 
may have a key role in tumour initiation in vivo. Interestingly, Atorrasagasti 
et al showed the opposite in human hepatocellular carcinoma. They showed 
that the overexpression of SPARC completely prohibits the in vivo 
tumourigenicity of these cells (Atorrasagasti et al. 2010) adding more 
complexity to the possible role of SPARC. 
 
Unlike in stroma independent 2-D cultures, SPARC deficient PC-3 cells do 
not migrate in 3-D. This could be related to VCAM-1 mediated adhesion and 
de-adhesion in stromal cell mediated migration. The results showing an 
increase in VCAM Fc binding by PC-3 cells deficient in SPARC could suggest 
a role for SPARC in regulating VCAM-1 bioavailability as previously 
described for monocyte transendothelial migration (Ronald et al. 2001). The 
addition of rhSPARC to wildtype PC-3 cells in a similar experiment showed 
the opposite effect – a drop in the levels of VCAM Fc binding to PC-3 cells. 
From these two experiments we can postulate that SPARC is acting as a 
secreted, or membrane bound ligand of VCAM-1 which blocks the binding of 
VCAM-1 by other ligands such as VLA-4. However, with the effects of 
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SPARC shRNA being seen in vitro in the absence of stromal cells, this is 
clearly not the only role for SPARC. 
 
In 3-D, migration of PC-3 cells deficient in SPARC was not significantly 
altered by the addition of soluble rhSPARC, however a slight upward trend 
was observed. In order to migrate, cells have to not only adhere to each 
other/the matrix, but they also need to release in order to move off. With no 
expression of SPARC, perhaps the PC-3 cells are so tightly bound to the 
stromal cells and each other by VCAM-1/VLA-4 interactions that it is 
difficult for cells to migrate. By adding rhSPARC the binding of VCAM-1 
maybe competed for allowing the release of VCAM-1 by VLA-4 and 
therefore directional migration may take over. However, Figure 5.5 does not 
necessarily show PC-3 cells tightly associated to the stromal cells and so this 
may not be the route that the addition of rhSPARC is taking. It would be 
interesting to assess the cell-cell levels of the two cell types and this ascertain 
whether there is a level of initial contact required between PC-3 cells and the 
stroma in order for migration to take place. This could be carried out by 
analysing time-lapse movies and quantifying the interactions in time. 
 
This hypothesis was further investigated by using an anti-VLA-4 blocking 
antibody in the 3-D migration assay. The migration of PC-3 cells was not 
completely inhibited but it was significantly reduced. Blocking VLA-4 would 
block the interaction of VCAM-1 with VLA-4. The blocking antibody was 
added to the media so all VLA-4, both stromal and PC-3 in origin, would 
have been affected. With no VCAM-1/VLA-4 binding it is possible that there 
would be no, or little attachment of PC-3 cells. The normal SPARC levels 
courtesy of using wildtype PC-3 cells, would not have a role in this system 
because the outcompeting of VCAM-1 by SPARC would be made redundant 
by the absence of VLA-4 ligands to bind. Although relatively few PC-3 cells 
were shown to express a4 integrin by FACS, this correlates with the small 
proportion of PC-3 cells that were observed migrating out of spheroids 
cultured with stroma in 3-D. It is possible that this population of PC-3 cells 
might be the same cells that express α4 and are therefore utilising the VCAM-
1-VLA-4 interactions as a mean to migrate. However, further experiments 
would need to be carried out to explore this such as α4 immunofluorescence 
studies of migrating PC-3 cells in 3-D. 
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5.6 Conclusions 
SPARC has a key role in PC-3 cell behavior both in 2-D culture and in 3-D 
tumour spheroids. Reports to date have linked SPARC to metastasis with 
SPARC having a chemoattractant role, particularly with regard to metastases 
to the bone. This chapter has shown it has a clear role in cell shape control, 
the function of focal adhesions, cell cycle regulation and cell migration in 
both 2-D and 3-D environments. 
 
There is a well established relationship between adhesion molecules and 
migration. Here, we show that VCAM-1 and two of its ligands VLA-4 and 
SPARC have a complicated role in tumour cell migration. This may well 
occur through controlling the attachment and detachment of PC-3 cells with 
stroma and the ECM to permit cell migration. This mechanism proposes a 
key role for the right balance of VCAM-1 adhesion via VLA-4, and the right 
level of SPARC to outcompete this binding at the focal adhesions to allow 
detachment and therefore forward migration. This is consistent with 
deficiencies or over expression of any of these proteins that may inhibit the 
metastasis process. A model for this hypothesis is presented in Chapter 6. ! !
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Figure 5.1 SPARC and !4 integrin expression across a range of primary tumour cells 
and prostate cancer cell lines by qRT-PCR.(A) SPARC expression in primary tumour 
cells shows an increase in expression with increasing grade. BPH SPARC expression 
is relatively high across independent samples. (B) Primary cell !4 integrin 
expression is less clear. (C) LNCaP or VCAP prostate cancer cell lines have little 
detectable SPARC expression. (D) !4 integrin expression is very low in VCAPs and 
undetectable in LNCaP cell lines (E) Representative FACS dot plots showing levels 
of !4 and "1 integrin expression independently, as well combined expression of !4"1 
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Figure 5.2 shRNA knockdown clones of PC-3 cells were successfully developed. (A) 
The pLKO inducible vector (Sigma) that was used to introduce SPARC shRNA. (B) 
Bulk cultures showed very little inducible knockdown of SPARC. (C) Single cell 
clones were made with varied degrees of knockdown of SPARC, with clone PS5 
exhibited the most efficient knockdown of SPARC. (D) Further clones were made 









































































































































































































































































































































































































































































































































Figure 5.3 SPARC knockdown changes the morphology of PC-3 cells. (A) Panel 
shows staining for DAPI (blue), f-actin(red) and SPARC (green) for control PC-3 WT 
cells compared to the three knockdown clones. Control panel shows secondary 
antibody only staining control. (B) SPARC expression as measured by mean 



















































































Figure 5.4 SPARC knockdown increases motility of PC-3 cells in 2-D. (A-C)) 
Representative image of cells (Bar:20%m) from (A) PC-3 WT cells, (B) SPARC 
shRNA knockdown clone PS5 and (C) PS1a. (D) Cells were tracked individually 
throughout the time-lapse video and the resulting tracks for both SPARC shRNA 
knockdown clones were significantly longer than the tracks for PC-3 WT cells. Bars 





Figure 5.5 SPARC knockdown in PC-3 cells results in decreased migration in 3-D in 
spheroids containing high Gleason grade stroma. (A) PC-3 WT cells (red) migrate in 
to the matrix along with the stromal cells (green). Scale unit: 64%m. (B) PC-3 SPARC 
knockdown cells do not migrate in to the matrix, however the stromal cells exhibit 
normal migratory behaviour. Scale unit: 64%m. (C) Quantification of cell 
displacement reveals no difference in the migration of stromal cells in the presence 
of PC-3 WT or PC-3 SPARC knockdown cells, whereas there is a significant 
reduction in cell displacement and therefore cell migration, in PC-3 SPARC 
knockdown cells. Bars represent mean±SEM, ns=not significant, ***p<0.001 (Mann-






Figure 5.6 In vivo tumours of PC-3 SPARC knockdown cells fail to establish. (A) The 
final volume of tumours resulting from PC-3 SPARC knockdown cells, or a 50:50 
mix of PC-3 SPARC knockdown cells and PC-3 WT cells, were both significantly 
smaller than the tumours resulting from 100% PC-3 WT cells. *p=0.025 (ANOVA 
with Tukey’s post hoc test) (B) The same pattern is observed when measuring the 
tumours by weight. P=0.076 (ANOVA with Tukey’s post hoc test) Bars represent 





Figure 5.7 PC-3 SPARC knockdown cells are blocked at G2/M but still do 
proliferate. (A) The cell cycle profile of PC-3 WT cells shows a clear G1 phase for 
65% of the population, with 16% and 18% of cells in S phase and G2/M phase 
respectively. (B) The cell cycle profile for PC-3 SPARC knockdown cells (clone PS5) 
shows a block at G2/M with 40% of cells now in G2/M, 12% in S phase and 46% in 
G1 phase. (C) PC-3 SPARC knockdown cells do still proliferate in vitro in tissue 
culture, however, this happens at a slower rate compared to PC-3 WT cells. Points 
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Figure 5.8 VCAM Fc binding of PC-3 WT cells is lower than that of PC-3 SPARC 
knockdown cells. Representative FACS dot plots showing that (A) 11.8% of PC-3 
WT cells bind VCAM Fc protein compared to (B) 21.1% of PC-3 SPARC knockdown 
cells. Red shows secondary antibody staining control, blue shows VCAM Fc binding 
(C) Quantifying this over 3 independent experiments shows a significant raise in 
VCAM Fc binding for PC-3 SPARC knockdown cells. (D) The addition of rhSPARC 
does block to a lesser extent, the binding of VCAM Fc to wildtype PC-3 cells. Bar 
represents mean±SEM, *p<0.01 (t test). !  
B!A!
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Figure 5.9 rhSPARC partially rescues phenotype of SPARC knockdown PC-3 cells in 
2-D & 3-D. (A&B) 2-D IF of (A) PC-3 SPARC knockdown cells (B) PC-3 SPARC 
knockdown cells grown in the presence of rhSPARC. DAPI (blue) f-actin (red) 
SPARC (green). (C) Quantification shows a decrease in cell size in the presence of 
rhSPARC. Bar represents mean±SEM, *p<0.001 (Mann-Whitney). (D&E) 3-D images 
of spheroids. PC-3 (red) High Gleason stroma (green). (F&G) Quantification of cell 
displacement shows increased migration of stromal cells in the presence of 
rhSPARC, and a small but not significant increase in PC-3 SPARC knockdown cell 
migration in the presence of rhSPARC protein. **p=0.006, ***p<0.001 (ANOVA with 




















Figure 5.10 Blocking VLA-4 reduced the migration of PC-3 cells in 3-D. (A&B) 3-D 
imaging of spheroids containing high Gleason stroma (red) and PC-3 WT cells 
(green) at the end of time-lapse imaging at 48 hours. (A) Control spheroids in 
normal growth media compared to (B) spheroids in media containing anti-VLA-4 
blocking antibody. (C) Quantification of cell displacement shows a significant 
reduction in cell migration over 48 hours. ***p<0.0001 (Mann-Whitney) 




Chapter 6  
Final discussion 
Although mechanisms involved in cellular transformation and growth are 
well understood, the molecular and cellular basis leading to secondary 
metastasis, the major cause of mortality in cancer, is not well understood and 
is a major medical challenge. Tumour metastasis is a complex process that 
requires tumour cells to express molecules that permit invasion and 
migration from the tumour mass into surrounding tissues, lymphatic and 
blood vessels and subsequent colonisation of peripheral tissue to form 
secondary tumours (Larkin et al. 2012). A considerable amount of focus has 
been on changes that occur to tumour cells, including the expression of 
MMPs that are required for the metastasis process (Nalla et al. 2010; Müller 
et al. 2010). In this thesis we have focused on the role of stromal cells in the 
tumour microenvironment and mechanisms of stromal mediated 
transformed epithelial cell migration. 
 
Role of stromal cells in epithelial cell migration: In vivo, prostate cancer tumour 
cells grow in a 3-D tumour microenvironment that contains both stroma 
(tumour fibroblasts, immune infiltrate and endothelial vessels) and normal 
and transformed epithelium, therefore to understand mechanisms of 
epithelial migration required development of a novel 3-D stroma-epithelial 
spheroid culture system that permitted real time imaging of tumour and 
stromal cell interactions and subsequent migration. Analysis of human 
prostate cancer cell migratory capacity in vitro showed that although 
migration in 2-D is not dependent on stroma, migration in 3-D is stromal cell 
dependent. PC-3 cells did not migrate in our 3-D culture model as single 
dispersed cells either alone, in the presence of a stromal cell monolayer or 
being cultured in stromal cell conditioned media. While MMP inhibitors 
increased the migration capacity of the HT-1080 fibrosarcoma cell line that 
could directly interact with collagen, it had no effect on PC-3 cell migration. 
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Using the 3-D spheroid tumour co-culture methodology we found that only 
primary human higher Gleason grade tumour stroma but not BPH stroma 
has the capacity to promote transformed epithelial cell migration. 
Additionally the capacity of tumour stroma to induce PC-3 cell migration 
diminishes over time in culture. Thus the induction of tumour cell migration 
requires cellular interactions with freshly isolated high Gleason grade 
stroma, consistent with a change occurring in stromal cells in tumour 
progression which is progressively lost when the cells are cultured in vitro in 
the absence of exogenous signals found in the tumour microenvironment. 
 
Gene expression analysis of stromal cells by microarray, verified using qRT-
PCR and antibody staining revealed a potential role for adhesion molecules 
VCAM-1 and ICAM-1 and the lymphatic endothelium marker podoplanin in 
stromal cell function in tumours. Specifically expression of these proteins on 
tumour stroma correlated with cancer progression. Tumour stroma that had 
been in culture for six or more passages lost both its migratory capacity and 
reverted to a BPH like stroma cell phenotype which was characterised by the 
expression of very low levels of VCAM-1, ICAM-1 and podoplanin. In the 
future, it would be important to build upon this and to generate a larger 
more comprehensive dataset of multiple tumours, across different patients 
and different tumour settings. This would, depending on outcome, 
strengthen the link between expression of VCAM-1, ICAM-1 and 
Podoplanin, and the ability of cancer stroma to promote tumour cell 
invasion. 
 
Potential role of inflammation in prostate cancer cell metastasis: Primary human 
high Gleason grade tumour stroma has a similar gene expression profile to 
tertiary lymphoid tissue (TLT) associated with chronic infections and 
autoimmune disease (Cupedo et al. 2004). TLTs are specialised 
immunological tissues containing both stroma and leukocytes providing the 
microenvironment for efficient local adaptive immune responses in situ. 
Analysis of xenograft tumours showed that although inflammation occurred 
in the tumour microenvironment including the presence of F4/80+ 
macrophages, CD11chi dendritic cells and a GR1+ neutrophil infiltrate, 
stromal cells failed to express VCAM-1, ICAM-1 or podoplanin, hallmarks of 
primary human tumour stroma. To further understand the mechanisms 
driving expression of these TLT stromal gene expression patterns, C57BL/6 
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syngenic Lewis lung carcinoma cells were injected subcutaneously into mice 
with immune deficiencies. Analysis of stromal cells from these mice was 
consistent with a key role for T lymphocyte subsets in efficient stromal cell 
induction, consistent with a role for inflammatory cytokines in tumour 
stroma activation as is found in TLT formation. Primary human tumour 
stroma that had lost the expression of these adhesion markers could be 
reactivated by inflammatory cytokines. After 3 days in culture media 
containing TNF-α, LTβ and IL-4, expression of VCAM-1, ICAM-1 and 
podoplanin reached expression levels found in early passage high Gleason 
grade tumour stroma. The rescue of stromal cell gene expression was 
mirrored by the regain of function in promoting PC-3 cell migration in our 3-
D model after stromal treatment with the cytokines. 
 
Whilst we did not sequence the primary stromal cells or investigate the 
genetic normality, there was no evidence of abnormality or uncontrolled cell 
growth. There is also no evidence in the literature to suggest that mutations 
are found in the stroma in carcinomas. However, investigating the genetic 
makeup of tumour stroma could prove useful for further analyses of the 
effect of stroma on carcinomas at the genetic level if indeed there are any 
genetic changes. 
 
SPARC, VLA-4 and VCAM-1; interactions driving prostate tumour cell migration: 
VCAM-1 has been shown to interact with two proteins that are expressed by 
PC-3 tumour cells, SPARC and VLA-4. VLA-4 is a heterodimer of the α4 
integrin combined with constitutively expressed β1 integrin (Alon et al. 1995) 
and is only expressed on a small percentage of PC-3 cells. SPARC is a 
secreted protein that can bind both VCAM-1 and ECM and is highly linked 
to high Gleason grade prostate cancer (R. Thomas et al. 2000). Collagen 
binding domains exist in the structure of SPARC and once secreted, SPARC 
has been shown to bind the collagen components of the ECM. However, 
antibody staining revealed possible intracellular and membrane bound 
SPARC in PC-3 cells, specifically at putative focal adhesion points. SPARC is 
expressed by both stromal cells and epithelial cells in tumours leading to 
additional complexity within the 3-D tumour microenvironment, however it 
is unclear if stromal cell SPARC has any role in the epithelial cell migration. 
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To directly determine if VCAM-1 can interact with ligands on tumour cells, 
the capacity of soluble recombinant human VCAM Fc to bind to PC-3 cells 
was determined. Similarly with the previously shown expression of VLA-4, 
VCAM Fc bound only a small population of PC-3 cells. Consistent with a role 
for soluble SPARC inhibiting this process, an increase in binding was found 
in SPARC deficient PC-3 cells and a decrease in binding in the presence of 
exogenous SPARC, directly demonstrating SPARC’s role in inhibiting VLA-
4-VCAM-1 interactions. Thus the expression of these two ligands might have 
a role in controlling tumour cell interactions with stroma by regulating the 
adhesion and de-adhesion process involved in cellular migration. 
 
To further determine the role of these two proteins we used gene knock-
down, soluble protein and inhibitor antibodies. SPARC expression was 
knocked down in PC-3 cells using shRNA. PC-3 clones deficient for SPARC 
showed altered morphology with the cells taking on a large and rounded 
shape in 2-D and were spherical in 3-D in contrast to the more mesenchymal 
phenotype found in control PC-3 cells. Surprisingly despite the increase in 
PC-3 SPARC knock down cell line’s migration in 2-D, in 3-D there was a 
complete inhibition of PC-3 cell migration, indicating an essential role for 
SPARC in 3-D tumour cell migration consistent with the elevated levels 
found in tumour cells. Therefore SPARC production by epithelial cells is 
required for their migration. The addition of recombinant human (rh) 
SPARC protein partially restored a wild type phenotype in 2-D and although 
not significantly, there was a small rescue in 3-D cell migration when growth 
media was supplemented with rhSPARC in the presence of tumour stroma. 
Although this did not completely rescue the phenotype this likely resulted 
from the high affinity binding of SPARC to collagen thus sequestering the 
majority of the protein in the ECM. To analyse the role of VLA-4 in PC-3 cell 
migration, an inhibitory antibody, anti-human α4 (Elan Pharmaceutical), was 
added to the spheroids. Although no change in stromal cell migration was 
observed there was a significant change in the migratory potential of PC-3 
cells. Additionally the PC-3 cells took on a more rounded phenotype similar 
to that observed in SPARC deficient clones. Thus both VLA-4 and SPARC 
have essential roles in PC-3 cell migration in 3-D co-culture tumour 
microenvironments but not in the 2-D stromal-free migration. 
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A new model for tumour cell migration: Utilising the 3-D spheroid model 
combined with gene expression analysis and functional assays we propose 
that prostate tumour cell invasion of ECM is dependent on the expression of 
the adhesion molecule VCAM-1 by tumour stroma. Thus we are proposing a 
new model for how transformed epithelial cells in prostate cancer migrate in 
the context of the tumour microenvironment. We propose the following 
model (Figure 6.1): 
 
1) Epithelial cells interact with stroma. 
2) Selective binding of VLA-4 to VCAM-1 leads to a specific adhesion. 
3) Secretion of SPARC at focal adhesions mediates detachment of VLA-4. 
4) New adhesions occurs inducing cell migration. 
 
In this model VLA-4 and VCAM-1 is required for stromal cell mediated 
adhesion and SPARC competes for binding of VCAM-1 leading to localised 
de-adhesion. Furthermore that not only is the mesenchymal/lymphocytic 
gene VLA-4 required for migration, but that SPARC levels are also critical for 
the correct adhesion and detachment of transformed cells with cancer 
associated stroma in order to allow successful cell migration. A lack of 
SPARC leads to tight binding of VCAM-1 to VLA-4 thereby not allowing cell 
migration. Excess SPARC would inhibit the initial binding, therefore not 
allowing attachment in order to migrate. Thus tumours that express very 
high levels of SPARC may have limited capacity to metastasise are consistent 
with observations that although SPARC expression correlates well with 
tumour grade and metastasis, very high levels of SPARC expression correlate 
with a favorable outcome (Figure 6.2).  
 
Does this process occur in vivo: Although we have shown a key role for 
expression of VCAM-1, VLA-4 and SPARC using an in vitro model of human 
prostate cancer it is entirely possible that the observations made in vitro do 
not correspond with what will occur in vivo. We have previously shown that 
xenogeneic tumour models are unlikely to provide a good model of tumour 
metastasis as the tumours do not contain reactive tumour stroma which in 
vitro is required for tumour cell migration. Thus we suggest the best models 
will be prostate tumours that spontaneously arise in mice selectively 
deficient for PTEN using the prostate specific probasin Cre (S. Wang et al. 
2003; Kasper 2005). In these mice metastasis of developing tumours occurs to 
! 159!
secondary tissues within 12 weeks of age (Maddison et al. 2004). Using anti-
VLA-4 we would predict that there would be a reduction in micro-
metastases to the lung. SPARC-/- TRAMP mice rapidly develop tumours at 
an accelerated rate (Brekken et al. 2003). This contradicts our data on the role 
of SPARC in human cell lines and the link between SPARC expression levels 
in aggressive prostate cancer and the expression of SPARC in many human 
cancer cell lines (Said et al. 2009). This might result from differences between 
the phenotype of epithelial cells in the TRAMP model (luminal 
transformation) compared to those found in human cancers (CSC/Basal) and 
cell lines. Thus it is possible SPARC has a very different role in luminal cells 
that lack expression of VLA-4 than it has in transformed CSCs and 
basal/transit amplifying cells that have a more mesenchymal like phenotype.  
 
Understanding the cell biology of SPARC in tumours: Analysis of SPARC 
expression was consistent with selective secretion associated with putative 
focal adhesions based on cytoskeletal staining. To better understand the 
biology of the focal adhesion we propose that the use of high magnification 
confocal imaging combined with antibodies against paxillin and other focal 
adhesion proteins to both PC-3 cells cultured on plastic, and PC-3 cells co-
cultured with stromal cells in monolayer cultures. We would like to expand 
these results combining TEM and SEM analysis of the focal adhesions with 
florescent imaging. SPARC clearly has other roles in PC-3 cells other than 
binding to VCAM-1. Loss of SPARC expression leads to changes in focal 
adhesions points that resemble a mesenchymal like phenotype and takes on 
an epithelial phenotype. Further characterisation of this process will provide 
additional insights into mechanisms of action. Focal adhesions are not 
readily detected in vivo because cells are embedded in a 3-D matrix so the 
role of focal adhesions in vivo are unknown, using the spheroid model it 
should be possible to image with sufficient resolution to start to understand 
the cell biology in 3-D culture systems. There is strong evidence that focal 
adhesion proteins, of which there are over 100, are important in tumour 
metastasis including focal adhesion kinase (FAK), paxillin and zyxin which 
are linked to metastatic potential in vivo (Fraley et al. 2010). Thus it is 
possible that the processes we observe in vitro are occurring within the 
tumour microenvironment in vivo. Through use of frozen sections of high 
Gleason grade tumours we believe it might be possible to determine if 
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SPARC expression is localised within primary tumour cells rather than a 
having uniform distribution. 
 
Is there SPARC-VLA-4-VCAM-1 interactions in tumours: By utilising the same 
VLA-4 blocking antibody used in the 3-D migration studies, it would be 
possible to assess the binding of VCAM Fc by PC-3s in the absence of VLA-4. 
This experiment would strength the model for VCAM-1-VLA-4 dependent 
cell migration. Another way of investigating this process is to generate mice 
where floxed integrin α4 (Itga4) is conditionally deleted using probasin-Cre 
and crossing the mice to PTENfl/fl mice to generate mice where both genes 
can be simultaneously deleted in prostatic epithelium. Itga4 is required for 
normal embryo development and immune function thus this would provide 
a specific method to determine the role of VLA-4 in tumour metastasis to the 
lung and draining lymph node. SPARC has a clear role in cell shape control, 
focal adhesions, cell cycle regulation and cell migration. We have shown that 
SPARC has a complicated role in VCAM-1-VLA-4 mediated cell migration 
through possibly controlling adhesion and detachment between transformed 
epithelial cells and the associated stroma. There seems to be the need for the 
correct balance of VCAM-1 adhesion to VLA-4 and the right levels of 
competition for this interaction by SPARC in order for forward migration via 
cell attachment and detachment. 
 
Is PC-3 cell migration a model cancer stem cell migration? We have shown that 
prostate CSCs are highly migratory in the spheroid model, rapidly migrating 
in a phenotype highly reminiscent of HT-1080 migration. Thus these cells 
which express high levels of SPARC may have unique potential to migrate. It 
is unclear if the highly migratory cells we observed in PC-3 cells upon 
stromal cell interactions represent a small population of stem-like cells 
within the PC-3 cell culture. At this stage we do not know if the migration of 
the stem cells was dependent on VCAM-1-VLA-4-SPARC interactions, or if 
primary CSCs can migrate in a stromal independent mechanism. 
 
Understanding the dark and light of anti-tumour immune responses: Interestingly 
there is a direct link between the anti-tumour immune response and the 
formation of reactive stroma in advanced cancers. Activated stromal cells 
usually form into TLOs at sites of chronic infection and inflammation 
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stimulating high affinity immune response in the local site of persistent 
inflammation (Cupedo et al. 2004). Anti-tumour immune responses have 
been known to have a key role in controlling cancer growth and metastasis, 
consistent with our observations that in the absence of immune responses 
increased tumour volume in LL/2 tumours was observed. Recently it has 
been shown that in clinical studies in humans with very advanced stage 
tumours that monoclonal antibody therapies directed against the inhibitory 
receptors cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and 
programmed death 1 (PD-1) expressed by activated T cells can lead to 
spontaneous tumour clearance in 10-30% of the patients consistent with the 
an active but unproductive immune response on-going in the patients 
(Schneider et al. 2006; Brahmer et al. 2012; Danielli et al. 2012). The presence 
of TLOs in cancer has been associated with poor prognosis and as shown in 
this project, the effect of T cell mediated inflammation acts to induce stromal 
cell-dependent cancer epithelial cell migration. Thus the linkage between 
poor prognosis and TLOs containing activated stroma, in the absence of a 
productive immune response, means that inflammation perpetuates at the 
tumour site. This in turn drives stromal cell activation leading to an 
environment that permits tumour cell invasion of the stromal compartment 
and into secondary sites. Thus a proportion of patients with high grade 
prostate tumours might benefit from inhibiting VLA-4 function, reducing the 
risk of secondary prostate metastasis to the bone or lymph node. Anti-human 
α4 integrin, Natalizumab (Tysabri), is a clinically approved treatment for the 
treatment of advanced multiple sclerosis thus in the future it might be 
possible to repurpose Natalizumab for the treatment of high Gleason grade 
tumours.  
 
Role of mesenchyme in secondary metastasis: Metastatic prostate tumour cells 
commonly form secondary tumours in the bone and lymph nodes, both sites 
that contain lymphoid stromal cells (Josson et al. 2010). These cells provide 
not only the chemokines to drive tumour cell recruitment but also provide 
growth factors and adhesion molecules permitting tumour adhesion and 
colonisation including VCAM-1, ICAM-1, and podoplanin all found 
expressed in the reactive stroma of the parental tumour. Mesenchymal 
stromal cell lines including the bone marrow stromal cell (BMSC) line and 
mesenchymal stromal cells (MSCs) will allow for in vitro and in vivo studies 
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of stromal specific genes. In preliminary studies using adipose derived stem 
cells we have shown that treatment with the inflammatory cytokines not 
only drives expression of lymphoid expression profile but also induced the 
rapid migratory capacity in PC-3 cells. Using siRNA/shRNA and 
overexpression vectors, it will be possible to study the role of these genes in 
tumour growth and migration potentially through the selective targeting of 
gene expression in stromal cells. 
 
Parallels to other epithelial tumours: Although all the data we have collected is 
specific for prostate stroma and epithelium we believe that other tumours 
may use similar mechanisms in their migration and metastasis. In order to 
investigate) whether) the) results) are) specific) to) prostate) cancer) it) will) be)
interesting) to) investigate) the)properties)of)other) tumour) stroma)and)cancer)
cell) lines/primary) tumour) cells) from)other) organs) including) lung,) breast) of)
colon.)This)might)including)creating)spheroids)with)breast)cancer)associated)
stroma) coupled) with) MCF7) or) MDAAMBA231) breast) cancer) cell) lines) for)
example. 
 
Alternative targets for the therapy of metastatic disease: In this thesis we have 
focused on the VCAM-1 role in tumour cell migration. We found that both 
ICAM-1 and podoplanin expression strongly correlates with VCAM-1 in 
activated stromal cells. The role for podoplanin in tumours is complex as 
podoplanin expression has been linked to both poor and favourable 
outcomes in different types cancers. CLEC-2 has been shown to be an 
important ligand for podoplanin and has a role in dendritic cell migration on 
secondary lymphoid stroma (Acton et al. 2012). CD44 is a glycoprotein that 
can bind to both SPARC and podoplanin (Martín-Villar et al. 2010), and 
variants in CD44 (CD44v) has been correlated with progressive tumour 
stages in colorectal carcinomas (Wimmenauer et al. 1997). Podoplanin 
directly associates with CD44 on squamous stratified epithelial cells to drive 
directional tumour cell migration (Martín-Villar et al. 2010). Thus a complex 
interplay between gene expression on stroma and epithelium in prostate 
cancer through podoplanin, VCAM-1 and ICAM-1 with CD44, SPARC and 




In summary, the data presented in this thesis reveals a key role for stroma 
mediated transformed cell migration, within an inflammatory environment 
created by TLT in activated stroma. Although perhaps contradictory at first, 
the presence of TLT in tumour stroma being poor for prognosis, the results 
shown here partly explain how the activation of an immune response in 
prostate cancer, can lead to a chronic T lymphocyte reaction. However, the 
tumour is unresponsive and indeed the large number of lymphocytes which 
provide high levels of inflammatory cytokines, causes the development of 
TLT in tumour stroma. Clinical trials with blocking antibodies, such as 
CTLA-4 which blocks T cell inhibitory signals allowing T cell activation, 
would not therefore work without TLT acting as a T cell source. However, 
assuming T cell activation once the inhibitory signals have been lifted, an 
increase in the level of inflammatory cytokines can occur, which as these 
results show can induce tumour cell migration and metastasis via a VCAM-
1-VLA-4 dependent process possibly mediated by SPARC expression levels. !  
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Figure 6.1 Prostate cancer epithelial cells have a complex interaction with the 
tumour stroma. VCAM-1 expressed by stromal cells binds VLA-4 on the surface of 
PC-3 cells leading to cell attachment. SPARC, expressed by the transformed cells, 
interferes with the interplay between VCAM-1 and VLA-4 by binding VCAM-1 
thereby blocking VCAM-1-VLA-4 interaction which therefore allows detachment of 













Figure 6.2 A proposed model for VCAM-1 – VLA-4 – SPARC interactions in tumour 










High Gleason Grade Tumour Stroma!
Rapid tumour cell migration of β1+ tumour cells."
Membrane-bound VLA-4 induces attached SPARC 
secreted at focal points of adhesion.!
Allows rapid attachment and detachment on 
stromal cells.!
Low Gleason Grade Tumour Stroma!
Low to no expression of VCAM-1 on stromal cells 
prohibits adherence between stroma and tumour 
cell.!
High Gleason Grade Tumour Stroma No SPARC!
SPARC is not available to outcompete VLA-4 for 
VCAM-1 binding.!
No detachment of cancer cells from stromal cells 
therefore no migration.!
High Gleason Grade Tumour Stroma No VLA-4!
Blocking VLA-4 prohibits binding of cancer cells 
to stromal VCAM-1 .!
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